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A systematic review and economic evaluation of
intraoperative tests [RD-100i one-step nucleic acid
amplification (OSNA) system and Metasin test] for
detecting sentinel lymph node metastases in breast cancer
Nicola Huxley,1 Tracey Jones-Hughes,1 Helen Coelho,1
Tristan Snowsill,1 Chris Cooper,1 Yang Meng,2 Chris Hyde1
and Rubén Mújica-Mota1*
1Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School,
Exeter, UK
2School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
*Corresponding author R.E.Mujica-Mota@exeter.ac.uk
Background: In breast cancer patients, sentinel lymph node biopsy is carried out at the same time as the
removal of the primary tumour to postoperatively test with histopathology for regional metastases in
the sentinel lymph node. Those patients with positive test results are then operated on 2–4 weeks after
primary surgery to remove the lymph nodes from the axilla (axillary lymph node dissection, ALND).
New molecular tests RD-100i [one-step nucleic acid amplification (OSNA); based on messenger RNA
amplification to identify the cytokeratin-19 (CK19) gene marker] (Sysmex, Norderstedt, Germany) and
Metasin (using the CK19 and mammaglobin gene markers) (Cellular Pathology, Princess Alexandra Hospital
NHS Trust, Harlow, UK) are intended to provide an intraoperative diagnosis, thereby avoiding the need for
postoperative histopathology and, in positive cases, a second operation for ALND.
Objective: To evaluate the clinical effectiveness and cost-effectiveness of using OSNA and Metasin in the
NHS in England for the intraoperative diagnosis of sentinel lymph nodes metastases, compared with
postoperative histopathology, the current standard.
Data sources: Electronic databases including MEDLINE, MEDLINE In-Process & Other Non-Indexed
Citations, EMBASE, The Cochrane Library and the Health Economic Evaluations Database as well as clinical
trial registries, grey literature and conference proceedings were searched up to July 2012.
Review methods: A systematic review of the evidence was carried out using standard methods.
Single-gate studies were used to estimate the accuracy of OSNA with histopathology as the reference
standard. The cost-effectiveness analysis adapted an existing simulation model of the long-term costs and
health implications of early breast cancer diagnostic outcomes. The model accounted for the costs of an
extended first operation with intraoperative testing, the loss of health-related quality of life (disutility)
from waiting for postoperative test results, disutility and costs of a second operation, and long-term
costs and disutility from lymphoedema related to ALND, adjuvant therapy, locoregional recurrence and
metastatic recurrence.
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Results: A total of 724 references were identified in the searches, of which 17 studies assessing test
accuracy were included in the review, 15 on OSNA and two on Metasin. Both Metasin studies were
unpublished. OSNA sensitivity of 84.5% [95% confidence interval (CI) 74.7% to 91.0%] and specificity
of 91.8% (95% CI 87.8% to 94.6%) for patient nodal status were estimated in a meta-analysis of five
studies [unadjusted for tissue allocation bias (TAB)]. At these values and a 20% node-positive rate, OSNA
resulted in lifetime discounted cost-savings of £498 and a quality-adjusted life-year (QALY) loss of 0.048
relative to histopathology, that is, £4324 saved per QALY lost. The most favourable plausible scenario for
OSNA in terms of the node-positive rate (range 10–40%), diagnostic accuracy values (91.3% sensitivity
and 94.2% specificity, from three reports that adjusted for TAB), the costs of histopathology, OSNA and
second surgery, and long-term costs and utilities resulted in a maximum saving per QALY lost of £10,500;
OSNA sensitivity and specificity would need to be ≥ 95% for this figure to be ≥ £20,000.
Limitations: There is limited evidence on the diagnostic test accuracy of intraoperative tests. The quality of
information on costs of resource utilisation during the diagnostic pathway is low and no evidence exists on
the disutility of waiting for a second surgery. No comparative studies exist that report clinical outcomes of
intraoperative diagnostic tests. These knowledge gaps have more influence on the decision than current
uncertainty in the performance of postoperative histopathology in standard practice.
Conclusions: One-step nucleic acid amplification is not cost-effective for the intraoperative diagnosis
of sentinel lymph node metastases. OSNA is less accurate than histopathology and the consequent loss of
health benefits in this patient group is not compensated for by health gains elsewhere in the health system
that may be obtained with the cost-savings made. The evidence on Metasin is insufficient to evaluate its
cost-effectiveness.
Study registration: This study is registered as PROSPERO CRD42012002889.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Axillary lymph node Lymph node located in the axilla or armpit.
Axillary lymph node dissection Removal of some or all of the lymph nodes within the axilla.
Cost-effectiveness analysis An economic analysis that converts effects into health terms and describes
the costs of additional health gain.
Cost-effectiveness threshold The maximum incremental cost-effectiveness ratio that a technology may
have if it is to be considered cost-effective. This may be interpreted as the maximum cost that the NHS is
willing to pay to produce one unit of benefit (e.g. quality-adjusted life-year or patient correctly diagnosed)
with the technology.
Crossing point The point during a quantitative polymerase chain reaction at which the level of
fluorescence is above background.
Decision modelling A theoretical construct that allows a comparison of the relationship between costs
and outcomes of alternative health-care interventions.
Distant metastases Cancer that has spread from the original (primary) tumour to distant organs or
distant lymph nodes.
Dominant A diagnostic option that costs less and results in more benefits (i.e. quality-adjusted life-years
or patients correctly diagnosed) than the alternative.
Dominated A diagnostic option that costs more and results in fewer benefits (i.e. quality-adjusted
life-years or patients correctly diagnosed) than the alternative.
Extendedly dominant A diagnostic option with a lower incremental cost-effectiveness ratio (relative to a
third option) and more benefits than the alternative.
Extendedly dominated A diagnostic option with a higher incremental cost-effectiveness ratio (relative to
a third option) and fewer benefits than the alternative.
False negative Incorrect negative test result – number of diseased persons with a negative test result.
False positive Incorrect positive test result – number of non-diseased persons with a positive test result.
Incremental cost-effectiveness ratio The difference in the mean costs of two interventions in the
population of interest divided by the difference in the mean outcomes in the population of interest.
This may be interpreted as the cost of producing one unit of benefit (e.g. quality-adjusted life-year or
patient correctly diagnosed) with NHS resources.
Index test The test whose performance is being evaluated.
Locoregional metastases Metastasis (spread) of a cancer only within the region in which it arose.
Lymph node An organ of the immune system that filters foreign particles and bacteria from lymph fluid.
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xvii
Meta-analysis Statistical techniques used to combine the results of two or more studies and obtain a
combined estimate of effect.
Metastatic disease The spread of cancer from one organ or body part to another organ or body part.
Polymerase chain reaction A technology used for amplifying deoxyribonucleic acid sequences.
Primary tumour A tumour growing at the anatomical site where tumour progression began.
Quality-adjusted life-year A measure of health gain, used in economic evaluations, in which survival
duration is weighted or adjusted by the patient’s quality of life during the survival period.
Quantitative reverse transcriptase-polymerase chain reaction The cloning of genes by reverse
transcribing the ribonucleic acid of interest into its deoxyribonucleic acid (DNA) complement through
the use of reverse transcriptase. Subsequently, the newly synthesised complementary DNA is amplified
using traditional polymerase chain reaction techniques and may be quantitatively measured using
fluorescent probes.
Receiver operating characteristic curve A graph which illustrates the trade-offs between sensitivity and
specificity that result from varying the diagnostic threshold.
Reference standard The best currently available diagnostic test against which the index test is compared.
Regional metastases The spread of cancer beyond the initial site to regional lymph nodes.
Reverse transcription loop-mediated isothermal amplification A technique to amplify messenger
ribonucleic acid directly from tissue lysates.
Sensitivity The proportion of people with the target disorder who have a positive test result.
Sentinel lymph node The first lymph node(s) to which cancer cells are likely to spread from a
primary tumour.
Specificity The proportion of people without the target disorder who have a negative test result.
Summary receiver operating characteristic plot or curve A diagram used to plot the results of studies
included in a systematic review of test accuracy. If a meta-analysis is performed it may include a summary
point or a summary curve or both.
Tissue allocation bias This occurs when tumour deposits exist in different portions of tissue, which are
separately allocated to the index and reference test.
True negative Correct negative test result – number of non-diseased persons with a negative test result.
True positive Correct positive test result – number of diseased persons with a positive test result.
GLOSSARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xviii
List of abbreviations
ALN axillary lymph node
ALND axillary lymph node dissection
B-CLOSER-I Breast Complete Lymphadenectomy
OSNA Study for Enhanced Review-I
CE Conformitée Européenne
CI confidence interval
CK19 cytokeratin-19
Cp crossing point
DCIS ductal carcinoma in situ
DES discrete event simulation
DNA deoxyribonucleic acid
DTA diagnostic test accuracy
EQ-5D European Quality of Life-5
Dimensions
ERG Evidence Review Group
FNAC fine-needle aspiration cytology
HEED Health Economic Evaluations
Database
HR hazard ratio
HRG Healthcare Research Group
HSROC hierarchical summary receiver
operating characteristic
ICER incremental cost-effectiveness ratio
ICTRP International Clinical Trials
Registry Platform
ITC isolated tumour cell
LN lymph node
MDT multidisciplinary team
mRNA messenger ribonucleic acid
NICE National Institute for Health and
Care Excellence
NPV negative predictive value
OSNA one-step nucleic acid amplification
PPV positive predictive value
QALY quality-adjusted life-year
qRT-PCR quantitative reverse transcriptase-
polymerase chain reaction
QUADAS Quality Assessment of Diagnostic
Accuracy Studies
RNA ribonucleic acid
ScHARR School of Health and
Related Research
SD standard deviation
SE standard error
SLN sentinel lymph node
SLNB sentinel lymph node biopsy
SROC summary receiver
operating characteristic
STARD Standards for the Reporting of
Diagnostic Accuracy Studies
TAB tissue allocation bias
TNM tumour, node, metastasis
VAT value added tax
WHO World Health Organization
YHEC York Health Economics Consortium
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Note
This monograph is based on the Technology Assessment Report produced for the National
Institute for Health and Care Excellence (NICE). The full report contained a considerable
number of data that were deemed academic-in-confidence. The full report was used by the
Appraisal Committee at NICE in their deliberations. The full report with each piece of
academic-in-confidence information (or data) removed and replaced by the statement
‘academic-in-confidence information has been removed’ is available on the NICE website:
www.nice.org.uk.
The present monograph presents as full a version of the report as possible while retaining
readability, but some sections, sentences, tables and figures have been removed. Readers
should bear in mind that the discussion, conclusions and implications for practice and research
are all based on the data considered in the original full NICE report.
LIST OF ABBREVIATIONS
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Scientific summary
Background
One of the key steps in the management of breast cancer is determining if there is spread to the axillary
lymph nodes (ALNs) from the main (primary) tumour.
Sentinel lymph node biopsy (SLNB) is first carried out at the same time as removal of the main tumour to
determine if there are regional metastases in the sentinel lymph nodes (SLNs), the first ALNs into which the
breast drains lymph. If there are any more than isolated tumour cells in the SLNs, complete axillary lymph
node dissection (ALND) is required because of the possibility that tumour cells have spread beyond the
SLNs into the other ALNs.
Whether the SLNB is positive or not is usually determined by histopathology – examining slides under a
microscope – after the operation to remove the primary tumour, and so there is a delay before an ALND is
performed, if required. If positivity of the SLNB could be established during the operation, intraoperatively,
ALND could be performed without delay, with potential benefits for the patient and the health service.
One-step nucleic acid amplification (OSNA) (Sysmex, Norderstedt, Germany) and Metasin (Cellular
Pathology, Princess Alexandra Hospital NHS Trust, Harlow, Essex, UK) are two types of test that claim to be
able to accurately diagnose regional metastases in the SLNs sufficiently quickly to be used intraoperatively.
OSNA is an automated molecular test in which genetic material (messenger ribonucleic acid, mRNA) is
amplified and the presence of the cytokeratin-19 (CK19) gene is detected. OSNA does not require the
mRNA to be extracted from the tissue and purified before being analysed. Minimal details are available for
the Metasin test, which detects the presence of CK19 and mammaglobin. However, for the Metasin test it
appears that ribonucleic acid (RNA) must be extracted from tissue, purified and quantified before nucleic
acid amplification and analysis.
The OSNA and Metasin tests could be used as a replacement for postoperative histopathology or as an
adjunct to it. If used as a replacement all of each SLN would be used in either the OSNA test or the Metasin
test intraoperatively; if used as an adjunct, half of each node would be used in either the OSNA test or the
Metasin test and half would be used for histopathology if the OSNA or Metasin test result was negative.
Tissue allocation bias (TAB) is a major challenge when evaluating OSNA and Metasin, particularly their
accuracy. The SLNs are divided between the test of interest (OSNA or Metasin) and the test with which
OSNA or Metasin is being compared (usually histopathology) and therefore tumour cells may be present in
only one of the sections. Apparent errors in identifying metastases may therefore not be the fault of the
test but rather a problem with sampling.
Objective
To evaluate the clinical effectiveness and cost-effectiveness of OSNA and Metasin, if used in the NHS in
England, for the intraoperative analysis of metastases in SLNs of breast cancer patients.
Methods
The assessment comprises a systematic review of clinical effectiveness and cost-effectiveness studies, a
review and critique of data supplied by the manufacturer and a de novo economic analysis.
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Clinical effectiveness systematic review
A systematic review was conducted to summarise the evidence on the clinical effectiveness of RD-100i
(OSNA) and Metasin for the intraoperative analysis of breast cancer metastases in SLNs. The search
strategy focused on the interventions specifically applied to lymph node diagnosis.
The following bibliographic databases were searched in this review: MEDLINE, MEDLINE In-Process & Other
Non-Indexed Citations and EMBASE (all via Ovid), Web of Science (including conference proceedings,
via ISI), The Cochrane Library (all) and the NHS Economic Evaluations Database (EED) (via The Cochrane
Collaboration). The searches did not use any form of limit (e.g. date).
The following trials registries were also searched: ClinicalTrials.gov, Current Controlled Trials, the World
Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and the European Union
Clinical Trials Register. The Google search engine (Google Inc., Menlo Park, CA, USA) was also used to
identify grey literature and conference publications. Items included after full-text screening were forward
citation chased using Web of Science (Thompson Reuters).
Critical appraisal was performed using the Cochrane risk of bias tool and the Quality Assessment of
Diagnostic Accuracy Studies (QUADAS-2) tool. Results were summarised in tables and text, stratified by
level of data (patient or node), node analysed (sentinel or axillary) and correction for TAB.
Cost-effectiveness systematic review
In addition to the electronic sources searched for the clinical effectiveness review, EconLit and the
bibliographies of relevant studies were searched for cost, cost-effectiveness and cost–utility studies of
intraoperative testing options for metastatic disease in early breast cancer.
Peninsula Technology Assessment Group cost-effectiveness analysis
The Peninsula Technology Assessment Group (PenTAG) model was split into two sections: the diagnostic
pathway and the management pathway.
The diagnostic pathway was a decision tree built to represent the diagnosis of regional metastases in the
SLNs. Three pathways were examined: current practice histopathology (the ‘gold standard’), replacement
testing of the full node by intraoperative testing and half-node intraoperative testing followed by
histopathology on the other half node.
In the diagnostic pathway, patients who were diagnosed with SLN metastases received ALND. For those
diagnosed intraoperatively this occurred during the same surgery as their SLNB; for those diagnosed by
histopathology this occurred during follow-up surgery.
Diagnostic accuracy was taken from the clinical effectiveness systematic review. For OSNA, studies were
split into those that included adjustment for TAB and those that did not include adjustment for TAB.
Patients incurred costs depending on their diagnostic strategy, their surgery, any additional hospital stay
and the occurrence of adverse events. The intraoperative test costs (OSNA and Metasin) were derived from
information provided by the technology sponsors. Costs for histopathology were taken from a previous
study based on data from the Queen Alexandra Hospital in Portsmouth. The costs of surgery were
obtained from NHS reference costs and from a previous microcosting study (York Health Economics
Consortium costs).
Short-term disutility for patients waiting for results or undergoing a second operation was investigated.
The management pathway was concerned with lifetime results and used an updated version of a
previously published discrete event simulation model that followed individual patients through a series of
health states, calculating their accrued costs and quality-adjusted life-years (QALYs) according to their
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different outcomes in the diagnostic pathway and, consequently, management pathway. The sum of the
short- and long-term costs and QALYs gave the overall lifetime costs and QALYs.
Most parameters for the management model were taken from the original report of the model published
in 2011, with costs updated when new reports were found, and reflating all costs to 2010 prices.
Sensitivity analysis adopted the range of sensitivity and specificity values identified by the clinical
effectiveness systematic review. In addition, the prevalence of SLN metastases was varied from 20%
(from the clinical effectiveness systematic review) to 10% and 40%. Costs of tests and surgeries and
management costs were varied by plus or minus 10%.
Results
Clinical effectiveness systematic review
Seventeen studies were included that investigated the performance, particularly test accuracy, of either
OSNA or Metasin for detecting metastases in the SLNs or ALNs of breast cancer patients. Two of the
studies reported on Metasin; however, both were unpublished and reported in draft form. The remaining
15 studies reported on OSNA, with one study reported in two papers.
The majority of studies were considered to be at low risk of bias, although many were considered to have
an unclear risk of bias with regard to their method of patient recruitment and patient characteristics.
No data were found for clinical outcomes such as patient anxiety and number of repeat operations.
Only one study provided evidence on time spent in the operating theatre.
In accuracy studies the reference standard (i.e. histopathology), although plausible, may be performed with
varying levels of analysis and, as such, it may not be a true indicator of the target condition.
The main issue within the included studies has been TAB. Some studies have dealt with this by reanalysing
both the histopathology and the molecular samples or by choosing to reanalyse just one technology.
It should also be noted that more than one SLN may be removed from a patient, which means that results
for a study may be presented by patient or by individual node or by both. There is also a potential conflict
of interest as one of the two unpublished Metasin studies was performed at the institution in which the
technology was developed and the majority of the OSNA studies were financially supported by Sysmex,
the company that manufactures OSNA.
All accuracy studies implicitly assumed that the reference standard, histopathology, is a true measure of
the target disorder.
The pooled OSNA patient node status sensitivity was 84.5% [95% confidence interval (CI) 74.7% to
91.0%] and its specificity was 91.8% (95% CI 87.8% to 94.6%), based on five available studies including
a total of 991 subjects. As only two studies reported on Metasin, a meta-analysis was not performed.
As these data were taken from draft papers, before peer review, the results, which indicate an increased
sensitivity and specificity relative to OSNA results, must be used with caution.
Some studies adjusted for TAB, generally taking a conservative approach by excluding affected samples.
This does improve the test accuracy, increasing sensitivity from 84.5% to 91.3% (95% CI 83.6% to
95.6%, with the SLN as the unit of analysis) and increasing specificity from 91.8% to 94.2% (95% CI
91.2% to 96.2%), based on three reports and 453 subjects.
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With regard to the time taken to perform OSNA, there was a lack of detail in the studies explaining which
aspects of the procedure were monitored. However, the time reported ranged from < 30 minutes to
39.6 minutes for one node. This increases by approximately 5–10 minutes per additional node analysed.
Cost-effectiveness systematic review
Two studies of the diagnostic phase were identified by the searches. One was a study of OSNA conducted
in one centre in Spain, which did not measure benefits to patients. The other study evaluated a diagnostic
testing option in the UK that has been withdrawn from the market (GeneSearch BLN assay; Veridex,
Warren, NJ, USA) and is therefore no longer relevant for the present evaluation. Therefore, a de novo
analysis was justified.
Independent Evidence Review Group assessment
In the base case, short-term results show that, in general, half-node OSNA was not cost-effective in terms
of cost per patient correctly diagnosed, cost per node-positive case detected or cost per node-negative
case detected. In all cases in which half-node OSNA was dominated or extendedly dominated, the cost per
additional diagnostic yield of histopathology compared with full-node OSNA was < £17,000. These results
were insensitive to setting the sensitivity and specificity of OSNA equal to TAB-adjusted values.
Long-term results revealed that histopathology resulted in more QALYs at a lower cost per QALY than
half-node OSNA when both were compared with full-node OSNA. The incremental cost-effectiveness ratio
(ICER) of histopathology relative to full-node OSNA was < £5000 per QALY gained, for both costing
strategies. When diagnostic test accuracy parameter values in the model were adjusted for TAB, half-node
OSNA remained extendedly dominated, except for TAB-adjusted diagnostic test accuracy values reported
by Snook et al. using NHS reference costs, which resulted in an incremental cost of £8063 per QALY
gained for half-node OSNA relative to full-node OSNA (Snook KL, Layer GT, Jackson PA, de Vries CS,
Shousha S, Sinnett HD, et al. Multicentre evaluation of intraoperative molecular analysis of sentinel
lymph nodes in breast carcinoma. Br J Surg 2011;98:527–35). Using TAB-adjusted values reported by
Snook et al., histopathology compared with full-node OSNA had ICERs of < £10,000 per QALY gained
using NHS reference costs or York Health Economics Consortium costs (Snook et al. 2011). However,
when values from the study by Khaddage et al. were used, full-node OSNA dominated both half-node
OSNA and histopathology under both costing scenarios (Khaddage A, Berremila SA, Forest F, Clemenson A,
Bouteille C, Seffert P, et al. Implementation of molecular intra-operative assessment of sentinel lymph
node in breast cancer. Anticancer Res 2011;31:585–90).
The long-term ICERs for histopathology compared with full-node OSNA remained at < £20,000 per QALY
gained for all values of sensitivity up to 95% and the ICER was £8430 per QALY gained when OSNA had
100% specificity.
Sensitivity analysis was also conducted on the effect of the prevalence of SLN metastases in the patient
population. This showed that the lower the prevalence the more attractive histopathology is.
Probabilistic analysis showed that, when comparing full-node OSNA with histopathology, the former has
less than a one in three probability of being cost-effective. This result was obtained by combining all of the
available accuracy estimates from the three studies that adjusted for TAB. This finding was driven by
the studies of Le Frère-Belda et al. and Snook et al., which contributed 88% of all patients with available data
(Le Frère-Belda MA, Bats AS, Gillaizeau F, Poulet B, Clough KB, Nos C, et al. Diagnostic performance of
one-step nucleic acid amplification for intraoperative sentinel node metastasis detection in breast cancer
patients. Int J Cancer 2012;130:2377–86; Snook et al. 2011).
Altering individual costs and utility parameter values in both sections of the model had very little impact on
overall cost-effectiveness results.
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Results for Metasin were provided on a purely illustrative basis as the only values available for the
sensitivity and specificity of Metasin are unpublished and have not been peer reviewed.
Conclusions
The evidence base for OSNA and Metasin is restricted to studies on their test accuracy (sensitivity and
specificity) relative to a reference standard of histopathology. All other conclusions are based on the
predictions of a health economic model in a linked-evidence approach.
One-step nucleic acid amplification and Metasin appear to be effective in reducing the number of separate
second ALND operations, which leads to cost-savings and benefits to patients. However, this is at the
expense of diagnostic errors, both false negatives and false positives.
Overall, the cost-effectiveness evidence on OSNA is inconclusive. The evidence on Metasin is incipient
and may only be suggestive. In general, the potential long-term benefits of increased accuracy with
histopathology more than compensate for its disadvantage in terms of expediency of test results, but such
balance is sensitive to how different studies address the issue of TAB.
The available evidence suggests that full-node OSNA is not cost-effective relative to histopathology.
The only study that contradicts this assertion (that by Khaddage et al. 2011) represents only 11% of the
total study subjects for whom robust evidence exists.
Exploratory analyses clearly suggest that the cost-effectiveness of intraoperative testing is inversely related
to the node-positive prevalence rate. Therefore, improvements in the detection of node-positive cases
before the first operation for newly diagnosed breast cancer will make the cost-effectiveness of
intraoperative testing less likely.
Suggested research priorities
Devoting resources to generating peer-reviewed published research evidence on the test accuracy of
Metasin, the costs of alternative tests and the variation in resource utilisation across individual patients is
warranted by current limitations in our knowledge on the value of diagnostic approaches in early breast
cancer. Observational studies may seek to test and quantify empirically the claimed reductions in the
numbers of operations, the anxiety experienced by patients who await test results, the quality of life lost
as a result of a second operation and the costs to hospitals that are associated with the introduction of
intraoperative testing in SLNB.
A key assumption in the report is that ALND is the usual best treatment if micro- and macrometastases are
identified in a SLNB. Evidence on this is evolving and needs to be followed closely as it could impact on
decisions about intraoperative testing in SLNB in the future.
Study registration
This study is registered as PROSPERO CRD42012002889.
Funding
The National Institute for Health Research Health Technology Assessment programme.
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Chapter 1 Background
Nature of the disease
Breast cancer affects the breast tissue of either women or men, although breast cancer in men is relatively
uncommon. In breast cancer, cells making up the breast begin to divide in an uncontrolled manner
forming tumours. Initially they are confined within the structures of the breast where the cells would
normally occur and the tumour is referred to as ductal carcinoma in situ (DCIS). Later the cells become
locally invasive extending into parts of the breast and surrounding tissue where they would not normally
occur. The breast cancer cells also enter the lymph drainage system, which leads to breast cancer cells
lodging and growing in lymph nodes (LNs), particularly those in the armpit – the axillary lymph
nodes (ALNs). These are called regional metastases. ALNs containing local metastases can vary from a
near-normal size of ≤ 0.5 cm in length to a greatly enlarged, 4 cm in length.
In addition, breast cancer cells can enter the bloodstream from where they can spread to distant parts of
the body such as the lungs, bones and the liver. These are called distant metastases. Without treatment
the proliferation of the breast cancer cells and their spread around the body leads to death. The reasons
why breast cancer develops are not completely understood, although genetic predisposition has been
increasingly recognised as a contributing factor in a minority of women.1
Breast cancer is a very important challenge to health. Each year in England2 and Wales3 approximately
40,000 individuals develop breast cancer. As illustrated in Table 1, the majority of these are women aged
> 40 years. Breast cancer is responsible for >10,000 deaths each year in England and Wales,4 although the
mortality rate has been declining from a peak in the mid-1980s (Figure 1). Breast cancer is the most
commonly occurring female cancer and the second most common cause of cancer death after lung cancer,
accounting for one in six of all female cancer deaths. Approximately one in nine women will develop
breast cancer at some stage of their life.
Staging of breast cancer
There is a well-defined system for recording the severity and extent of the spread of breast cancer.
This is called the TNM (tumour, node, metastasis) classification and is based on tumour size, spread to LNs
and presence of distant metastases5–8 (Tables 2 and 3).
Increasing size of the main tumour and spread to ALNs are two of the key features denoting worsened
stage. The presence of distant metastases denotes the worst stage IV, irrespective of the size of the main
TABLE 1 Breast cancer incidence (number of new cases) for England and Wales, 2010
Population
and country
Age (years)
10–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+ Total
Women, Walesa 90 133 241 278 280 358 357 219 262 184 223 2625
Women, Englandb 1798 2528 4164 4637 4005 5618 5009 3430 3492 3073 3505 41,259
Men, Walesa 0 0 0 0 4 1 2 5 0 2 1 15
Men, Englandb 7 11 11 19 30 37 47 59 47 48 37 353
Total 1895 2672 4416 4934 4319 6014 5415 3713 3801 3307 3766 44,252
a Welsh Cancer Intelligence and Surveillance Unit. Cancer Incidence in Wales 2006–2010. Cardiff: Public Health
Wales; 2012.
b Office for National Statistics.2
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FIGURE 1 Age-standardised rates for female breast cancer mortality in the UK, 1971–2010.4 Reproduced with
permission from Cancer Research UK. URL: www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/
mortality/uk-breast-cancer-mortality-statistics#trends (accessed 5 August 2014).
TABLE 2 Description of TNM stages
Stage Description
T: tumour stage
Tx Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour ≤ 2 cm across
T2 Tumour > 2 cm to 5 cm across
T3 Tumour > 5 cm across
T4 Tumour of any size with direct extension to skin or chest wall, or inflammatory breast cancer
N: LN stage
Nx Nodal stage cannot be assessed
N0 No metastases to any ipsilateral LNs
N1 Metastases to one to three axillary nodes or axillary nodes that are mobile
N2 Metastases to four to nine axillary nodes or axillary nodes that are fixed to one another or other structures or
clinically apparent metastases to internal mammary nodes
N3 Metastasis to nodes above or below the collarbone (supraclavicular/infraclavicular) or to both axillary and internal
mammary nodes, or to 10+ axillary nodes
M: metastasis stage
Mx Presence of metastases cannot be assessed
M0 No distant metastases
M1 Distant metastases
Source: redrawn from Cooper et al.9
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tumour or spread to regional LNs. The majority of patients present with stage I or stage II cancer, as
illustrated in Table 4.10 These figures, combined with information on how tumour size inter-relates with
nodal status, suggest that in the UK 33% of patients present with spread to LNs.11 This agrees with a
systematic review12 including 13 studies undertaken to inform the National Institute for Health and Care
Excellence (NICE) clinical guideline13 on early and locally advanced breast cancer, which reported a mean
prevalence of LN-positive status of 31.4%, with a range of 18–59%. Other sources have suggested a
higher value of 41% for the percentage of patients presenting with spread to LNs.9
By definition, early breast cancer is cancer that has not spread beyond the breast or the ALNs on the same
side as the tumour, that is, stages I (any), II (any) or IIIA.
Recent modifications to the staging system for breast cancer also recognise the size of the local metastases
in the LNs. Macrometastases are defined as tumour deposits in which one dimension is > 2mm.
Micrometastases, deposits that are only discernible microscopically, measure > 0.2 mm with no dimension
being > 2mm. Isolated tumour cells (ITCs) are also recognised as part of the N0 category and by definition
no dimension of any collection of ITCs must exceed 0.2mm.
TABLE 3 Summary of TNM stages
Stage T N M
0 (DCIS/LCIS) Tis N0 M0
I T1 N0 M0
IIA T0–1 N1 M0
T2 N0 M0
IIB T2 N1 M0
T3 N0 M0
IIIA T0–2 N2 M0
T3 N1–2 M0
IIIB T4 N0–2 M0
IIIC T (any) N3 M0
IV T (any) N (any) M1
LCIS, lobular carcinoma in situ; M, metastasis; N, lymph node; T, tumour; Tis, tumour in situ.
Source: redrawn from Cooper et al.9
TABLE 4 Proportions of breast cancer patients by stage among east of England residents, 2006–9
Stage n % among all patients
% among patients
with known stage
I 6788 38 41
II 7361 41 45
III 1490 8 9
IV 821 5 5
Unknown 1376 8 N/A
All (excluding unknown) 17,836 (16,460)
N/A, not applicable.
Source: Lyratzopoulos et al.10
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Prognosis
With early identification and treatment the outlook for patients with breast cancer is good. The overall
5-year survival rate is approximately 80%.14 The survival rate varies with age, with patients aged > 80 years
having survival rates of < 80%, as shown in Table 5.
Stage also influences survival, as shown in Table 6. In women diagnosed with breast cancer in the West
Midlands between 1985 and 1989 and followed up until 1999, the 5-year survival rate was 88% for stage
I, 69% for stage II, 43% for stage III and 12% for stage IV.15 This pattern is maintained in data from the
National Cancer Data Base in the USA for patients who were diagnosed in 2001 and 2002.16
In addition to age, tumour size and spread, prognosis is also related to tumour grade and receptor status.
With respect to the latter, positive oestrogen receptor status and positive progesterone receptor
status denote better prognosis and overexpression of human epidermal growth factor 2 denotes poorer
prognosis. These additional factors are incorporated into tools to estimate prognosis, such as the
Nottingham Prognostic Index17 and Adjuvant! Online,18 which are used to guide treatment, particularly
the use of adjuvant chemotherapy in early breast cancer. The effectiveness and cost-effectiveness of gene
expression profiling and expanded immunochemistry tests to enhance the Nottingham Prognostic Index17
and Adjuvant! Online18 are currently under consideration by the NICE Diagnostic Assessment Committee.19
The implications for the prognosis of micrometastases compared with macrometastases are currently
unclear, but micrometastases are counted as local metastasis and are treated in a similar manner to
macrometastases (see Clinical pathway for staging of breast cancer and subsequent surgery to the axilla
and Other approaches to treating the spread of breast cancer tumour cells beyond the sentinel lymph
nodes). In contrast, ITCs are not currently counted as local metastasis and they are assumed to have a
similar prognosis to no LN metastases (N0).20
Management of disease
General clinical pathway for suspected breast cancer
The tests and treatment advised for patients with suspected breast cancer are outlined in the NICE clinical
guideline on early and locally advanced breast cancer.13 This is summarised as an algorithm and
reproduced in Figure 2.
TABLE 5 Five-year survival rates for female breast cancer according to age in England, 2005–9
Age (years)
15–39 40–49 50–59 60–69 70–79 80–99 All ages
5-year survival rate (%) 84 89 90 90 81 69 85
Source: www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/survival (accessed 4 January 2013).
TABLE 6 Five-year survival rates (%) according to stage of disease
Data source
Stage of disease
I
II III
IVIIA IIB IIIA IIIB IIIC
UKa 88 69 43 12
USAb 88 81 74 67 41 49 15
a From West Midlands Cancer Intelligence Unit.15
b From American Cancer Society.16
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FIGURE 2 Clinical pathway for breast cancer. a, Following the publication of the Cancer Reform Strategy,21 by
December 2009 all patients presenting with breast problems and referred by their general practitioner to a
specialist should be seen within 2 weeks in England. b, Include repeat core biopsy/open biopsy/magnetic resonance
imaging, etc. c, Not all patients will require staging.22 d, For elderly or unfit patients, surgery may not be
appropriate. For locally advanced but not metastatic cancer, primary systemic therapy precedes therapeutic surgery
in order to reduce the size of the tumour. e, Could include breast conservation (wide local incision), mastectomy
and axillary staging (SLNB, sampling or clearance). FNAC, fine-needle aspiration cytology; MDT, multidisciplinary
team. Source: National Institute for Health and Care Excellence.13
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In the initial assessment, anyone suspected of breast cancer, whether through primary care or through the
breast screening programme, is referred to an assessment clinic where the clinical examination is repeated,
mammography and ultrasound are undertaken and a biopsy of the lesion(s) is performed (usually a core
biopsy). Ultrasound of the axilla is performed and further biopsies of suspicious LNs are taken (fine-needle
aspirations or core). A multidisciplinary team (MDT) meeting considers the results from these investigations
and makes a definitive recommendation regarding proposed management to discuss with the patient.
If breast cancer is detected, surgery is usually performed to remove the cancer unless neoadjuvant therapy
is considered appropriate. Staging of the axilla is performed in cases of invasive breast cancer in the
manner described in the next section. All findings, including the pathology of the removed tumour and
the results of any staging procedures, are then discussed at a further MDT meeting where decisions
are made about further surgery and whether adjuvant hormone therapy, chemotherapy, immunotherapy
or radiotherapy is required.
Clinical pathway for staging of breast cancer and subsequent surgery to
the axilla
The detailed steps for investigating if a suspected breast cancer has spread to the axilla and the degree
of that spread are also outlined in the NICE guideline.13 These are summarised in Figure 3.
Further information on key steps in this pathway is given in the following sections.
Four different scenarios are recognised depending on the findings of the initial assessment:
(a) Likely DCIS. Provided axillary ultrasound reveals no abnormalities and the patient is not considered
high risk, no further investigations of the axilla are undertaken.
(b) Likely invasive breast cancer with negative axillary ultrasound (no abnormal LNs identified). In these
patients, at the time of the surgical removal of the main breast tumour, a sentinel lymph node biopsy
(SLNB) is undertaken. In a SLNB a weakly radioactive solution and a blue dye are injected into the
breast before surgery to identify the first LN(s) to which the breast drains lymph in a particular
individual. The sentinel lymph nodes (SLNs) become blue and/or can be detected using a radioactivity
counter. They are most frequently found in the axilla of the same side. These SLNs are then removed
to determine if the cancer has spread from the original site. This is carried out by histopathology,
Invasive breast cancer
Ultrasound – 
Further treatment (if required) and follow up
Assessment clinic
Main tumour biopsy
DCIS
Ultrasound +
Fine-needle aspiration +
Surgery to remove
tumour
Surgery to remove
tumour and perform
axillary lymph
node dissection
Ultrasound – 
Ultrasound +
Fine-needle aspiration –
Sentinel lymph
node biopsy –
Sentinel lymph
node biopsy +
Axillary lymph
node dissection
Surgery to remove tumour and perform
sentinel lymph node biopsy
and contingent
axillary lymph node dissection
FIGURE 3 Clinical pathway for staging of breast cancer and subsequent surgery to the axilla. –, negative; +, positive.
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which involves cutting very thin slices of the SLNs, staining them and then a medically qualified specialist
carefully examining them under a microscope. Histopathology takes several days and sometimes further
investigations are required for a definitive diagnosis, for example immunohistochemistry. If no breast
cancer cells meeting the criteria for metastasis or single ITC are found in the SLN(s) no further action
needs to be taken. However, if the breast cancer has spread to the SLNs, all of the relevant LNs in
the axilla need to be removed in a further operation called axillary lymph node dissection (ALND).
This provides treatment by removing all of the tumour cell-bearing LNs and others within a defined
anatomical boundary and it provides detailed staging information by allowing the number of LNs with
metastases to be precisely quantified, as the LNs removed are subjected to further histopathological
examination. Occasionally, a SLNB cannot be undertaken. In this case four-node sampling, in which
four LNs are removed and examined without specific evidence that they are the SLNs, may be performed
instead to provide further information.
(c) Likely invasive breast cancer with positive axillary ultrasound but normal ultrasound-guided fine-needle
aspiration cytology (FNAC). At the time of the surgical removal of the main breast cancer a SLNB is
undertaken, followed by the same actions as in (b) if cancer is not found or is confirmed to have
spread to the SLNs.
(d) Likely invasive breast cancer with positive axillary ultrasound and confirmed abnormality on
ultrasound-guided FNAC. In this case the patient would proceed directly to ALND without
undergoing a SLNB.
The preference in NICE guidance for the use of a strategy employing ultrasound and FNAC to triage the
need for a SLNB was underpinned by a model-based cost-effectiveness analysis undertaken as part of
the preparation of the NICE clinical guideline on early and locally advanced breast cancer.13
Accuracy of clinical examination
Clinical examination of the axilla involving palpation is subject to error as a method of detecting the spread
of breast cancer to the ALNs. The sensitivity of the technique has been estimated as 46% based on
pooling of a number of studies.24–29 The fact that over half of axillary metastases are not detected by
palpation is the reason why additional investigations are required. The main reason why palpation is
unsuccessful is often because the presence of metastases does not always lead to a change in size or
texture of the ALNs, coupled with the fact that the ALNs are not always easy to examine.
Accuracy of ultrasound-guided fine-needle aspiration cytology
Like palpation, ultrasound and FNAC are imperfect techniques. Their accuracy was considered in detail
as part of the NICE clinical guideline on early and locally advanced breast cancer (guidance 1.1.3 on
preoperative staging of the axilla13 and section 2.2, pages 77–8, of the evidence review report12).
The key facts identified were:
l LNs can be visualised by ultrasound in 81% of cases, although there is considerable variation.
l Using LNs that were suspicious on ultrasound based on their size (>5mm) and configuration as the
diagnostic criteria, sensitivity was 69% and specificity was 75% when patients with palpable and
non-palpable ALNs were combined. The accuracy was improved when cases with palpable LNs only
were included and was worse when cases with non-palpable LNs were included.
l The staging performance of ultrasound-guided FNAC was a sensitivity of 43% and a specificity of
100%, with an accompanying positive predictive value (PPV) of 99% and a negative predictive value
(NPV) of 72%.
Accuracy and adverse effects of axillary lymph node dissection
Axillary lymph node dissection, described earlier, has been considered the ‘gold standard’ procedure for
staging the axilla. It is very accurate in establishing the presence of axillary disease and has the therapeutic
advantage of being associated with a high long-term local disease control rate.9
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However, ALND is associated with significant complications, including a 21% incidence of arm
lymphoedema (general swelling),29–31 a 22% incidence of seromas (pockets of fluid under the skin)29,32
and a 14% infection rate.29,33 In addition, insertion of a surgical drain during surgery is commonplace
(79%) and usually necessitates prolongation of hospital stay.33 Pain, limited mobility, numbness and
sensory loss are also common. In total, 80% of women are claimed to suffer some adverse event.34 It is
for these reasons that there has been a focus on performing ALND for its therapeutic effects, applicable in
patients with the spread of breast cancer to the ALNs, rather than as a more widely applied
diagnostic tool.
Accuracy and adverse effects of sentinel lymph node biopsy
Sentinel lymph node biopsy, described earlier, although still a surgical procedure of the axilla, is much
simpler than ALND and is associated with a much lower rate of side effects. Thus, the incidence of
lymphoedema falls to 7%,35 seroma to 7%29,32 surgical drain requirement to 2%33,36 and infection
incidence to 2%.29,33,36
Sentinel lymph node biopsy was considered in detail as part of the NICE clinical guideline on early and
locally advanced breast cancer (guidance 1.4.1–1.4.4 on surgery to the axilla, invasive breast cancer,13
and section 3.3, pages 308–10, of the evidence review report12). The key features identified were:
l The overall SLN localisation rate was 96.4%.
l The pooled estimate of the false-negative rate was 7%, that is, sensitivity is 93%.
l The mean proportion of patients with positive SLNs was 42%.
l Patients treated by SLNB do not appear to have poorer rates of disease-free survival or overall survival,
or of axillary recurrence in the short term, than patients treated by axillary clearance employing ALND.
Challenge to measuring accuracy: tissue allocation bias
Accuracy indicates the degree to which a test of interest correctly identifies if a patient/sample
has the target disease (its sensitivity) or correctly identifies that the patient/sample does not have the
disease (its specificity), the true disease state being identified by applying a reference standard to all
patients/samples.
A challenge for measuring the accuracy of tests aiming to identify if breast cancer has spread to ALNs is
that the tumour cells are not evenly distributed throughout the LN. Further, the tests of interest often
consume the LN so that once it has been used for one test it cannot be used by another, necessitating that
the sample be partitioned if multiple tests are to be carried out. Thus, apparent errors in accuracy may be
introduced not just because a new test truly fails to identify tumour cells that are present, but also because
the portion of the LN used in the test was not the portion that contained the tumour cells. This is referred
to as tissue allocation bias (TAB) or sampling bias, which can lead to underestimation of sensitivity when
the portion allocated to the new test does not contain the tumour cells. This is illustrated in Figure 4.
Underestimation of specificity can also occur if the new test is allocated a portion of the LN containing
tumour cells and the reference standard is allocated the portion without the tumour cells.
The impact of TAB needs careful consideration both in the context of the particular new technologies
under consideration and because histopathology is a commonly used reference test and it is itself affected
by TAB as the portion of the LN submitted to histopathology may not contain the tumour cells. This is
further complicated by the fact that histopathology examines only a finite number of the slices in the
portion of the LN allocated to it, which, even though likely to be equally spaced throughout the LN portion,
do not represent all of it.
The implications of TAB are revisited later in this chapter and throughout the report.
BACKGROUND
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
Other approaches to treating the spread of breast cancer tumour cells
beyond the sentinel lymph nodes
The current management indicated above, particularly that micrometastases and macrometastases in the
SLNs should be followed by ALND, is based on the consensus at the time the current NICE guideline on
the subject was published in 2009.
Pre-eminently this has been precipitated by the results of a randomised controlled trial comparing ALND
with no ALND in women with invasive breast cancer and SLN spread – the American College of Surgeons
Oncology Group Z0011 trial.37 The participants were adult women with histologically confirmed invasive
breast cancer with a clinical size of ≤ 5 cm, no palpable adenopathy and a SLN metastatic breast cancer
documented by frozen section, touch preparation or haematoxylin–eosin staining on permanent section.
They were ineligible if they had three or more positive SLNs, matted nodes or gross extranodal disease or if
they had received neoadjuvant hormonal therapy or chemotherapy. In total, 445 women were randomly
allocated to ALND following SLNB and 446 were randomly allocated to no ALND following SLNB, although
this number of participants was well below the target for recruitment (total of 1900). At a median
follow-up of 6.3 years, 5-year overall survival was 91.8% with ALND and 92.5% without ALND. This is
equivalent to an adjusted hazard ratio (HR) of 0.87 [95% confidence interval (CI) 0.62 to 1.23]. At the
same follow-up, 5-year disease-free survival was 82.2% with ALND and 83.9% without ALND. This is
equivalent to an adjusted HR of 0.88 (95% CI 0.65 to 1.25). The conclusion was that, among patients
with limited SLN metastatic breast cancer treated with breast conservation and systemic therapy, the use of
SLNB alone compared with SLNB and ALND did not result in inferior survival. Although the lack of power
of the study and the limited radiotherapy quality assurance are important provisos, it does explain why
there is growing caution about the use of ALND when the amount of spread to the SLNs is limited and
women are also likely to receive adjuvant therapy.
In addition to possible changes in the use of ALND, there is also debate about the role of axillary
irradiation as an alternative to ALND when SLNB is positive. Currently there are no prospective data to
guide indications for axillary irradiation in the absence of ALND. The results of the ongoing AMAROS
(After Mapping of the Axilla, Radiotherapy or Surgery?) trial38 comparing axillary irradiation with ALND
after SLNB are awaited. In the absence of level 1 evidence, pragmatic recommendations for locoregional
Disease-positive LN
Tumour cells
LN split 
into four portions
Two portions allocated to the 
new test – no tumour 
cells detected because no 
tumour cells present in 
allocated portions
New test
Two portions allocated to 
the reference test contain  
tumour cells which are 
detected
Tissue allocation or 
sampling bias results in 
the new test apparently 
‘missing’ a disease- 
positive LN
Reference
test
FIGURE 4 Diagram illustrating the effect of TAB or sampling bias.
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irradiation have been suggested.39 It may be appropriate, for example, to consider axillary irradiation
after SLNB for patients with low-volume macrometastases (one to two positive nodes) or high-risk
micrometastases. It should be noted that there are no data on the role of axillary irradiation after a
positive sentinel node analysed by one-step nucleic acid amplification (OSNA) or equivalent technologies.
Description of the technologies under assessment
Rationale
One of the problems with current practice with respect to investigating whether breast cancer has spread to
the ALNs is the need to wait for the histopathology results from the SLNB indicating whether or not spread
has occurred. Thus, if spread to the ALNs has occurred, there is inevitably a delay before performing ALND
relative to a situation in which excision of the suspected breast cancer and ALND could be carried out in one
operation. Also, the individual must be admitted to hospital, receive an anaesthetic and be operated on for
a second time. The ALND itself may be more difficult because of the recent previous operation and, as a
result, complication rates may be higher than if the ALND immediately followed the SLNB. Adjuvant
treatments, if required, may also be delayed.
Two new methods of examining LNs removed in SLNB intraoperatively, similar in approach, have been claimed
as ways to achieve SLNB followed immediately by ALND when required, avoiding any delays and a second
operation. However, the new methods may limit the opportunity for a MDT to consider the appropriateness of
ALND, taking account of all of the information that could potentially be available at the time of the second
operation under current practice, unless each possible outcome has been discussed preoperatively.
One-step nucleic acid amplification
The RD-100i OSNA system (henceforth referred to as OSNA) (Sysmex, Norderstedt, Germany) is an
automated molecular test that uses OSNA technology. The test analyses and amplifies genetic material
(messenger ribonucleic acid, mRNA) from solubilised biopsy samples of SLN tissue and detects the presence
of the cytokeratin-19 (CK19) gene, a biological marker associated with breast cancer and not normally
present in LN tissue. It is claimed that OSNA will provide a result within a short time and can therefore be
used during breast surgery to determine whether other LNs should be removed at the same time as the
initial tumour.
One-step nucleic acid amplification does not require the mRNA to be extracted from the tissue and
purified before being analysed. The expression level of CK19 mRNA correlates with the size of the
LN tumour cell foci. As the foci may not be evenly distributed throughout the node, the system provides
more accurate results if more of the node is analysed because there is less risk of TAB (sample bias).
The result is most accurate if the entire node is used but in this case no follow-up histopathology is
possible. The system can be used with half of the LN (one piece or alternate slices), allowing for the
possibility of follow-up histopathology but potentially decreasing the accuracy of the results because
of the increased risk of TAB. The time to receive results is dependent on the number of LNs analysed,
but the test takes approximately 30–45 minutes. This includes the time to prepare the LNs, dissect
them out and trim away fat, solubilise them and run the test. The OSNA test result is expressed both
quantitatively and qualitatively; – for LN-negative test results, + for LNs with a micrometastatic tumour
burden (> 250 copies of CK19 mRNA/µl) and ++ for LNs with a macrometastatic tumour burden
(> 5000 copies of CK19 mRNA/µl). Thus, 250 copies of CK19 mRNA/µl is the threshold or cut-off level
defining the tumour load in the SLNs, above which further treatment with ALND is triggered.
The analyser amplifies and detects the CK19 mRNA by using six different primers that have been
specifically designed to avoid the amplification of CK19 pseudogenes or their transcripts; amplification
of these would lead to false-positive results. Undesired amplification of genomic deoxyribonucleic acid
(DNA) is avoided by precipitation of DNA at low pH during sample preparation and by using an isothermal
reaction temperature of 65°C.
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The manufacturer estimates that 1% of breast tumours do not express CK19 mRNA and therefore,
if cancer spreads to the LNs from these tumours, CK19 mRNA will not be detected even though the LNs
are metastatic. Prescreening of tumour biopsies for CK19 expression could be carried out before using the
OSNA test to reduce the small risk of false-negative results for SLNs with actual tumour cell foci.
A (Conformitée Européenne) CE mark has been obtained for this technology.
Metasin
The Metasin test is an intraoperative molecular test developed within the NHS at the Princess Alexandra
Hospital in Harlow, Essex. The claims for its effect on the management of patients with breast cancer are
similar to those for OSNA. The test has similarities to a discontinued commercial test (GeneSearch BLN
assay; Veridex, Warren, NJ, USA) and uses the technique of quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR) to detect two predictive markers of metastases, CK19 and mammaglobin.
Mammaglobin is expressed mainly by breast epithelial cells and high levels are associated with breast
cancer. A reference gene, porphobilinogen deaminase (PBGD), is used to confirm the validity of the mRNA
used in the test and two other controls, positive and negative, are also included. The test uses reagents
that can be purchased from Roche and QIAGEN and can be used on any platform (PCR machine).
This in-house test differs from the discontinued commercial test by using distinctly different and unique
primer–probe combinations to detect the CK19 and mammaglobin genes. It is reported to take
6–10 minutes to extract and purify mRNA from the tissue followed by 26 minutes to obtain the
results of the test.
Although somewhat unclear, Metasin appears to be semiquantitative according to Sundaresan.40
The thresholds are calculated by crossing-point (Cp) values, the points at which the fluorescence from
the DNA-associated fluorescent probes increase above background during amplification. The values for
micrometastasis are quoted as Cp> 25 and < 32 for CK19 and Cp> 25.9 and < 32 for mammaglobin.
Presumably, the values for macrometastasis are above these ranges.
Prescreening of tumour biopsies for CK19 and mammaglobin mRNA expression could be carried out
before using the Metasin test because, like the CK19 biomarker, mammaglobin is not expressed in all
breast tumours. The proportion of breast cancer tumours that do not express mammaglobin mRNA is
not known.
A CE mark has very recently been obtained for this technology.
Proposed clinical pathway
Either OSNA or Metasin could be used as a replacement for current normal practice, in which case the
SLNs are used in their entirety. However, OSNA or Metasin could also be used adjunctively, in which
half of each LN (one piece or alternate slices) is used for OSNA or Metasin intraoperative testing and the
remaining half is examined using standard postoperative histopathology. Where the new tests have been
introduced in practice the first model is the most commonly followed as it maximises the claimed benefits
of the new technology.
The proposed clinical pathways are illustrated in Figures 5 and 6. This emphasises that changes to the
clinical pathway occur only in patients whose ultrasound is negative or in patients whose ultrasound is
positive but whose FNAC is negative.
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Invasive breast cancer
Ultrasound – 
Further treatment (if required) and follow-up
Assessment clinic
Main tumour biopsy
DCIS
Ultrasound +
Fine-needle aspiration +
Surgery to remove
tumour
Surgery to remove
tumour and perform
ALND
Ultrasound – 
Ultrasound +
Fine-needle aspiration –
Surgery to remove tumour
SLNs examined by
OSNA/Metasina
Immediate ALND if
OSNA/Metasin +
No immediate surgery if
OSNA/Metasin –
FIGURE 5 Proposed clinical pathway for staging of breast cancer and subsequent surgery to the axilla: OSNA or
Metasin used as a replacement for SLNB. a, In cases in which the OSNA/Metasin test does not provide a result or
provides a result that is uninterpretable, the OSNA/Metasin test would first be repeated using the remaining
solubilised LN. Failing this, four-node sampling could be carried out, followed by delayed ALND in the case of
positive LNs being identified in the sample or immediate ALND with the patient’s prior informed consent
for contingency.
Invasive breast cancer
Ultrasound – 
Further treatment (if required) and follow-up
Assessment clinic
Main tumour biopsy
DCIS
Ultrasound +
Fine-needle aspiration +
Surgery to remove
tumour Surgery to remove
tumour and perform
ALND
Ultrasound – 
Ultrasound +
Fine-needle aspiration –
OSNA/Metasin +b OSNA/Metasin –
SLN histopathology
Delayed ALN
 histopathology
Surgery to remove tumour
50% SLNs examined by
OSNA/Metasina
50% SLNs retained for histopathology
Immediate ALND if
OSNA/Metasin +
No immediate surgery if
OSNA/Metasin –
– +
FIGURE 6 Proposed clinical pathway for staging of breast cancer and subsequent surgery to the axilla: OSNA or
Metasin used adjunctively. a, In cases in which OSNA/Metasin does not provide a result or provides a result that is
uninterpretable, the OSNA/Metasin test would first be repeated using the remaining solubilised LN. Failing this,
histopathology is performed on the remaining 50% of the SLN. b, No histopathology is performed on the SLN if the
OSNA/Metasin test is positive. The ALND sample is still examined histopathologically as normal. –, negative; +, positive.
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Other technologies
There are two other pathological methods that can be used intraoperatively, frozen section and touch
imprint cytology. Frozen section involves a section of the LN being snap frozen, stained and sliced before
being viewed by a consultant histopathologist. Touch imprint cytology involves the LN being sliced
followed by the cut surface of the node being imprinted on to a slide, which is then stained and viewed by
a consultant histopathologist. Both intraoperative pathological methods can be used to determine if ALND
needs to be performed at the same time as the first surgery, and postoperative histopathology analysis is
usually carried out to reduce the risk of a false-negative result. However, in practice, these intraoperative
methods are rarely used because they have low accuracy and pathology resources are very limited within
the NHS.41
Measuring the accuracy of one-step nucleic acid amplification and Metasin
As already introduced earlier, one aspect of the evaluation of new tests is measuring their accuracy by
calculating their sensitivity and specificity. This requires specification of the best available method of
identifying the target condition of interest, the reference standard. In the case of the new technologies in
question the target condition is the true presence of breast cancer cells in the SLNs. The ideal reference
standard is thus histopathological examination of the SLNs in their entirety. However, practically this is
impossible because tissue is required by both the test of interest and the reference standard. This leads to
a compromise reference standard, with LNs split into several sections, often four, and alternate sections
being allocated to either the test whose accuracy is being evaluated or the reference standard. However,
as described earlier, this means that tissue allocation or sampling bias will operate, which needs to be
carefully considered when interpreting the results of test accuracy studies. This can include a careful
analysis of discrepant results to try to identify if sampling is a potential explanation for apparent
false-negative or false-positive results, recognising that there are other reasons for these. The limitations of
histopathology as a reference standard, given that all of the LN sample can never be examined because
of the finite number of slices that can be taken, are important among these.
Further, it is known that histopathological examination of SLNs has a false-negative rate relative to
examining all LNs removed in an ALND. Accepting the use of histopathological examination of SLNs as
the reference standard for OSNA and Metasin implies that these error rates of SLNB histopathology
are also suffered by the new tests of interest. Whether or not these errors could be avoided by the new
tests could theoretically be investigated by using ALND findings as the reference standard, but the ethical
considerations of exposing all OSNA-/Metasin-negative patients to the side effects of ALND greatly reduce
the acceptability of such an approach.
Implications for comparing the effectiveness and cost-effectiveness of one-step
nucleic acid amplification and Metasin with that of current practice
The following report needs to extend its assessment beyond the accuracy of the new tests of interest to
their impact on patients and the health service. In the situation in which there is no direct and rigorous
research evidence on whether introducing OSNA or Metasin will lead to improved patient outcomes, a
linked evidence approach using economic modelling is likely to be required. In this, the likely consequences
of errors in diagnosis are translated into outcomes. The estimates of sensitivity and specificity from
accuracy studies are generally used to capture the difference in error rates between the new tests and
current practice, so it is important that the use of the new tests in the accuracy studies is similar to the use
of the tests in practice and that the reference standard used in the accuracy studies is as close as possible
to that used in current diagnostic practice. The issues raised in the preceding section suggest that the
similarity between current histopathological practice and the reference standard in the accuracy studies
may require close attention. An immediate difficulty, however, is that what constitutes average current
practice with regard to histopathological examination of SLNs is difficult to define. As a consequence, it is
assumed that histopathology as typically performed in current practice is of the same standard as that used
by diagnostic research studies reviewed for the purpose of this report.
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Main potential consequences of using one-step nucleic acid amplification
and Metasin compared with current practice
Although based on claims that require substantiation (one of the main purposes of this study), the
previous background information suggests that the main anticipated effects of introducing intraoperative
OSNA or Metasin for those undergoing SLNB are:
l ALND will be performed as a single operation following immediately after primary tumour removal,
rather than as a separate second operation as in current practice.
l This in turn may lead to reduced anxiety in patients who no longer have to wait to find out if they
need a second operation and to a reduced time to adjuvant treatment, if this is required.
l The reduced time to ALND may, however, complicate the decision-making process of the MDT.
l There may be fewer adverse effects of ALND when it is performed immediately after primary tumour
removal than when it is performed later as a second operation.
l One rather than two operations may also lead to reduced hospital costs.
l There will be increased costs associated with OSNA or Metasin, which will be offset by reduced
histopathology costs when OSNA or Metasin are used as replacement tests.
l Any potential benefits of OSNA and Metasin will be offset if they introduce diagnostic errors, indicated
by either their sensitivity or their specificity being < 100%.
l If false negatives are introduced, women with macro- or micrometastases will be misidentified as
SLNB negative and will not undergo ALND, which may compromise their outcome with respect to
breast cancer.
l If false positives are introduced, women who are SLNB negative will be misidentified as having
macro- or micrometastases, with any resulting side effects but without any outcome benefits with
respect to breast cancer.
The economic model will need to attempt to capture all of the above potential consequences.
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Chapter 2 Definition of the decision problem
The question addressed by this health technology assessment is as set out in the final scope published byNICE and reproduced here for reader convenience.
A protocol was developed a priori by the authors to address the decision problem. The aspects
of this involving systematic review were registered on the PROSPERO website (registration
number CRD42012002889).
The methods used to address specific aspects of the decision problem are detailed at the beginning of
each of the relevant chapters that follow.
Decision question
Are the RD-100i OSNA system and any alternative technologies identified during scoping clinically effective
and cost-effective if used in the NHS in England?
Population
Individuals with invasive breast cancer who undergo a SLNB.
Intervention
l The RD-100i OSNA system using a whole-node sample.
l The RD-100i OSNA system using a half-node sample with postoperative histopathology confirmation.
Alternative diagnostic technologies
l The Metasin test using a whole-node sample (intraoperative in-house molecular test developed
at Princess Alexandra Hospital, Harlow, Essex).
l The Metasin test using a half-node sample with postoperative histopathology confirmation.
Comparators
Postoperative standard histopathology alone.
Health-care setting
Secondary and tertiary care settings.
Health outcomes
Clinical considerations
The intermediate measures for consideration include:
l diagnostic test accuracy (DTA)
l test failure rate
l discordant test results
l time to test result
l duration of anaesthesia.
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The clinical outcomes for consideration include:
l patient anxiety associated with waiting time for results and not knowing the extent of surgery before
the operation
l the number of repeat operations (except for re-excision of positive margins)
l time in operating theatre
l time to start of and nature of adjuvant therapy
l morbidity and mortality from biopsies, axillary dissections, first and second operations and treatment
of cancer
l adverse events from false test results including patient distress and sequelae.
Data on these outcomes are likely to be used along with clinical utility scores to estimate quality-adjusted
life-years (QALYs).
Cost considerations
The cost analysis will be based on the UK NHS setting and will comprise both NHS and Personal Social
Services costs.
The costs for consideration include:
l the costs of equipment, any additional tests (pre-screening), reagents and consumables
l staff and staff training costs
l equipment maintenance costs
l costs associated with surgeon time and the management of operating theatre time
l medical costs arising from ongoing care following test results, including those associated with surgery,
time spent in hospital and treatment of cancer
l medical costs arising from adverse events, including those associated with biopsies, surgery, cancer
treatment and false test results.
The cost of the hardware for the RD-100i OSNA system is approximately £70,000 [excluding
value-added tax (VAT)] The cost of consumables is approximately £150–250 per patient (excluding VAT).
This consumable cost is dependent on the number of tests performed per theatre day and the number of
patient samples tested. The maintenance cost is £6180 per annum (excluding VAT) following the expiry
of the 1-year warranty.
DEFINITION OF THE DECISION PROBLEM
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Chapter 3 Assessment of clinical effectiveness
Methods for reviewing clinical effectiveness
The diagnostic accuracy of the OSNA and Metasin tests was assessed by a systematic review of research
evidence. The review was undertaken following the principles published by the NHS Centre for Reviews
and Dissemination.42
Identification of studies
The following bibliographic databases were searched: MEDLINE, MEDLINE-In Process & Other Non-Indexed
Citations and EMBASE (all via Ovid), Web of Science (including conference proceedings, via ISI), The
Cochrane Library (all) and the NHS Economic Evaluations Database (EED) (via The Cochrane Collaboration).
The searches did not use any form of limit (e.g. date) and covered up to 2012, weeks 29–30 (see Appendix 1
for details).
The following clinical trials registries were also searched: ClinicalTrials.gov, Current Controlled Trials,
the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and the
EU Clinical Trials Register. The Google search engine (Google Inc., Menlo Park, CA, USA) was also used to
identify grey literature and conference publications.
Items included after full-text screening were forward citation chased using Web of Science
(Thompson Reuters).
Searches were deduplicated and managed using EndNote X5 (Thomson Reuters, CA, USA).
Relevant studies were identified in two stages. Titles and abstracts returned by the search strategy
were examined independently by two researchers (TJH and HC) and screened for possible inclusion.
Disagreements were resolved by discussion. Full texts of the identified studies were obtained.
Two researchers (TJH and HC) examined these independently for inclusion or exclusion and
disagreements were again resolved by discussion.
Inclusion and exclusion criteria
Population
Studies of individuals with invasive breast cancer who underwent a (sentinel) LN biopsy during the primary
operation to excise a suspected breast cancer were included.
Interventions and comparators
Studies of OSNA or Metasin as used at the thresholds recommended by the manufacturer or designer
were included. The reference standard was postoperative histopathology, performed on fresh sections of
tissue. Frozen section and touch imprint cytology were excluded as comparators as they were not felt to be
sufficiently feasible for widespread implementation (or intervention).
Outcomes
No study was excluded on the basis of outcomes, provided that it appeared relevant to those listed in the
decision problem:
l test failure rate
l DTA
l discordant test results
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l time to test result
l duration of anaesthesia/time in operating theatre
l number of repeat operations (except for re-excision of positive margins)
l time to start of, and nature of, adjuvant therapy.
The clinical outcomes for consideration include:
l patient anxiety associated with waiting for results and not knowing the extent of surgery before
the operation
l adverse events from false test results including patient distress and sequelae
l morbidity and mortality from biopsies, axillary dissections, first and second operations and treatment
of cancer.
Study design
For the review of test accuracy, the protocol made provision for all study designs unless evidence on the
intervention and outcome of interest was already available from designs less open to bias as judged with
reference to standard hierarchies of evidence.42
Systematic reviews were used as a source for finding further studies and to compare with our systematic
review. For the purpose of this review, a systematic review was defined as including:
l a focused research question
l explicit search criteria that are available to review, either in the document or on application
l explicit inclusion/exclusion criteria defining the population(s), intervention(s), comparator(s) and
outcome(s) of interest
l a critical appraisal of included studies, including consideration of internal and external validity of
the research
l a synthesis of the included evidence, whether narrative or quantitative.
Studies were excluded if they did not match the inclusion criteria and, in particular, were:
l preclinical and animal studies
l reviews, editorials and opinion pieces
l case reports
l studies with< 10 participants.
Data extraction strategy
Data were extracted by one reviewer (TJH) using a standardised data extraction form in Microsoft Access
2010 (Microsoft Corporation, Redmond, WA, USA) and were checked by a second reviewer (HC).
Disagreements were resolved by discussion, with involvement of a third reviewer if necessary.
Data extraction forms for each included study can be found in Appendix 2.
Critical appraisal strategy
The methodological quality of the studies was assessed, when applicable to the design of the study,
according to criteria specified by The Cochrane Collaboration’s tool for assessing risk of bias.42 The Quality
Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was used for test accuracy studies.43
Quality was assessed by one reviewer and judgements were checked by a second. Any disagreement was
resolved by discussion, with involvement of a third reviewer as necessary. The two instruments are
summarised in the following section. The results were tabulated and the relevant aspects described in the
data extraction forms.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Internal validity
The instruments sought to assess the following considerations.
The Cochrane Collaboration’s tool for assessing risk of bias
l Was the allocation sequence adequately generated?
l Was allocation adequately concealed?
l Was knowledge of the allocated intervention adequately prevented during the study?
l Were incomplete outcome data adequately addressed?
l Are reports of the study free of suggestion of selective outcome reporting?
l Was the study apparently free of other problems that could put it at high risk of bias?
Quality Assessment of Diagnostic Accuracy Studies tool
l Description of patient selection:
¢ Was a consecutive or random sample of patients enrolled?
¢ Was a case–control design avoided?
¢ Did the study avoid inappropriate exclusions?
¢ Could the selection of patients have introduced bias?
¢ Are there concerns that the included patients do not match the review question?
l Description of index and reference tests:
¢ Was the index test assessor blind to the results of the reference standard and vice versa?
¢ Was a threshold prespecified?
¢ Could the conduct or interpretation of the index test or reference standard have introduced bias?
¢ Are there concerns that the conduct or interpretation of the question have introduced bias for the
index test or reference standard?
¢ Is the reference standard likely to classify the target condition?
l Description of patient flow and timing:
¢ Did all patients receive a reference standard and was it the same test for each?
¢ Were all patients included in the analysis?
¢ Could the patient flow have introduced bias?
External validity
External validity was judged according to the ability of a reader to consider the applicability of findings
to a patient group and service setting. Study findings can be generalisable only if they provide
enough information to conclude that a cohort is representative of the affected population at large.
Therefore, studies whose samples appeared to be typical of the UK breast cancer population were
judged to be externally valid.
Methods of data synthesis
Details of the extracted data and quality assessment for each individual study are presented in structured
tables and as a narrative description. Any possible effects of study quality on the effectiveness data are
discussed. Data on test accuracy are presented as sensitivity, specificity and concordance, when available.
Meta-analysis
Meta-analysis of DTA was performed using the bivariate method44 implemented in Stata/SE 12.1
(StataCorp LP, College Station, TX, USA) using the command metandi.45 Studies were included in the
meta-analysis only if the numbers of true positives, true negatives, false negatives and false positives were
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all reported in the text or could be unambiguously inferred from other figures in the text. Meta-analysis
using the full bivariate method was not performed when there were fewer than four included studies as
the model cannot generally be estimated with fewer than four studies. When the full bivariate model
could not be estimated (either because of too few studies or because of other convergence errors) we
reduced the complexity of the model (as, for example, in Pennant et al.46) by setting the correlation
parameter to zero (effectively reducing the model to two independent univariate random-effects analyses)
and performing the analysis directly using the Stata command xtmelogit.
The bivariate method, when calculated using maximum likelihood estimation and without covariates,
is equivalent to the hierarchical summary receiver operating characteristic (HSROC) model47–49 and this
can be used to provide a summary receiver operating characteristic (SROC) curve and prediction region
as well as a summary estimate and confidence region of sensitivity and specificity.
The SROC curve is designed to show how sensitivity and specificity are traded off against each other in
different studies, through variation of the positivity threshold. If, and only if, there is reason to believe that
the positivity threshold might vary between studies, we provide a SROC curve and prediction region.
Interpreting the results from the diagnostic studies
Test accuracy
In most of the studies, the accuracy of the interventions has been evaluated against the reference (gold)
standard of postoperative histopathology. The results are generally reported as follows:
l Sensitivity= true positives/(true positives+ false negatives). This is the probability of detecting
the presence of metastases in someone with metastases.
l Specificity= true negatives/(false positives+ true negatives). This is the probability of not detecting
metastases in someone without metastases. In this instance a high specificity is required to avoid
unnecessary ALND.
l PPV= true positives/(true positives+ false positives). This is the probability of someone with a positive
result actually having metastases.
l NPV= true negatives/(true negatives+ false negatives). This is the probability of someone with a
negative test result actually not having metastases.
l Accuracy or concordance with reference standard= (true positives+ true negatives)/(true
positives+ true negatives+ false positives+ false negatives). This is the percentage of test results
correctly identified by the test, that is, the rate of agreement with the reference standard.
l Discordance= cases of disagreement between the reference standard and the index test
Discordant case analysis
Many studies used a single-gate design whereby, in a single sample of individuals with unknown
metastatic status, portions of the same node were allocated to either a molecular assay or histopathology.
However, because of the spatial distribution of metastasis within a LN, and the use of different parts of
the LN for different diagnostic tests, TAB may occur (i.e. discordant results between tests may result
from genuine differences between the tissue samples). Unfortunately, it is not possible to use the same
tissue for both tests; the tissue used for the molecular assays cannot be used for histology, and the
formalin-fixed and paraffin-embedded tissue required for permanent sections is not suitable for
quantitative mRNA measurements.
Some studies have attempted to address this issue by performing extensive histopathological and
molecular analysis on discordant cases to ascertain whether the test results are true and occur because of
differences in the allocated tissue. The results are then adjusted (discordant cases resulting from TAB
are removed).
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Results of test accuracy
The results of the assessment of clinical effectiveness will be presented as follows:
1. an overview of the quantity and quality of available evidence together with a table summarising all
included trials (see Table 8), a table of patient characteristics (see Table 9) and a summary table of key
quality indicators (see Table 10)
2. a critical review of the available evidence for each of the stated research questions including the
quantity and quality of available evidence; a summary table of the study characteristics; a summary
table of the population characteristics; study results in terms of sensitivity, specificity and discordant
case analysis presented in narrative and tabular form; a comparison of the results in terms of time to
analysis; and a summary table of abstracts identified but not included in the review.
Quantity and quality of research available
Number of studies identified
The electronic searches retrieved a total of 665 titles and abstracts. Fifty-nine additional papers were
found by searching the bibliographies of included studies and by forward chasing. A total of 589 papers
were excluded, based on screening titles and abstracts. The full texts of the remaining 135 papers were
requested for more in-depth screening, of which 16 published papers50–65 (two reporting the same study)
and two unpublished papers40,66 were included in the review. The process of study selection is shown
in Figure 7.
Titles and abstracts identified
(n = 724)
Full-text paper retrieved
(n = 135)
Included: 18 full papers (including
2 unpublished papers)
49 abstracts summarised but not
reviewed
Does not fulfill inclusion criteria
(n = 589)
Not an appropriate study design or
relevant SR (n = 13)
Unobtainable (n = 1)
No relevant intervention (n = 23)
No relevant comparison (n = 20)
No relevant population (n = 3)
No relevant outcome (n = 3)
Not in English (n = 3)
Duplicate (n = 2)
FIGURE 7 Summary of study selection.
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Number of studies excluded
Papers were excluded for at least one of the following reasons: duplicate publication, narrative review and
publication (systematic reviews and individual studies) not considering relevant intervention, population,
comparison or outcomes. The bibliographic details of studies retrieved as full papers and subsequently
excluded, along with the reasons for their exclusion, are detailed in Appendix 3.
Number and description of included studies
Sixteen test accuracy papers were included for OSNA,50–65 with two papers reporting the same study.
Two unpublished papers40,66 for Metasin were identified and assessed using the Standards for the
Reporting of Diagnostic Accuracy Studies (STARD) in Table 7.
The search also identified 49 abstracts,67–115 some of which repeated the data in the full papers, some of
which provided supplementary information and some of which were not associated with a full paper.
The data in the abstracts are presented in Appendix 4. However, because of the lack of accompanying
details, no quality assessment has been performed.
Summary information for the 18 test accuracy studies included in the review is provided in Table 8.
TABLE 7 Standards for the Reporting of Diagnostic Accuracy Studies assessment for Metasin papers
Section and
topic STARD criteria Sundaresan40 McDowell66
Title/abstract/
keywords
1. Identify the article as a study of diagnostic
accuracy
✗ Academic-in-confidence
information has been removed
Introduction 2. State the research questions or study aims, such as
estimating diagnostic accuracy or comparing
accuracy between tests or across participant groups
✓ Academic-in-confidence
information has been removed
Methods
Participants 3. Describe the study population: the inclusion and
exclusion criteria, setting and locations where
the data were collected
✗ Academic-in-confidence
information has been removed
4. Describe participant recruitment: was
recruitment based on presenting symptoms,
results from previous tests or the fact that the
participants had received the (evaluated) index
tests or the (gold) reference standard?
✗ Academic-in-confidence
information has been removed
5. Describe participant sampling: was the study
population a consecutive series of participants
defined by the selection criteria in items 3 and
4? If not, specify how participants were
further selected
✗ Academic-in-confidence
information has been removed
6. Describe data collection: was data collection
planned before the index test and reference
standard were performed (prospective study) or
after (retrospective study)?
✓ Academic-in-confidence
information has been removed
Test methods 7. Describe the reference standard and its rationale ✓ Academic-in-confidence
information has been removed
8. Describe technical specifications of material and
methods involved including how and when
measurements were taken, and/or cite
references for index tests and reference standard
✗ Academic-in-confidence
information has been removed
9. Describe definition of and rationale for the units,
cut-offs and/or categories of the results of the
index tests and the reference standard
✗ Academic-in-confidence
information has been removed
10. Describe the number, training and expertise of
the persons executing and reading the index
tests and the reference standard
✗ Academic-in-confidence
information has been removed
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TABLE 7 Standards for the Reporting of Diagnostic Accuracy Studies assessment for Metasin papers (continued )
Section and
topic STARD criteria Sundaresan40 McDowell66
11. Describe whether or not the readers of the index
tests and reference standard were blind (masked)
to the results of the other test and describe any
other clinical information available to the readers
✗ Academic-in-confidence
information has been removed
Statistical
methods
12. Describe methods for calculating or comparing
measures of diagnostic accuracy, and the
statistical methods used to quantify uncertainty
(e.g. 95% CIs)
✓ Academic-in-confidence
information has been removed
13. Describe methods for calculating test
reproducibility, if done
✗ Academic-in-confidence
information has been removed
Results
Participants 14. Report when study was done, including
beginning and ending dates of recruitment
✗ Academic-in-confidence
information has been removed
15. Report clinical and demographic characteristics
of the study population (e.g. age, sex, spectrum
of presenting symptoms, comorbidity, current
treatments, recruitment centres)
✗ Academic-in-confidence
information has been removed
16. Report the number of participants satisfying the
criteria for inclusion that did or did not undergo
the index tests and/or the reference standard;
describe why participants failed to receive either
test (a flow diagram is strongly recommended)
✗ Academic-in-confidence
information has been removed
Test results 17. Report time interval from the index tests to the
reference standard, and any treatment
administered between
NA Academic-in-confidence
information has been removed
18. Report distribution of severity of disease (define
criteria) in those with the target condition; other
diagnoses in participants without the
target condition
✗ Academic-in-confidence
information has been removed
19. Report a cross-tabulation of the results of the
index tests (including indeterminate and missing
results) by the results of the reference standard;
for continuous results, the distribution of the test
results by the results of the reference standard
✓ Academic-in-confidence
information has been removed
20. Report any adverse events from performing the
index tests or the reference standard
✗ Academic-in-confidence
information has been removed
Estimates 21. Report estimates of diagnostic accuracy and
measures of statistical uncertainty (e.g. 95% CI)
✓
(no CIs)
Academic-in-confidence
information has been removed
22. Report how indeterminate results, missing
responses and outliers of the index tests
were handled
✗ Academic-in-confidence
information has been removed
23. Report estimates of variability of diagnostic
accuracy between subgroups of participants,
readers or centres, if done
✗ Academic-in-confidence
information has been removed
24. Report estimates of test reproducibility, if done ✗ Academic-in-confidence
information has been removed
Discussion 25. Discuss the clinical applicability of the study
findings
✓ Academic-in-confidence
information has been removed
✗, not reported; ✓, reported; NA, not applicable.
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TABLE 8 Summary information for the test accuracy studies included in the review
Study Year Patients, n SLN or ALN, n Centre Designa Outcomes
Metasin
McDowell66 (Academic-in-
confidence
information has
been removed)
(Academic-in-
confidence
information has
been removed)
(Academic-in-
confidence
information has
been removed)
(Academic-in-
confidence
information has
been removed)
(Academic-in-
confidence
information
has been
removed)
(Academic-in-
confidence
information
has been
removed)
Sundaresan40 Unpublished 1265 2279 SLNs Multicentre, UK Single gate Test accuracy,
time to analysis
OSNA
Bernet50 2011 NR 55 SLNs Multicentre, Spain Observation Time to analysis
Bernet Vegue51 2012 55 567 non-SLNs Multicentre, Spain Single gate Test accuracy
Castellano52 2012 279 Unclear Turin, Italy Cohort Test accuracy,
non-SLN
involvement
Choi53 2010 199 284 SLNs Seoul, Korea Single gate Test accuracy
Feldman54 2011 496 1044 SLNs Multicentre, USA Single gate Test accuracy
Godey55 2012 723 Unclear Rennes, France Cohort Test accuracy
Guillen-
Paredes56
2011 80 114 SLNs Murcia, Spain Cohort Operating time,
days in hospital,
costs
Khaddage57 2011 46 80 SLNs Saint-Etienne,
France
Single gate Test accuracy
Le Frère-Belda58 2012 233 503 SLNs Multicentre,
France
Single gate Time to
analysis, test
accuracy
Osako59 2011 183 Non-SLNs Cancer Institute
Hospital, Tokyo,
Japan
Cohort Test accuracy
Schem60 2009 93 343 ALNs University Clinic of
Schleswig-Holstein,
Albertinen Hospital,
Germany
Single gate Test accuracy
Snook61 2011 204 395 SLNs Multicentre, UK Single gate Test accuracy,
time to analysis
Tamaki62 2009 198 674
ALNs+ SLNs
Multicentre, Japan Single gate Test accuracy
Tamaki63 2012 417 775 SLNs Multicentre, Japan Single gate Test accuracy
Tsujimoto64 2007 101 325
ALNs+ SLNs
Multicentre, Japan Single gate Test accuracy
Visser65 2008 32 346 ALNs Alkmaar and
Amsterdam
Single gate Test accuracy
NR, not reported.
a Single gate – a study design in which only patients with the target condition are recruited and receive both the index
test and the reference standard.
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Study characteristics
One-step nucleic acid amplification and Metasin have standard procedures and thresholds; therefore,
unless otherwise stated, the included studies have complied with the manufacturers’ instructions.
Both methods are semiquantitative and differentiate between micro- and macrometastases,
(academic-in-confidence information has been removed).
In contrast to the molecular methods, there is some heterogeneity with regard to the reference standard,
particularly in the number of levels examined, for example one-level analysis will involve analysis of one
section of node, whereas five-level analysis will examine five sections. As such, for one-level histopathology
it is likely that macrometastases will be identified but micrometastases may be missed. A micrometastasis is
considered to be > 0.2mm and < 2mm and a macrometastasis is considered to be > 2mm. As there is no
way to analyse the whole node, this method cannot be 100% sensitive.
Some studies report cases of ITCs with histopathological analysis. These will fall below the threshold for
OSNA and Metasin and are generally considered LN negative as their clinical significance is unknown.60
The majority of included studies comply with a single-gate design, in which a single sample of individuals
with unknown metastatic status is assessed by both the diagnostic test under scrutiny and the reference
standard. No studies utilising a two-gate design, in which the test under scrutiny is performed on a sample
that includes individuals with known metastatic status (using the reference standard), were identified.
However, three cohort studies have been included in which different patient populations were utilised for
each test. The inclusion of cohort studies enabled the identification of data based on whole-node analysis,
something that would not be possible for OSNA or Metasin using classic DTA study designs, such as the
single-gate or the two-gate design.
A general issue for all of the studies is that a portion of node tissue is allocated to the index test and a
portion is allocated to the reference standard. As such, the tests are analysing different samples of tissue,
which cannot be reused between tests. As metastases may be distributed unevenly, TAB may occur, that
is, metastases may exist in the tissue sample provided for one test but not in the tissue sample provided for
the other test.
It should also be noted that studies examining ALNs as well as, or instead of, SLNs were included.
Metasin
There is currently no published evidence for the test accuracy of Metasin; however, we have received draft
reports of two single-gate studies.
Sundaresan40 reports on a postoperative evaluation of Metasin using 2279 nodes from 1265 patients with
breast cancer in which 608 of the 1265 cases were from patients already assessed using the GeneSearch
BLN assay. Six centres contributed tissue homogenates, although two centres were able to provide frozen
ribonucleic acid (RNA) only. Three-level histology, that is, examination of three sections, was performed
although the author states that all laboratories followed their own standard operating procedures for
analysis of slides. The author also mentions that there was no uniformity in the protocols followed
for sentinel and axillary clearance.
(Academic-in-confidence information has been removed.)
One-step nucleic acid amplification
Cohort studies An assessment of the reliability of OSNA as a single test for SLNs was reported by
Castellano et al.52 This was a single-centre cohort study with 279 patients. Histology was performed
on fresh SLNs, initially sliced at 2mm after which further step sections at 100 µm were performed.
Positive rates for both cohorts were presented.
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A cohort study reported by Godey et al.55 compares the positivity rate of OSNA performed in a routine
clinical setting with historical postoperative histology results for 723 patients. Histology was performed on
250-µm sections of the node until no tissue was left.
Guillen-Paredes et al.56 present a retrospective cost–benefit analysis. This cohort study aimed to analyse
the economic costs of the intraoperative OSNA assay compared with the costs of the conventional
postoperative histological and immunohistochemical assay. Histology was performed on 4-mm sections
of the node. Results include operative time, days in hospital, costs and postoperative complications.
Osako et al.59 report on a retrospective cohort study of 183 patients at a single centre. Intraoperative
OSNA was compared with one-level histology (examination of one slice) performed on five to seven
non-SLNs from the same patient. Positive rates were described for both methods.
Single-gate studies The aim of a multicentre study presented by Bernet et al.50 was to compare OSNA
with histology and evaluate its feasibility intraoperatively. Fifty-five SLNs were investigated using a
single-gate study design; however, the results appear to include touch imprint and frozen section analysis
supported by postoperative histopathology and therefore these results are not included in the review.
Relevant outcomes that are included in the review are times of extraction, dissection, preparation
and analysis.
A paper by Bernet Vegue et al.51 reported on the Breast Complete Lymphadenectomy OSNA Study for
Enhanced Review-I (B-CLOSER-I). Eight hospitals were involved in this single-gate study comparing
histopathology and OSNA for the pathological staging of ALNs after identification of positive SLNs in
patients with primary breast cancer. Fifty-five patients were recruited consecutively, providing 567
non-SLNs for analysis. Both OSNA and histopathology were performed postoperatively. Tissue used for
OSNA analysis was stored at –80°C. Two phases are reported, both utilising a single-gate design: the
validation phase and routine use. For the validation phase, histopathology was five level (examination of
five slices) whereas for routine use a central 1-mm slice was used for histopathology (one level), with the
remainder being used for OSNA. For both phases discordant cases were investigated using additional
molecular analysis, performed by qRT-PCR. Discussed outcomes include discordance during the
validation phase.
The sensitivity, specificity and accuracy of intraoperative OSNA compared with that of three-level histology
are described in a study by Choi et al.,53 in which 199 patients had 284 SLNs analysed. With regard to
discordance, clinical information, status of non-SLNs and expression of CK19 protein in LN metastasis foci
were evaluated on a patient basis.
A multicentre single-gate study reported by Feldman et al.54 recruited 496 patients, providing 1044 SLNs
for analysis. The node was sectioned into six with alternate slices used for histopathology and OSNA.
The slices for histopathology were then dissected at 200-µm intervals for haematoxylin–eosin staining and
pan-CK immunohistochemistry. The results were evaluated by blinded pathologists. For discordant case
analysis, blank histopathology was checked and OSNA was retested using Western blot analysis and
qRT-PCR. This study used the RD-110i system with a reagent kit that was different from that used in the
other included studies.
Khaddage et al.57 reported on a multicentre, single-gate study based in France, with concordance,
sensitivity and specificity as outcomes. The study included a validation phase with 46 patients and a
routine phase with 197 patients. Histopathology for the validation phase was five level and for the routine
phase was one level. Both node- and patient-level analyses are presented. The results of the OSNA
investigation were not known to the histopathologist and vice versa. Discordant case analysis of the
validation phase was performed by qRT-PCR.
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Le Frère-Belda et al.58 reported a study assessing the intraoperative diagnostic performance of OSNA
compared with extensive histological evaluation. This was a multicentre single-gate study involving eight
clinical centres in France. Alternate slices of dissected SLNs were used, along with five-level histology.
It should be noted that two centres reused frozen section samples, which may impair integrity for final
histology. In cases of discordance, with positive OSNA and negative histology, 200-µm skip spaces for all
slices were analysed. Samples were also sent to Sysmex for blind molecular analysis by qRT-PCR.
A study by Schem et al.60 considered the performance of OSNA compared with that of five-level histology.
This two-centre study used a blinded, single-gate, experimental design and analysed 343 ALNs. OSNA
samples were stored frozen at –80°C. Discordant samples were analysed by further levels of histology,
Western blot analysis and qRT-PCR. In addition, 120 histopathologically negative samples were cut into
further levels for determining specificity. Sensitivity and discordance were also reported.
Snook et al.61 reported on a UK single-gate, prospective, multicentre evaluation of OSNA involving four
centres. In total, 204 patients were recruited, providing 395 SLNs, although there are no further details on
recruitment. OSNA slices were snap frozen at –80°C. Five-level histology was performed and molecular
analysis for discordant samples was carried out by qRT-PCR. Sensitivity, specificity, accuracy, PPV, NPV and
discordance were reported.
A Japanese multicentre study including two single-gate trials is reported by Tamaki et al.62 This study
examined the validity of OSNA for clinical use. Seven centres were involved, two in trial 1, three in trial 2
and two in both. Trial 1 compared intraoperative OSNA with detailed histology for the detection of
metastases in 124 ALNs. Alternate slices of the node were allocated to each technology; for histology,
the tissue was dissected into 0.2-mm sections. Trial 2 was designed to replicate routine use and so only
one-level histology was performed. For discordant cases, however, histology was performed as in trial 1,
alongside Western blot analysis. Sensitivity, specificity and discordance were reported.
The same trial was reported by Tsujimoto et al.,64 who present data from six centres for 101 patients and
325 ALNs. Intraoperative OSNA was compared with three-level histology. The results were examined by
three third-party (blinded) pathologists. The authors state that calculations for sensitivity and specificity
were not appropriate because separate tissue was used for both tests; therefore, the results were
evaluated as concordance with histology. Discordant samples were analysed using qRT-PCR and
Western blotting.
A subsequent Japanese multicentre study by Tamaki et al.63 investigated the clinical use of OSNA
compared with one-level histology. This study used a single-gate design and involved 198 patients and
674 ALNs and SLNs.
Finally, Visser et al.65 reported on a single-gate study that tested OSNA on 346 ALNs compared with
five-level histology. To investigate if the results were influenced by sampling bias, the histological work-up
was extended to all levels in the first 120 histologically negative LN samples (and also to paraffin blocks of
discordant cases). In addition, the homogenised LN lysates of samples were subjected to qRT-PCR and
Western blot analysis.
Population characteristics
In general, patient characteristics were poorly reported, as were inclusion and exclusion criteria. Not
all studies provided the age range of participants and, often, only information on tumour staging was
provided. Patient characteristics are presented in Table 9.
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TABLE 9 Summary of patient characteristics
Characteristic
Bernet
201150
Bernet
Vegue
201251 Castellano 201252
Choi
201053
Feldman
201154
Godey
201255
Guillen-Parades
201156
Intervention O+H O+H O H O+H O+H O H O+H H
n 55 55 110 169 199 496 258 355 233 45
Age (years),
median (range)
59 (23–87) 66.7 (38–82) 61.2 (23–86) 44.5a 58.8b
(28–88)
56.8b 56.9b 58
(30–93)
61.89b
Clinical stage, n (%)
0 11 (5.5)
I 21 (38.2) 132 (66.3)
II 22 (40.0) 54 (27.1)
III 12 (21.8) 2 (1.0)
IV 11 (5.5)
Unknown
Tumour size, n (%)c
≤1 cm 33 (30) 41 (24)
1.1–1.5 cm 19 (17) 45 (27)
>1.5 cm 58 (53) 83 (49)
Clinical tumour classification, n (%)
T0
Tis 1 (1.8) 8 (4.0) 21 (4.2) 2 3
T1 32 (58.2) 129 (64.8) 327 (65.9) 16 13
T2 21 (38.2) 56 (28.1) 124 (25) 17 29
T3 1 (1.8) 2 (1.0) 5 (1)
T4
Tx 4 (2.0) 19 (3.8)
Nodal status, n (%)
pN0 153 (76.9) 387 (78)
pN1 37 (18.6) 84 (16.9)
pN2 5 (2.5) 14 (2.8)
pN3 4 (2.0) 4 (0.8)
Histopathological type, n (%)
IDC 44 (80.0) 81 (74) 109 (64) 165 (82.9) 348 (70.2) 212 313 31 37
ILC 7 (12.7) 16 (14) 29 (17) 9 (4.5) 40 (8.1) 46 42 2 5
DCIS 1 (1.8) 9 (4.5) 1 2
Other 3 (5.5) 13 (12) 31 (18) 16 (8.1) 109 (21.7) 1 1
HER2, n (%)
Negative 49 (89.1) 108 (98) 144 (85)
Positive 6 (10.9) 2 (2) 25 (15)
H, histopathology; HER2, human epidermal growth factor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma;
O, OSNA.
a Mid-range of age category (40–49 years) where the median age was found; only the frequency distribution of patients
across age ranges (i.e. 0–29 years, 30–69 years in 10-year bands, and age 70+ years) was reported.
b Mean.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
Khaddage
201157
Le Frère-Belda
201158 Osako 201159
Schem
200960
Snook
201161 Tamaki 200962
Tamaki
201263
Tsujimoto
200764
Visser
200865
O+H
clinical
O+H
routine
O+H O H O+H O+H O+H
trial 1
O+H
trial 2
O+H O+H O+H
46 197 233 119 64 93 204 36 185 439 101 32
58 (30–93) 53 (27–86) 56 (39–81) 55.9b 54.7b 56.1b (25–90)
41 (17.7) 2 (6) 14 (9) 5 0
175 (75.4) 8 (24) 51 (31) 183 (43.9) 41 8
13 (5.6) 14 (41) 64 (40) 110 (26.4) 49 15
2 (0.9) 5 (15) 7 (4) 70 (16.8) 5 7
1 (0.4) 0 0 1 2
2 (6) 0 54 (12.9) 5
7 1
0 21 50 (12)
34 141 46 133 254 (60.9)
2 30 36 60 111 (26.6)
2 1 4 5 2 (0.5)
1 1 7
225 (97.0) 46 60 14
7 (3.0) 115 (96.6) 62 (96.9) 27 35 10
3 (3.4) 2 (3.1) 13 2 6
7 4 2
36 148 164 (70.4) 110 (92.4) 57 (89.1) 68 160 (78.8) 32 (94) 130 (79) 305 (73.1) 87 30
5 16 34 (14.6) 4 (3.4) 2 (3.1) 21 22 (10.8) 1 (3) 7 (4) 24 (5.8) 4 2
5 21 23 (9.9) 0 18 (11) 53 (12.7) 5
0 12 12 (5.2) 4 16 (7.9) 1 (3) 9 (5) 35 (8.4) 5
106 (89.1) 55 (85.9) 334 (87.8)
13 (6.3) 13 (10.9) 9 (14.1) 51 (12.2)
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Metasin
(Academic-in-confidence information has been removed.) Sundaresan et al.40 provide no details on
patient characteristics.
One-step nucleic acid amplification
Two52,59 of the cohort studies reveal reasonably homogeneous patient populations with regard to age and
clinical status. A relatively small sample size was used for each patient group in the study reported by
Guillen-Paredes,56 with a difference of ∼7 years for mean age. The histology group had proportionally
more participants with a T2 tumour classification than the OSNA group.
Across many of the single-gate studies, minimal information is given regarding population characteristics.
In general, the populations are heterogeneous, with studies including patients across the spectrum of
tumour and nodal staging, although some studies have included patients with cancer of only one or
two stages. It should also be noted that, for some studies, the number of recruited patients is small
whereas the number of nodes analysed is comparatively large.
Assessment of study quality
A summary of the quality assessment of studies included in the review is provided in Table 10; this is
followed by a narrative summary. The main issue within the included studies is TAB, which occurs when
tissue cannot be reused between the index test and the reference test. In short, because of an uneven
distribution of metastases, the test results may be discordant but accurate for the tissue received. Many
studies attempted to address this, either by more extensive histology or by additional molecular analyses,
such as qRT-PCR and Western blotting for CK19 protein. The results should then be recalculated after
adjustment for TAB, generally with an increase in OSNA sensitivity and specificity.
Other concerns included lack of detail on patient recruitment, minimal information on patient
characteristics and unclear sampling methods, that is, no evidence was given on sample replicates and
reproducibility for molecular analysis. Furthermore, unless otherwise mentioned, test failures, such as
operator or instrument error, were not reported. It was also often not mentioned whether or not the
outcome assessors were blinded. For example, it is not inconceivable that the pathologist performing the
intraoperative molecular analysis also performed the more subjective postoperative histopathology. Papers
were also often unclear on the robustness of the histopathology, for example if results were checked by a
second party.
A potential conflict of interest also features heavily, (academic-in-confidence information has been
removed) and the majority of the OSNA studies were financially supported by Sysmex.
Metasin
(Academic-in-confidence information has been removed.)
The second draft paper was presented by Sundaresan,40 who created the Metasin test. This study design is
experimental, with six centres contributing tissue homogenates that were then compared with historical
three-level histology. As such, no patient characteristics are included. Two centres were able to provide
only frozen homogenates, which may impact on the quality of the RNA. Technical details for the Metasin
test are not provided. No cases were excluded because of suspected TAB and no retrospective discordant
case analysis was performed. However, when possible, RNA was reanalysed using an independent panel of
markers. It is not clear if the initial analysis was performed by blinded pathologists. The failure rate for
assays was reported (1.2%). According to the authors this was possibly because there was insufficient RNA
in the samples.
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One-step nucleic acid amplification
Cohort studies Castellano et al.52 provide a comprehensive flow chart. Patients were not selected
randomly, although patient groups were compared and no significant differences were found for the
characteristics reported. Histology involved 2-mm slices of the whole node, which were then sectioned
at 100 µm.
Godey et al.55 compare a historical cohort using a 1-mm central slice sectioned every 250 µm. A flow
diagram documents the pathway of patients through the study. However, reporting of information on
patient characteristics for the whole study is minimal. The authors mention that for three patients there
were technical problems with OSNA, but this was not elaborated on.
Guillen-Paredes et al.56 provide a retrospective cost–benefit analysis using two relatively small patient
groups. Inclusion criteria are detailed but few patient characteristics are presented. Histology involved
preparing 4-mm sections of the LN, subsectioned into 15 × 4-µm slices for examination.
In the final cohort study, reported by Osako et al.,59 OSNA is compared with historical single-section
histology. Detailed exclusion criteria and comprehensive patient characteristics are included, with no
significant heterogeneity being found between the groups. Some of the nodes were frozen at –80°C
before OSNA, which may affect the quality of the mRNA. Laboratory consumables were funded
by Sysmex.
Single-gate studies Bernet et al.50 report two trials within one paper. For trial 1 it was unclear whether
fresh or frozen sections were used as the comparator; therefore, the results from this trial are not included
in the review. Trial 2 investigates the timing of the procedural steps for OSNA for 55 cases and was
therefore included in the review.
The study by Bernet Vegue et al.51 reports on a single-gate study using only one-level histopathology, with
the remaining tissue used for OSNA, which is likely to result in substantial TAB. The authors claim that this
approach was chosen to replicate routine use. Patients were recruited consecutively across eight hospitals,
although the achieved sample size is relatively small at 55 patients. Reasonably comprehensive reporting of
patient characteristics was provided. No details were given on blinding of pathologists and there was no
further investigation into discordant cases, although further details such as copies/µl were provided.
There may be a conflict of interest as the study was funded by Sysmex.
The study reported by Choi et al.53 does not provide any information on recruitment or a diagram of
patient flow. However, analysis on all appropriate samples appears to have been performed and
clinicopathological characteristics of patients are given. Of note, macrometastasis or micrometastasis was
confirmed by both or either of intraoperative histopathological examination of frozen section specimens
and postoperative histopathological (three-level) examination of permanent tissue specimens. Although it
appears from this that some of the reference standard data may therefore have been based on frozen
section specimens alone, closer examination of the entirety of the data has led us to believe that this is not
the case. In particular, data are presented on discordant frozen section and final histopathology results and
these suggest that there were no cases for which frozen section results were positive and final histology
was negative. As such, it appears that a positive histology result was based on two scenarios: first, both
the frozen section and the final histology were positive and, second, the frozen section results were
negative and the final histology was positive. Therefore, all positive histology cases would have had a
positive final histology result.
The study is unclear on whether or not the pathologists were blinded and provides no detail on test
failures or replicates for OSNA. Discordance was evaluated using clinical information, status of non-SLNs
and CK19 protein expression in metastatic foci of LNs. It is unclear how the CK19 protein expression was
determined. This study was also supported by Sysmex.
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TABLE 10 Summary of the assessment of study quality
QUADAS-2 domain
Study
OSNA
aBernet
201150
Bernet
Vegue 201251
Castellano
201252 Choi 201053
Feldman
201154
Godey
201255
Guillen-
Paredes
201156
Khaddage
201157
Patient selection
Was a consecutive or
random sample of
patients enrolled? (Y/N/U)
N Y U U U U U U
Was a cohort study
design avoided? (Y/N/U)c
NA Y N Y Y N N Y
Did the study avoid
inappropriate exclusions?
(Y/N/U)
U Y Y Y Y N Y Y
Could the selection of
patients have introduced
bias? (H/L/U)
U L U U U U U U
Concerns that the
included patients do not
match the review
question? (H/L/U)
L L L L L L L L
Index test
Were the index test results
interpreted without
knowledge of the results
of the reference standard?
(Y/N/U)
U U NA U Y NA Y Y
If a threshold was used,
was it prespecified?
(Y/N/U)
Y Y Y Y N Y Y Y
Could the conduct or
interpretation of the index
test have introduced bias?
(H/L/U)d
L U L L L U L L
Are there concerns that
the index test, its conduct
or its interpretation differ
from the review question?
(H/L/U)
L L L L L U L L
Reference standard
Is the reference standard
likely to correctly classify
the target condition?
(Y/N/U)
Y Y Y Y Y Y Y Y
Were the reference
standard results
interpreted without
knowledge of the results
of the index test? (Y/N/U)
NA U NA U Y U NA Y
Metasin
Le Frère
Belda
201258
Osako
201159
Schem
200960
Snook
201161
Tamaki
200962
Tamaki
201263
Tsujimoto
200764
Visser
200865
Academic-in-confidence
information has
been removed Sundaresan40
U Y U U U U U U b U
Y N Y Y Y Y Y Y b Y
Y Y U Y Y Y U Y b U
U L U U U U U U b U
L L U L L L L L b L
U U Y Y Y U Y U b U
Y Y Y Y Y Y Y Y b Y
L L L L L L H L b U
L L L L L L L L b L
Y Y Y Y Y Y Y Y b Y
Y U U Y Y U U U b U
continued
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TABLE 10 Summary of the assessment of study quality (continued )
QUADAS-2 domain
Study
OSNA
aBernet
201150
Bernet
Vegue 201251
Castellano
201252 Choi 201053
Feldman
201154
Godey
201255
Guillen-
Paredes
201156
Khaddage
201157
Could the reference
standard, its conduct or
its interpretation have
introduced bias? (H/L/U)e
L U U U L U U L
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
(H/L/U)
L L L L L U L L
Flow and timingf
Did all patients receive a
reference standard?
(Y/N/U)
NA Y N Y Y N NA Y
Did all patients receive the
same reference standard?
(Y/N/U)
NA Y Y Y Y N NA Y
Were all samples (that
should have been)
included in the analysis?
(Y/N/U)
U Y Y Y Y Y Y Y
Could the patient flow
have introduced bias?
(H/L/U)
U L U U U U U L
Additional items
Were samples suspected
of TAB excluded from the
analysis? (Y/N/U)
g
NA N NA N Y NA NA Y
Are there concerns about
selective reporting of
outcomes? (H/L/U)
U L L L L H L L
H, high risk of bias; L, low risk of bias; N, no; NA, not applicable; U, unclear; Y, yes.
a Study assessed only on trial 2.
b Academic-in-confidence information has been removed.
c QUADAS-2 asks whether a case–control design has been avoided (i.e. a two-gate DTA study). No two-gate studies
were found for this review but cohort studies (i.e. those comparing a population receiving histology with a separate
population receiving OSNA/Metasin) were identified. It was decided that these studies should be included because they
provide OSNA/Metasin data when the whole node is used. This question has therefore been adapted to flag up whether
the study is a cohort study or a single-gate diagnostic accuracy study.
d None of the molecular tests provided evidence of reproducibility; however, this is not considered an issue with regard
to bias.
e The reference standard is prone to observer bias.
f The QUADAS-2 question ‘Was there an appropriate interval between index test(s) and reference standard?’ has been
omitted because the review protocol was designed such that studies with an inappropriate interval between
intervention and reference standard (i.e. those using intraoperative histology as a reference standard) were excluded
from the review.
g This question is designed to ensure that bias has not been introduced by excluding samples. However, discordant
samples that are likely to result from TAB should be excluded. A ‘yes’ response here therefore refers to all samples
other than those deemed to be subject to TAB (irrespective of whether TAB samples were excluded or not).
Metasin
Le Frère
Belda
201258
Osako
201159
Schem
200960
Snook
201161
Tamaki
200962
Tamaki
201263
Tsujimoto
200764
Visser
200865
Academic-in-confidence
information has
been removed Sundaresan40
U L U U L U L U b U
L L L L L L L L b L
Y N Y Y Y Y Y Y b Y
Y Y Y Y Y U Y Y b Y
Y Y Y Y Y Y Y Y b Y
L L U U L L U U b U
Y NA Y Y Y N N Y b N
L L L L L L U L b L
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Feldman et al.54 report a study funded by Sysmex comparing OSNA with ‘extensive’ histology of 200-µm
intervals of approximately 3 × 1mm slices. Patient recruitment is not mentioned although patient
characteristics are comprehensively reported. No patient flow diagram is included and the number of
SLNs after discordance (n= 1018) does not comply with the numbers before discordance (n= 1044) minus
the resolved cases. The population is somewhat heterogeneous, including all classifications of tumour and
LN status. Histopathologists were blinded and discordant case analysis was performed using Western
blotting and qRT-PCR, although no details of this are given.
A single-gate study reported by Le Frère-Belda et al.58 provides a flow chart of the SLN samples as well
as patient characteristics. This study investigates a reasonably heterogeneous population, although the
majority had pN0 node status. No information was given on recruitment other than inclusion criteria.
Duplicate samples were used for OSNA. Five-level histology was performed, although it should be noted that
in five centres frozen sections were reused for this, which may have resulted in degradation of the sample.
Discordant case analysis was performed by extensive histopathology and blind molecular analysis (SLN
homogenates were shipped to Sysmex for this analysis). It is unclear if the original analysis was blinded. One
sample was excluded because of a manipulation error. Laboratory consumables were funded by Sysmex.
The study reported by Khaddage et al.57 compared OSNA with five-level histology for clinical evaluation and
with one-level histology for routine use. Although replicates are not mentioned, positive and negative controls
are confirmed. No patient flow diagram is provided and there are no details on recruitment other than
minimal inclusion/exclusion criteria. However, clinical characteristics of the patient population are given and all
samples appear to have been analysed. Pathologists were blinded to both test results. Discordant case analysis
was performed only on the clinical study using only qRT-PCR (two cases), with TAB likely to be less of an issue
in this study than in the routine study (17 cases). No details of test failures, other than one case of a false
positive as a result of an invalid control, were given. The study was funded by Sysmex.
The study reported by Schem et al.60 provides minimal information on patient characteristics or
recruitment. Five-level histology was used as the reference standard and the outcome assessors were
blinded. The samples for OSNA were frozen at –80°C. Specificity was calculated on the first 120 negative
nodes (out of 343) using extended histology. Histology was also extended on discordant cases with
Western blotting and qRT-PCR performed on the homogenates. Comprehensive details are provided on all
of these techniques other than the replicates and test failures. This study was also supported by Sysmex.
Snook et al.61 report a prospective study comparing OSNA with five-level histology. No patient flow
diagram is included, although numbers appear accurate, and minimal patient characteristics are provided.
It is unclear if recruitment was consecutive. Outcome assessors were blinded to the OSNA results.
Discordant case analysis was performed by Western blotting and qRT-PCR. No financial contribution was
received from any organisation; however, support in the form of training and advice and compensation for
the additional workload as a result of the study protocol and all necessary material for OSNA analysis were
provided by Sysmex.
Tamaki et al.62 present one of two papers on a Japanese multicentre study. A validity and a routine
use trial are reported. For the validity trial, histopathology was extensive, with node sections taken at
0.2-mm intervals. For routine use, a more standard three-level method was used. Brief patient characteristics
are presented for each trial with no details on recruitment. No patient flow diagram is provided but the
numbers of nodes extracted and analysed comply. Outcome assessors were blinded and discordant cases
were analysed by Western blotting and qRT-PCR, although technical details are not provided. This study was
supported by Sysmex.
Tsujimoto et al.64 appear to report on the same trial as Tamaki et al.,62 with OSNA compared with
three-level histology. Minimal details are provided on patient characteristics and there is no description
of recruitment. LNs were stored at –80°C until needed. Samples were analysed in duplicate. It is unclear
from this report if pathologists were blinded, although if this is in fact the same trial as described
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in Tamaki et al.62 then it is reported that they were. Histopathological samples were examined by three
third-party pathologists. As in Tamaki et al.,62 discordant case analysis was performed by Western blotting
and qRT-PCR, although it is reported here that these tests were not performed on all samples. Sysmex are
acknowledged but there is no explicit mention of financial support.
A second paper by Tamaki et al.63 reports another multicentre study based in Japan. Comprehensive
patient clinical characteristics are given with minimal details provided on recruitment. The description
of the OSNA assay is sparse and only one-level histology is employed. No discordant case analysis
was performed.
The final study by Visser et al.65 employed three-level histology on ALNs, which, if negative, underwent a
further four-level investigation. The number of patients included was relatively low at 32, although the
total number of nodes analysed was 346. No details were provided on patient recruitment and patient
characteristics were minimally reported. There was no evidence of replicates for OSNA, but for discordant
case analysis qRT-PCR was performed in duplicate. Frozen samples were used for OSNA (the first
120 histologically negative samples). The pathologists do not appear to have been blinded.
Assessment of test accuracy
The assessment of test accuracy for both OSNA and Metasin is hindered by TAB and by comparison with
an inconsistent reference standard. When discordant samples are further investigated (usually using either
more extensive histopathology or molecular analysis by qRT-PCR or Western blotting) and attributed to
TAB, analyses can be adjusted by excluding such cases; however, adjustment cannot be made for
heterogeneity between studies with regard to the reference standard; histopathology may be performed
extensively across five levels of a LN or more perfunctorily using only one level of a central slice.
It should be noted that ITCs which are found by immunohistochemical staining and not detected by OSNA
are considered LN negative as their clinical significance is unknown.65
Individual results are described alongside a narrative description in the following sections. Summarised
results, which have been stratified, are presented in Tables 27–32.
Metasin
(Academic-in-confidence information has been removed.)
TABLE 11 Academic-in-confidence information has been removed
Academic-in-confidence
information has been removed
Academic-in-confidence information has been removed
Academic-in-confidence
information has been removed
Academic-in-confidence
information has been removed
Academic-in-confidence information
has been removed
Academic-in-confidence information
has been removed
Academic-in-confidence information
has been removed
Academic-in-confidence information
has been removed
Academic-in-confidence information
has been removed
Academic-in-confidence information
has been removed
The second paper on Metasin, by Sundaresan,40 which like the first is unpublished and therefore has not
undergone formal peer review, reports a sensitivity of 92%, a specificity of 97% and an accuracy of 96%.
(Academic-in-confidence information has been removed.) Sundaresan40 used three-level histology as the
reference standard. In total, 20 cases (1.6%) were reported as failed assays, which the authors consider
may have been because of insufficient RNA in the material submitted for molecular analysis. The authors
report 56 patients to be discordant and, although they do not present evidence, they consider TAB to be
largely responsible (Table 12).
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One-step nucleic acid amplification
Cohort studies
In the study by Castellano et al.52 the rate of negative cases determined by standard histology (73%) was
highly comparable with the rate of negative SLNs determined by OSNA (71%), with no adjustment for
TAB. The rate of micrometastases detected by OSNA was significantly higher (18%) than that determined
by the standard procedure (8%; p< 0.01), whereas the rate of macrometastases detected by OSNA was
lower (11% vs. 20%). The authors mention that this may be a reflection of different patient populations
rather than the different techniques. Nevertheless, the positive rates were similar between the two
techniques (Table 13).
The authors hypothesise that the morphological evaluation of the diameter of metastases does not
perfectly correlate with the tumour load as evaluated by mRNA copies of CK19 and that there could be an
overestimation of macrometastases (> 2mm) compared with micrometastases by histology (> 0.2mm and
< 2mm) or an underestimation of macrometastases compared with micrometastases by OSNA.
The study by Godey et al.55 reports a positive rate of 24.4% for OSNA, which is comparable to the rate
reported for OSNA by Castellano et al.52 (29%) (see Table 13). The time required to obtain the final results
of the OSNA assay (including transport to the laboratory) depended on the number of SLNs studied.
The mean time to receive the final results was 32.9 minutes [standard deviation (SD) 4.9 minutes] for one
SLN (n= 94), 36.4 minutes (SD 4.5 minutes) for two SLNs (n= 144), 41.6 minutes (SD 5.2 minutes) for
three SLNs (n= 87) and 48.5 minutes (SD 8.7 minutes) for four SLNs (n= 39).
Guillen-Paredes et al.56 present a cost–benefit analysis. They report a shorter total operative time for
OSNA patients, with the mean total time difference between histopathology [mean (SD) 78 (48.02)
minutes] and OSNA [mean (SD) 62.14 (21.93) minutes] being statistically significant (p< 0.005). However,
when considering only the time of the first operation, the time for histology is shorter (histology
57.11 minutes vs. OSNA 62.14 minutes), although this difference was not statistically significant (p= 0.15).
In the histology group the mean hospital stay after the first operation was 1.8 days (range 1–13 days,
SD 2.04 days) and after the second operation was 2.41 days (range 1–6 days, SD 1.29 days, n= 12 patients),
resulting in a total hospital stay of 2.44 days, compared with a mean of 1.54 days for OSNA (range 1–4 days,
SD 0.78 days); this difference was statistically significant (p< 0.001). In the analysis of complications
(minor, major and no complications), there was a statistically significant difference between the
histology group 1 (57 patients with complications, considering the first and second operations) and
the OSNA group38 (p= 0.015).
TABLE 12 Concordance between Metasin and histopathology in the study by Sundaresan40 (n= 1245 patientsa)
Metasin
Three-level histopathology (number of cases)
Positive Negative
Positive 249 36
Negative 20 940
a Twenty cases reported as invalid; therefore, n reduced from 1265 to 1245.
TABLE 13 Positive rates (%) for metastases reported in cohort studies
Test Castellano 201252 Godey 201255 Osako 201159
Histology 28 24.8 20.3 (95% CI 11.7 to 32.6)
OSNA 29 24.4 55.5 (95% CI 46.1 to 64.5)
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The final cohort study is presented by Osako et al.59 The entire node was used in the OSNA group whereas
only a single section of the node was used in the histology group. No significant difference was seen
between the positive rate of histological macrometastases and the positive rate of OSNA (++) (18.8%,
95% CI 10.5% to 30.8% vs. 25.2%, 95% CI 17.9% to 34.2%; p= 0.420). However, a significant
difference was seen between the positive rate of histological micrometastases and the positive rate of
OSNA (+) (1.6%, 95% CI 0.1% to 9.5% vs. 30.3%, 95% CI 22.3% to 39.5%; p< 0.001).
Single-gate studies
The study by Bernet et al.50 has been included in the review only for the data on the time taken for
OSNA analysis (see Assessment of analysis time).
The study by Bernet Vegue et al.51 investigated only a 1-mm central node slice by histopathology, with the
remainder allocated to OSNA (therefore, a high rate of discordance was predicted). Values for sensitivity
and specificity were not provided in the paper. A statistically significant overall discrepancy was shown
between OSNA and histopathology (p< 0.001).
Discordant results were observed in 51 (9%) nodes, although the discordant case analysis table shows
discordant results for only 47 nodes (Table 14). Of the histopathology-negative nodes, 14 were identified
as ++ (2.7% of total) 25 as + (4.9% of total) and 8 as low expression (1.6% of total) by OSNA (the
authors reported the respective results as 2.5%, 4.5% and 1.4%). The authors suggest that OSNA is of
particular relevance for the identification of low-volume metastases.
When individual nodes were considered, there were no false negatives for OSNA. In contrast, > 80% of
the discordant nodes found to be positive for metastases were not identified by conventional one-level
histology. The authors state that one-level histology was chosen to reflect the minimum standard used in
many laboratories.51
The study by Choi et al.53 reported a sensitivity of 77.8% (95% CI 60% to 90%) for OSNA, which is
comparatively low. The authors indicate that this is likely to be the result of TAB; however, the dissection
of the node was carried out using a similar method to that used in other studies. The authors report a
specificity of 96.3% (95% CI 92% to 99%) and an accuracy of 93% (95% CI 88% to 96%).
Fourteen cases of discordance occurred (Table 15). In one false-positive case (OSNA positive, histology
negative), the histopathological result of ITC detection as well as the existence of metastasis in other SLNs
(not used for this study) was attributed to the localisation of metastatic foci in the LN. For three more
discordant cases the OSNA result was close to the cut-off value, indicating the existence of weak positivity
in the sample. For another, even though the OSNA assay provided a ++ judgement, the authors were
unable to find any other evidence to support this judgement. They hypothesised that this result was due to
the localisation of metastatic foci in the LN as the probability of OSNA false positives is considered to be
very low based on the results of previous studies. For another OSNA-positive, histology-negative case, the
OSNA assay provided positive results for each of two LNs from this patient. This was also considered to be
due to the localisation of metastatic foci in the LNs.
TABLE 14 Concordance between OSNA and histopathology in the study by Bernet Vegue et al.51 (n= 567 non-SLNs)
OSNA
One-level histopathology (number of cases)
Macrometastasis Micrometastasis Negative
++ 1 4 14
+ 0 1 25
+ i (low expression) 0 0 8
– 0 0 514
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The false-negative cases (OSNA–, histology+) were investigated immunohistochemically to confirm the
protein level of CK19 in tumours. Four cases showed expression of CK19 protein in < 10% of the tumour.
The cause of these discordant results may have been the inability of the OSNA assay to detect metastasis
of breast cancers with low CK19 expression. In two other cases, metastases were histopathologically
detected by the postoperative examination of permanent specimens. CK19 immunohistochemical analysis
of two cases was not performed because of insufficient tissue and these results remain inconclusive.
Following adjustment for TAB, the study by Feldman et al.54 reported a sensitivity of 82.7%, a specificity of
97.7% and an accuracy of 95.8% for OSNA compared with reference pathology.
Seventy-one cases were considered discordant, including two pathology assessment reversals because of
TAB. (Table 16). Although OSNA failed to detect nine macrometastases and 22 micrometastases that
were identified by reference pathology, it detected nine macrometastases and 29 micrometastases
that were identified as negative or as ITCs by reference pathology. All of these nine macrometastases
were identified as true misses by reference pathology, and recalculation of the assay performance for
macrometastasis yielded a PPV of 100% for an OSNA (++) result.
For macrometastases, all nine discordant OSNA (++) results were identified as true positives, and nine of
29 discordant OSNA (+) results were also identified as true positives on discordant case analysis. Although
20 of the 29 discordant OSNA (+) results could not be confirmed, the median CK19 copy number in these
samples was close to the assay cut-off, suggesting that these cases involved very small micrometastases,
and this did not rule out the possibility of TAB.
The sensitivity and specificity of OSNA were lower than the values reported in previous smaller studies,
possibly because this study evaluated solely SLNs; slicing was at 1-mm intervals rather than at 2-mm
intervals; and there were a large number of micrometastases.
TABLE 15 Concordance between OSNA and histopathology in the study by Choi et al.53 (n= 199 patients)
OSNA
Three-level histopathology (number of cases)
Macrometastasis Micrometastasis ITCs Negative
++ 19 2 1 1
+ 3 3 0 4
+ i (low expression) 1 0 0 0
– 4 4 3 154
TABLE 16 Concordance between OSNA and histopathology in the study by Feldman et al.54 (n= 1044 SLNs)
OSNA
Three-level histopathology (number of cases)
Macrometastasis Micrometastasis ITCs Negative
++ 77 9 1 8
+ 9 12 0 29
– 9 22 14 854
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The study by Le Frère-Belda et al.58 reported a sensitivity of 91.1% (95% CI 80.3% to 97.1%) and a
specificity of 97.2% (95% CI 95.1% to 98.6%) for OSNA compared with five-level histology after
adjustment for TAB.
The authors report 39 cases of discordance (Table 17) and mention that, as different parts of the node
were used for each method, because each technique required a different method of tissue preparation,
discrepancies between the OSNA results and the histological results were expected.58 Twenty-seven cases
were histology negative/OSNA positive. All 27 samples remained histologically negative after further
examination of histological slices, whereas 15 samples had OSNA-positive lysates after further molecular
analysis by qRT-PCR; this was suggested by the authors to be due to TAB. Twelve histology-positive/
OSNA-negative samples were found. One was not investigated by further molecular analysis and seven
were found to be negative on further molecular analysis.
For the study presented by Godey et al.,55 a positive rate of 24.4% is reported for OSNA and a positive
rate of 24.8% is reported for histology; the rate of 24.4% for OSNA is comparable to the rate of 29%
for OSNA reported by Castellano et al.52
Khaddage et al.57 reported on OSNA compared with both five-level histology and routine one-level histology.
For the extensive histology after adjustment for TAB, presented in Table 18, the sensitivity, specificity and
accuracy of OSNA were 100%, 98.4% and 98.7% respectively.
Only three results appear to be discordant for five-level histology. In the two cases in which micrometastases
were detected by histology but the OSNA sample was negative, further molecular analysis by qRT-PCR of
CK19 and two breast cancer-specific markers displayed negative results; therefore, TAB was assumed to
have occurred. For the one case with a positive result for OSNA but not histopathology, the sample was very
close to the cut-off level, indicating very small tumour deposits. Seventeen cases were discordant for routine
use histology, all histology negative and OSNA positive, three of which had non-SLN involvement and
fourteen of which indicated micrometastases and the likelihood of TAB.
The study by Schem et al.60 reported a sensitivity of 98.1% and a specificity of 91.7% for OSNA compared
with five-level histopathology. After adjustment for TAB, sensitivity increased to 100% and specificity to
96.5%. A total of 28 cases were considered discordant (Table 19).
Ribonucleic acid and proteins were extracted from the lysates of the 28 discordant cases, followed by
analysis for CK19 by qRT-PCR and Western blotting. If the data obtained by the additional analyses were
consistent with the results obtained by OSNA, TAB was considered likely and these samples were excluded
from the sample cohort.
TABLE 17 Concordance between OSNA and histopathology in the study by Le Frère-Belda et al.58
OSNA
Five-level histopathology (number of cases)
Macrometastasis Micrometastasis ITCs Negative
n = 503 SLNs
++ 37 6 0 3
+ 5 3 1 23
– 3 9 27 386
n = 233 patients
++ 22 6 0 3
+ 2 3 3 17
– 2 7 17 151
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In both of the OSNA-negative/histology-positive samples and in 11 out of the 26 OSNA-positive/histology-
negative samples, discordant case analysis revealed equivalent results to those obtained with the OSNA assay.
As such, it cannot be fully excluded that an even higher proportion of discordant results was due to TAB
because the homogenates were exposed to long storage and transport times, which might have lowered the
concentration and quality of the RNA and proteins. A further six OSNA-positive/histology-negative samples
had a CK19 mRNA copy number of < 1000/µl. The authors suggest that, with a cut-off level of 250 copies/µl,
these positive OSNA results very likely indicate a low tumour burden in the LNs, which was probably absent in
the tissue sections used for histological investigation. For samples close to the cut-off level, long storage and
travel times can affect the concentration and quality of the RNA and proteins.
Snook et al.61 compared OSNA with five-level histology. OSNA was reported to have a sensitivity of 91.7%,
a specificity of 96.9% and an accuracy of 96.0%, after adjustment for TAB.
TABLE 18 Concordance between OSNA and histopathology in the study by Khaddage et al.57
OSNA
Five-level histopathology (number of cases)
Macrometastasis Micrometastasisa ITCs Negative
n = 80 SLNs (validation study)
++ 11 2 – 0
+ 2 0 – 1
– 0 0 (2) 2 60
n = 46 patients (validation study)
++ 6 2 0 0
+ 0 0 0 1
– 0 0 (2) 2 33
One-level histopathology
Macrometastasis Micrometastasis ITCs Negative
n = 197 patients (routine use)
++ 9 1 1 2
+ 8 7 1 13
– 0 0 1 154
a Values in parentheses indicate case numbers before discordant case investigation.
TABLE 19 Concordance between OSNA and histopathology in the study by Schem et al.60 (n= 343 ALNs)
OSNA
Five-level histopathology (number of cases)
Macrometastasis Micrometastasis ITCs Negative
++ 90 7 0 9
+ 7 – 1 16
– 0 2 2 209
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A total of 33 cases were considered to be discordant, with 17 reported to be due to TAB following
qRT-PCR and Western blot analysis. Sixteen samples were reported as truly discordant, 10 false positives
and six false negatives (Table 20). The OSNA false positives with a low copy number were attributed to
the possible presence of small micrometastases that were not apparent on histology, although the authors
also mention that there is a possibility of contamination as CK19 is expressed on the surface of cells of
epithelial origin, benign or malignant, such as breast, colonic or gastric cells.116 Ideally, the cut-off value for
the OSNA test reduces the likelihood of this.
As histopathology is prone to sampling bias, that is, the number of levels of histopathology can influence
the result, the authors also question if histopathology is appropriate as a gold standard. With regard to
further molecular analysis, the authors consider the possibility of a reduction in RNA concentration in
the frozen lysates of SLN samples because of the freeze–thaw effect, which could account for some
of the discordant cases, despite repeat molecular testing.
Tamaki et al.62 present results for two trials, as reported in Table 21, which are also reported on by
Tsujimoto et al.64 Trial 1 compared the specificity of OSNA with that of detailed histology (0.2-mm
sections), to confirm the validity of the index test. Trial 2 was intended to replicate routine use and only
three-level histology took place.
TABLE 21 Concordance between OSNA and histopathology in the study by Tamaki et al.62
OSNA
0.2-mm section histopathology, number of cases (n= 124 ALNs, trial 1)
Macrometastasis Micrometastasis ITC Negative
Positive 16 3 NR 3
Negative 0 1 NR 101
OSNA
Three-level histopathology (n= 551 ALNs, trial 2)
Macrometastasis Micrometastasis ITC Negative
Positive 64 6 NR 22
Negative 4 6 NR 348
NR, not reported.
TABLE 20 Concordance between OSNA and histopathology in the study by Snook et al.61
OSNA
Five-level histopathology (number of cases)
Macrometastasis Micrometastasis ITCs Negative
n = 395 SLNs
++ 48 1 0 0
+ 8 9 0 10
– 4 2 20 293
n = 194 patients
++ 33 1 0 0
+ 5 5 1 7
– 4 1 11 126
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Sensitivity and specificity for trial 1 were reported as 95% and 97%, respectively, whereas sensitivity
and specificity for trial 2 were reported as 87.5% and 94%, respectively, before adjustment for TAB and
87.7% and 94.3%, respectively, after adjustment for TAB.
In trial 2, 32 nodes displayed discordant results (7.1%). For eight of the 10 false-negative nodes,
not all of the serial sections contained metastasised foci and therefore they may not have been in the
OSNA samples. Two nodes from different patients among the false-negative cases displayed very weak
expression of CK19 mRNA. The primary tumours of these patients also stained negative for CK19
on immunohistochemistry.
Isolated tumour cells were found in the remaining specimens of five of the 22 false-positive nodes after
additional sectioning, which had not been detected by routine pathological examination using 2-mm
interval sections. In another eight false-positive nodes, no tumour cells were found in the pieces remaining
after pathological examination, but lymphatic vascular invasions were observed in the main tumours.
In addition, the lysates of two of the nodes preserved for the OSNA assay contained a significant amount
of CK19 protein.
As for the pathologically positive LNs (diameter of metastasis > 0.2mm), 87.7% could be detected using
the OSNA assay, whereas 94.1% of the macrometastases (> 2mm) were assessed as positive.
The second paper by Tamaki et al.63 compared OSNA with one-level histology (Table 22).
Forty-four cases were discordant, considered to be inevitable by the authors because of the method of
tissue sampling used. In eight cases OSNA was negative but postoperative pathological examination
identified metastasis. Of these, seven patients had micrometastases and discordance was suspected to be
due to uneven allocation of minuscule metastases in a SLN. However, in the remaining patient with
macrometastasis, low expression of the CK19 protein in the main tumour was confirmed, leading to a
negative OSNA result, although, the authors state that it is not necessarily the case that low expression of
CK19 protein is reflected in low expression of CK19 mRNA.
There were also 36 OSNA-positive, histology-negative discordant cases, including two with ITCs in the
SLNs as assessed by pathology. Of these, non-SLN metastases were subsequently identified in seven
patients; therefore, the OSNA results in these patients were accurate. Microinvasion was suspected in a
core-needle biopsy specimen from one patient. Two patients had widespread DCIS that measured > 6 cm
and another had multiple lesions. A further two patients had high-grade DCIS.
The authors suggest that, despite the cut-off, OSNA can detect metastases with high sensitivity even in
tumours diagnosed pathologically as DCIS and that such findings may result in an upgrade of the clinical
stage of such tumours.
Tsujimoto et al.64 report on the same trial as Tamaki et al.62 Compared with three-level histology (n= 325
SLNs and ALNs), OSNA sensitivity was reported as 91.1% and accuracy was reported as 98.2% (Table 23).
TABLE 22 Concordance between OSNA and histopathology in the study by Tamaki et al.63
OSNA
One-level histopathology, number of cases [n= 417 patients (SLNs)]
Positive Negative
Positive 58 36
Negative 8 315
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Six discordant cases were observed (for the trial with 325 nodes) between the OSNA assay and
histopathology. Western blot analysis of two discordant cases (OSNA positive/histology negative) showed
the presence of an amount of CK19 protein equivalent to micrometastasis. The authors considered that,
although the possible presence of benign epithelial cells such as glandular inclusions in the LNs cannot be
eliminated, the results may be better explained by the presence of metastatic foci in the LNs in light of the
results of the specificity study and the amount of CK19 protein expression. This is further supported by
the lack of false positives reported for the pN0 patients. Two other cases were negative according to the
OSNA assay but were judged positive for micrometastasis according to three-level histopathology. The two
remaining cases were not tested.
The final single-gate study included in this review was presented by Visser et al.,65 who compared OSNA
with five-level histology (Table 24). After adjustment for TAB, a sensitivity of 95.3%, specificity of 97.1%
and accuracy of 96.8% were reported.
TABLE 23 Concordance between OSNA and histopathology in the study by Tsujimoto et al.64
OSNA
Three-level histopathology, number of cases (n= 325 SLNs and ALNs)
Macrometastasis Micrometastasis ITC Negative
++ 34 0 0 0
+ 6 3 0 4
– 0 2 13 263
OSNA
Three-level histopathology, number of cases (n= 81 SLNs)
Macrometastasis Micrometastasis ITC Negative
++ 11 0 0 0
+ 1 2 0 1
– 0 2 3 61
OSNA
0.2mm-interval histopathology, number of cases (n= 144 SLNs from pN0 patients)
Macrometastasis Micrometastasis ITC Negative
++ 0 0 0 0
+ 0 0 0 0
– 0 0 3 141
TABLE 24 Concordance between OSNA and histopathology in the study by Visser et al.65
OSNA
Five-level histopathology, number of cases (n= 346 ALNs)
Macrometastasis Micrometastasis ITC Negative
++ 50 4 0 2
+ 2 5 0 13
– 1 2 3 264
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To establish the level of discordance as a result of TAB, the first 120 histologically negative LNs, as
determined by five-level histology, were cut into further levels at intervals of 250 µm.
Seven discordant cases, considered to be due to TAB, are not included in Table 24. A further
18 unresolved cases were reported. In eight cases, only Western blot results for CK19 protein could be
obtained because poor-quality RNA did not allow qRT-PCR analysis to be performed. One of three
histology-positive/OSNA-negative samples yielded negative results. In the lysates of the other two
samples, CK19 protein levels were slightly above the cut-off value, suggesting the presence of small
tumour deposits. In 11 histologically negative/OSNA-positive samples, low CK19 mRNA copy numbers
(250–750/µL) were found with OSNA. Six of these could be further analysed by qRT-PCR, whereas the
remaining five samples suffered from poor RNA quality. The same was true for one sample with a high
CK19 mRNA copy number.
Discordance
Studies show a range of discordance, from 1.8% to 8.6% (Table 25); further details are provided in
Table 26. The greatest discordance was generally for OSNA false positives. This is a concern as it would
potentially lead to unnecessary complete axillary dissection in patients. This may be due to epithelial
contamination although, for OSNA, the CK19 copy number cut-off corresponds to the presence of
5000 tumour cells. Therefore, it is unlikely that positive results would occur because of epithelial
displacement or illegitimate transcription, which involves only 500–1000 non-tumour cells.65 By contrast,
false-negative tests may result in a lack of treatment in the early stages of cancer, leading to a worse
prognosis. The patient may also be required to undergo a second operation for ALND.
TABLE 25 Cases of discordance by node
Study Total cases (%)
Attributed to
TAB (%)
H+/O– or
H+/M– (%)
H–/O+ or
H–/M+ (%)
OSNA
Bernet Vegue 201251 8.3 NR 0 8.3
Choi 201053 7 NR 4 3
Feldman 201154 6.6 2.7 3.0 3.6
Khaddage 201157
(study phase)
3.7 0 2.5 1.2
Khaddage 201157
(routine use)
8.6 NR 0 8.6
Le Frère-Belda 201258 7.7 4.3 2.3 5.4
Schem 200960 8.2 3.8 0.6 7.6
Snook 201161 8.3 4.3 3.0 5.3
Tamaki 200962 (trial 2) 7.1 NR 2.2 4.9
Tamaki 201263 5.7 NR 1.0 4.6
Tsujimoto 200764 1.8 NR 0.6 1.2
Visser 200865 5.2 2 0.9 4.3
Metasin
Academic-in-
confidence
information has
been removed
Academic-in-
confidence
information has
been removed
Academic-in-
confidence
information has
been removed
Academic-in-
confidence
information has
been removed
Academic-in-
confidence
information has
been removed
Sunderasan40 4.2 NR 1.5 2.6
–, negative; +, positive; H, histology; M, Metasin; NR, not reported; O, OSNA.
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Although the true number of discordant cases and the number that result from TAB cannot be fully
differentiated, the studies that have adjusted their results display increased specificity and sensitivity for
OSNA. Interestingly, the studies that analyse a full node with extensive histology showed no significant
difference in positive rates between OSNA and histology,52,55 whereas the study using one-level histology
demonstrated a significantly higher positive rate for OSNA.59
Summary of test accuracy
The results are summarised and stratified according to SLNs, ALNs, patients, before TAB and after TAB in
Tables 27–32. An overall summary is provided in Table 33.
With regard to Metasin, the results must be used with caution as they have been taken from unpublished,
non-peer-reviewed papers. These papers are also very much in draft form and therefore lacking in detail.
That said, with regard to quality, many of the issues (such as lack of information about replicate
measurements and therefore no estimate of the reproducibility and the robustness of the test) apply to
both papers reporting OSNA and (academic-in-confidence information has been removed).
One-step nucleic acid amplification detects only CK19 mRNA expression. It has been reported that 98.2%
of breast cancer tumours express CK19 protein, leaving 1.8% of patients for whom this technique may
be invalid.60 However, Tamaki et al.62 suggest that it is not necessarily the case that low expression of
CK19 protein is reflected in low expression of CK19 mRNA. In contrast, Metasin, which also identifies
mammaglobin, (academic-in-confidence information has been removed) compared with that of OSNA,
which ranges from 77.8% to 80%.40
As the reference standard, immunohistochemistry is capable of detecting ITCs, unlike OSNA (and
presumably Metasin). However, as the American Society of Clinical Oncology (ASCO)117 and the NICE
clinical guideline for early breast cancer13 indicate that ITCs have an unknown clinical significance, and
there are insufficient data to recommend appropriate treatment, ITCs were considered histologically
negative throughout this review.
Although the aim of OSNA and Metasin is to perform intraoperative molecular analysis, some studies
employed a more experimental approach and used frozen samples of RNA, either initially or in discordant
case analysis. Both storage and the freeze–thaw effect have been known to adversely affect RNA,
effectively leading to a reduction in concentration.
Histopathology will always be limited by sampling bias as only a certain number of slices are taken.
This can be increased or reduced according to requirements but will have cost implications and there will
always be unanalysed tissue. Furthermore, there is the possibility of observer subjectivity. In contrast, for
OSNA or Metasin the whole node can be used and the semiquantitative test is objective.
There is also the issue of TAB. Unfortunately, because of the nature of the OSNA/Metasin tests and of
histopathology, it is not possible to use the same tissue sample for both tests and thus TAB is likely to
occur. There is no DTA study design that can resolve this issue and, although cohort studies can provide us
with some data on whole-node analysis, the tissue being analysed by each test is still, of course, different.
Studies have attempted to mitigate the issue of TAB by investigating discordant cases. However, there is a
lack of consistency between studies with regard to the methods used to investigate discordant cases, and
there will always be uncertainty attached to decisions about whether TAB has occurred.
With regard to the overall results, the range for specificity is lower for results presented by patient rather
than by node, before and after adjustment for TAB, as shown in Tables 27–33. The results produced by
meta-analysis agree with this (Table 34). Sensitivity before adjustment for TAB is similar for both patients
and nodes, whereas, after TAB adjustment, sensitivity is slightly greater for nodes. This may be because
some studies use a larger number of nodes from a small number of patients.
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TABLE 30 Results for SLNs after adjustment for TAB
Study Sample, n
Histology
level H+/O+ H–/O– H+/O– H–/O+
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
OSNA
Feldman 201154 1018 Three NR NR NR NR 82.7a 97.7a
Khaddage
201157
78 Five NR NR NR NR 100a 98.4a
Le Frère-Belda
201258
481 Five 51 413 5 12 91.1
(80.3 to 97.1)
97.2
(95.1 to 98.6)
Snook 201161 395 Five 66 313 6 10 91.7
(82.7 to 96.9)b
96.9
(94.4 to 98.5)b
–, negative; +, positive; H, histology; NR, not reported; O, OSNA.
a CI could not be calculated because of insufficient information in the study report.
b CI calculated by the Peninsula Technology Assessment Group (PenTAG).
TABLE 31 Results for ALNs before adjustment for TAB
Study Sample, n
Histology
level H+/O+ H–/O– H+/O– H–/O+
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
OSNA
Bernet 201150 567 ALNs One 6 522 0 39 100
(60.7 to 100)a
93.0
(90.6 to 95.0)a
Schem 200960 343 ALNs Five 104 211 2 26 98.1
(93.4 to 99.8)b
91.7
(84.3 to 92.7)c
Tamaki 200962 124 ALNs Sectioned
at 0.2-mm
intervals
19 101 1 3 95
(75.1 to 99.9)
97.1
(91.8 to 99.4)
Tamaki 200962 450 ALNs Three 70 348 10 22 87.5
(78.2 to 93.8)
94.1
(91.0 to 96.3)
Tsujimoto
200764
325
ALNs/SLNs
Three 43 276 2 4 95.6
(84.9 to 99.5)a
98.6
(96.4 to 99.6)a
Visser 200865 346 ALNs Three 61 267 3 15 95.3
(84.9 to 99.5)b
94.7
(96.4 to 99.6)b
–, negative; +, positive; H, histology; O, OSNA.
a CI, sensitivity and specificity calculated by the Peninsula Technology Assessment Group (PenTAG).
b CI calculated by PenTAG.
c Specificity calculated by PenTAG shown to be 89%.
TABLE 32 Results for ALNs after adjustment for TAB
Study Sample, n
Histology
level H+/O+ H–/O– H+/O– H–/O+
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
OSNA
Schem 200960 330 ALNs Five NR NR NR NR 100a 95.6a
Tamaki 200962 450 ALNs Sectioned
at 0.2-mm
intervals
71 348 10 21 87.7
(78.5 to 93.9)
94.3
(95.3 to 98.8)
Visser 200865 339 ALNs Three NR NR NR NR 95.3a 97.1a
–, negative; +, positive; H, histology; NR, not reported; O, OSNA.
a CI could not be calculated because of insufficient information in the study report.
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With the exception of the study by Feldman et al.,54 the ranges for sensitivity and specificity for ALNs and
SLNs appear to be similar. The results of the meta-analysis for OSNA are shown in Table 34.
For the meta-analysis of test accuracy based on analysis of SLNs without adjustment for TAB, we were not
aware of a compelling reason to believe that the positivity threshold might vary between studies and so for
consistency with meta-analyses for the other subgroups (see below) we do not include a HSROC curve or
prediction region. Figure 8 shows the results of this meta-analysis.
As there were only three studies available to estimate the test accuracy of OSNA for patients after
adjustment for TAB, we set the correlation parameter to zero as described in Assessment of test accuracy.
The results are displayed in Figure 9.
For the meta-analyses of the test accuracy of OSNA for SLNs and ALNs we do not present SROC curves or
prediction regions because the studies report the same copies/µl thresholds of 250 and 5000 for the OSNA
results of + (micrometastases) and ++ (macrometastases) respectively.
We attempted to perform meta-analyses of the test accuracy of OSNA for SLNs with and without
adjustment for TAB using the full bivariate method. In both of these meta-analyses we encountered
atypical results in the output such that the between-study correlation parameter (σAB=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
σ2Aσ
2
B
p
in Reitsma
et al.44) is estimated as –1 with no estimate of standard error (SE) or CI. This phenomenon has been
recognised before and Riley et al.118 conclude that it is likely to occur when there are few studies or the
within-study variation is large (i.e. the studies themselves are small) and is due to sensible bounds being
placed on the model to avoid the maximum likelihood estimation including a correlation outside the range
[–1,1]. Riley et al.118 also conclude that there is no systematic bias in the summary estimates of sensitivity
and specificity introduced by this phenomenon and that CIs of the summary points are conservative.
However, as described in Assessment of test accuracy, we set the correlation parameter to zero and
TABLE 33 Overall range of central estimates for sensitivity and specificity
Sample type Sensitivity (%) Specificity (%)
Patients before adjustment for TAB (Metasin) Academic-in-confidence
information has been removed
Academic-in-confidence
information has been removed
Patients before adjustment for TAB (OSNA – SLNs) 77.8–80.0 88.0–97.2
Patients after adjustment for TAB (OSNA – SLNs) 89.8–100 93.3–97.2
SLNs before adjustment for TAB (OSNA) 77.5–88.2 93.9–98.4
SLNs after adjustment for TAB (OSNA) 82.7–100 96.9–98.4
ALNs before adjustment for TAB (OSNA) 87.5–98.1 91.7–97.1
ALNs after adjustment for TAB (OSNA) 87.7–100 94.3–97.1
TABLE 34 Meta-analyses of OSNA test accuracy
Sample type Adjustment for TAB Number of studies Sensitivity (%) (95% CI) Specificity (%) (95% CI)
Patient No 5 84.5 (74.7 to 91.0) 91.8 (87.8 to 94.6)
Patient Yes 3 91.3 (83.6 to 95.6) 94.2 (91.2 to 96.2)
SLN No 4 79.9 (74.2 to 84.6) 95.5 (94.1 to 96.5)
SLN Yes 5 89.0 (82.1 to 93.4) 97.5 (96.6 to 98.2)
ALN No 6 95.1 (90.0 to 97.6) 94.9 (91.2 to 96.9)
ALN Yes 4 96.5 (87.3 to 99.1) 96.2 (93.4 to 97.8)
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repeated the analysis, the results of which are shown in Figures 10 and 11. Computed summary points
and CIs differed only at the third decimal point.
Figures 12 and 13 show the results of the meta-analyses of the test accuracy of OSNA in ALNs before and
after adjustment for TAB respectively. The bivariate method converged with no abnormal results. Note that
there were six studies to inform the meta-analysis before adjustment for TAB but only four studies to
inform the meta-analysis after adjustment and we believe that this accounts for the significantly larger
confidence region shown in Figure 13 as removing two studies from the subgroup without adjustment for
TAB gives a confidence region of a comparable size.
Assessment of analysis time
The time taken for analysis of LNs in the different studies is displayed in Table 35. It is unclear if the
timings are directly comparable as the description of exactly which procedures were being monitored was
sometimes ambiguous. That said, the results seem fairly consistent for both methods: between < 30 and
39.6 minutes for one node, increasing by approximately 5–10 minutes per additional node analysed.
It was also noted by Bernet et al.50 that the longest and most variable time period corresponded to the stage
when the node was transported from the operating room to the pathology department. The time taken for
macroscopic processing of the samples could also fluctuate significantly depending on the training level of the
pathologist involved. The least variable time period corresponded to the homogenisation of the tissue,
preparation of the diluted sample and amplification using the amplification equipment.
The study be Guillen-Paredes et al.56 did not provide a time to analysis but compared operative time, days
in hospital and complications between histology and OSNA, as shown in Tables 36 and 37.
Table 37 indicates that, overall, patients undergoing OSNA experienced fewer complications, although the
one major complication occurred in the OSNA group.
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TABLE 35 Time to analysis
Nodes,
n
Median time to analysis (minutes)
OSNA Metasin
Bernet
201150a,b
Choi
201053a,c
Feldman
201154d
Godey
201255a,e
Khaddage
201157f
Le Frère-
Belda
201258g
Snook
201161h
Tsujimoto
200764i Sundaresan40
1 39.6
(range 26–70)
35.2 33.0 32.9
(SD 4.9)
33 32
(range 22–97)
< 30 36
2 44.8 39.6 36.4
(SD 4.5)
37 40 42
(range 30–73)
42
3 50.4 45.2 41.6
(SD 5.2)
48 51
(range 38–73)
46
4 50.0 48.5
(SD 8.7)
54 62
(range 46–90)
a Mean.
b Time from receipt of node to report.
c Turnaround time.
d Interquartile mean from homogenisation to analyser output.
e Time required for results.
f Time from receipt of node to the result.
g Time needed for OSNA assay.
h Time from node preparation to end of analysis.
i All OSNA assays completed in < 30 minutes.
TABLE 36 Effect of OSNA on operative time
Test
Mean (SD) intervention time (minutes) Mean (SD) days in hospital
First
operation
Second
operation Total
First
admission
Second
admission Total
Histology 57.11 (23.93) 78.33 (NR) 78 (48.02) 1.8 (2.04) 2.41 (1.29) 2.44 (3.00)
OSNA 62.14 (21.93) NA 62.14 (21.93) 1.54 (0.78) NA 1.54 (0.78)
Test
Absolute no. intervention time (minutes) Absolute no. days in hospital
First
operation
Second
operation Total
First
admission
Second
admission Total
Histology 2570 940 3510 81 29 110
OSNA 2175 NA 2175 54 NA 54
NA, not applicable; NR, not reported.
TABLE 37 Number of complications per group
Test
Complications in first intervention Complications in second intervention
None Minor Major None Minor Major
Histology 28 17 0 4 8 0
OSNA 24 10 1 NA NA NA
NA, not applicable.
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Chapter 4 Assessment of cost-effectiveness:
systematic review
Systematic review of existing cost-effectiveness evidence
Search strategy
The main objective of this review was to identify and evaluate published studies that examine the
cost-effectiveness of intraoperative tests in the diagnosis of ALN metastases. As a secondary objective,
we also used the studies to inform the design of the model used in our independent economic assessment.
We reviewed published economic evaluations of intraoperative molecular assessment for metastasis in early
breast cancer to identify evidence relevant to current NHS practice. In addition to the electronic databases
searched in the effectiveness review, EconLit and the bibliographies of relevant studies were searched for
cost, cost-effectiveness and cost–utility studies. Forward citations of identified studies were searched
for any relevant publications published after the initial search.
Relevant studies were then identified in two stages. Titles and abstracts returned by the search strategy
were examined independently by two researchers (NH and RM) and screened for possible inclusion.
Disagreements were resolved by discussion. Full texts of the potentially relevant studies were obtained.
Two researchers (NH and RM) examined these independently for inclusion or exclusion and disagreements
were resolved by discussion.
Description of the included studies
The initial search identified a total of 13 abstracts, seven82,87,110,111,114,119,120 of which were conference
presentations and six9,56,121–124 of which represented four individual studies. One study measured the costs
of intraoperative options that are not relevant to the UK (touch imprint and frozen section)121 and one
study analysed the diagnostic pathway leading to SLN biopsy or ALND.9,122 The remaining two studies56,123
were identified as relevant to our review. A second report of the study by Cutress et al.123 was available
from the NHS Technology Adoption Centre124 and was used to complement the information from
Cutress et al.123 See Appendix 5 for the quality assessment of all available studies reported in journal
articles and Appendix 6 for details of the excluded studies.
The characteristics of the studies are summarised in Table 38. Both were single-centre observational
studies that compared an intraoperative test with histopathology as the gold standard for assessing SLNB.
The study by Cutress et al.123 was set in the UK and assessed the GeneSearch assay whereas the study by
Guillen-Paredes et al.56 was conducted in Spain and evaluated the OSNA assay. Both found their respective
intraoperative test to be cost-effective compared with histopathology, with both assays being cost-saving
while reducing theatre time and length of hospital stay. The UK study also considered a strategy in which
axillary clearance was performed on all patients instead of assessing them using SLNB, but this practice is
no longer recommended by NICE13 and the study did not find it to be cost-effective. Guillen-Paredes
et al.56 also measured the benefits of each strategy by assessing the incidence of minor and major
complications during surgery. They found significantly fewer complications in the OSNA group, although
this group was also the only one to have a major complication (no details were given). Neither study
looked at outcomes beyond the diagnostic phase.
It must be noted that the study by Cutress et al.,123 although providing a unique source of evidence on
resource use and costs of intraoperative molecular testing in the UK, provides limited, if any, evidence
on the economic outcomes of a specific intraoperative test as it refers to a test that has been withdrawn
from the market (GeneSearch). Metasin, one of the intraoperative testing technologies being evaluated in
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this assessment, uses the same markers as GeneSearch, CK19 and mammaglobin, but different
primer–probe combinations and it is therefore expected to perform differently in routine practice
from GeneSearch.
Quality appraisal
A quality appraisal was carried out on the two studies using the checklist of Drummond and Jefferson.125
A summary of the results is provided in Table 39.
Study design
Both studies were observational and are therefore open to bias and confounding. They both stated their
research question and the approach to economic evaluation but no justification was given by either study
for the economic evaluation study design used in relation to the research question. The viewpoint of both
analyses was implicitly justified by the public health systems in which the studies were conducted and the
local practice at the respective centres, and both studies acknowledged the limited generalisability of their
findings because of the availability of different intraoperative testing technologies in other centres.
Data
Details of the methods of patient recruitment were given. Although both studies were based on
single-gate designs and are thus subject to TAB, neither adjusted for it in the analysis of accuracy. Both
studies reported the methods of collecting health-care resource use data and applying unit costs to them,
but only the Spanish study56 explicitly stated the primary outcome measures of its evaluation in terms of
the health benefits of intraoperative diagnosis. Both studies reported unit costs and quantities separately
but they provided explanations only for the estimation of unit costs not quantities. The Spanish study56 did
not state the date for the unit costs used and neither study provided details on whether any price and
currency conversion adjustments were made. Neither study valued health benefits nor examined changes
in productivity or its associated costs.
Analysis and interpretation of the results
Neither study analysed outcomes beyond the end of the diagnostic phase and therefore the studies did
not require the use of a discount rate. As no sensitivity analyses were provided, the degree to which the
reported cost differences may have been the result of chance alone cannot be established.
In summary, only one study was found for OSNA56 and none for Metasin. One study was found on
GeneSearch,123 which served as the basis for the development of Metasin (see Chapter 1, Metasin) but
may not produce the same outcomes. Although the OSNA study56 is likely to reflect the study centre’s
practice in Spain, the GeneSearch study123 is no longer relevant as the technology has been withdrawn
from the market. The results in both studies are likely to be biased because of the inherent limitations of
observational studies, which commonly lack control for the effect of confounders on outcomes. The
validity of these studies’ findings is made more uncertain by their lack of reporting of the methods used to
measure diagnostic accuracy outcomes. Further, the degree of uncertainty in the estimates, and the extent
to which the observed differences may be explained by chance, cannot be established. Nor can it be
known to what extent the results may be generalisable across countries or indeed jurisdictions within
the UK. This suggests that the existing evidence on economic outcomes is unlikely to serve to inform
medical decision-making in the context studied here.
Submissions from sponsoring companies
No economic studies of Metasin were submitted by its sponsor. For this technology, only one conference
abstract114 was found that included any information on costs; it reported only the cost per assay (£35.00;
a different estimate, based on more detailed information obtained from the sponsor, was used in the
model; see Model parameter values, Costs). As for OSNA, only a file with illustrations of spreadsheets
from a decision model of its costs and accuracy, developed for Belgium by Professor Lieven Annemanns
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(Ghent University, Belgium), was made available, as unpublished and academically confidential work
(NICE technical management team technical analyst Sarah Byron, 1 July 2012, personal communication of
information provided by the manufacturer). (Academic-in-confidence information has been removed.)
The model considered only the cost differences between OSNA and the status quo for diagnostic testing of
metastatic early breast cancer. The status quo was mixed: 90% of patients underwent intraoperative
testing by touch imprint cytology or frozen section, with confirmatory postoperative histopathology for
patients with negative test results, and the remaining 10% of patients were subject to postoperative
TABLE 39 Quality assessment of studies included in the economic review using the checklist of Drummond
and Jefferson125
Criteria
Cutress
2010123
Guillen-Paredes
201156
Study design
The research question is stated ✓ ✓
The economic importance of the research question is stated ✓ ✓
The viewpoint(s) of the analysis are clearly stated and justified
The rationale for choosing alternative programmes or interventions compared is stated Partial ✓
The alternatives being compared are clearly described ✓ ✓
The form of economic evaluation used is stated ✓ ✓
The choice of form of economic evaluation is justified in relation to the
question addressed
✗ ✗
Data collection
The source(s) of effectiveness estimates used are stated ✓ ✓
Details of the design and results of the effectiveness study are given (if based on a
single study)
✓ ✓
Details of the methods of synthesis or meta-analysis of estimates are given (if based on
a synthesis of a number of effectiveness studies)
NA NA
The primary outcome measure(s) for the economic evaluation are clearly stated Partial ✓
Methods to value benefits are stated ✗ ✗
Details of the subjects from whom valuations were obtained are given NA NA
Productivity changes (if included) are reported separately ✗ ✗
The relevance of productivity changes to the study question is discussed NA NA
Quantities of resource use are reported separately from their unit costs ✓ ✓
Methods for the estimation of quantities and unit costs are described
Currency and price date are recorded ✓ Partial
Details of currency of price adjustments for inflation or currency conversion are given ✗ ✗
Details of any model used are given NA NA
The choice of model used and the key parameters on which it is based are justified NA NA
Analysis and interpretation of results
Time horizon of costs and benefits is stated ✓ ✓
The discount rate(s) are stated NA NA
The choice of discount rate(s) is justified NA NA
NA, not applicable.
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histopathology testing only. The analysis assumed a SLN-positive rate of 39%. In addition to the costs of
the diagnostic tests, the analysis included the costs of further investigations after a negative intraoperative
test result, the initial surgery without LN dissection, the extended surgery with intraoperative testing and
ALND, and the cost of the second surgery including the hospital stay. The model analysed the costs
accruing over a 1-year period following primary surgery for breast cancer. The authors’ rationale for this
choice was that ‘it is anticipated that the systematic application of OSNA will lead to equivalent test
results and long term patient management as current postoperative testing’ (NICE technical management
team technical analyst Sarah Byron, 1 July 2012, personal communication of information provided by
the manufacturer).
Using values of 95.6% for sensitivity and 96.7% for specificity, the mean per patient costs were estimated
to be €771 (£603; at gross domestic product purchasing power parity126) for the status quo and €604
(£473) for OSNA, resulting in a mean per patient cost saving with the latter of €167 (£131). The authors
argue that their analysis ‘would be equally applicable to the UK but should show a greater economic
benefit given that most sentinel lymph node analysis in breast cancer patients in the UK market is
performed post-operatively so savings in second surgery would be more pronounced’ (NICE technical
management team technical analyst Sarah Byron, 1 July 2012, personal communication of information
provided by the manufacturer).
The results of this analysis are of limited value because of the lack of information made available to the
Evidence Review Group (ERG) on the methods behind the analysis. The analysis was based on aggregate
measures of costs and so quantities of resource use were not discernible. The analysis claims to account for
costs up to 1 year after the initial operation but from the available detail it is unclear if any costs other
than those associated with the diagnostic pathway were included. The analysis did not attempt to account
for the costs of adverse events nor the effects in terms of health benefits and quality of life. No account
was made of the degree of uncertainty in the model estimates, thus preventing an assessment of the
likelihood that chance alone may explain the reported cost effects of OSNA.
Independent Evidence Review Group assessment
Objective of the analysis
The main analysis compares OSNA and Metasin with histopathology from the perspective of the NHS.
The evaluation is presented for the outcomes occurring up to staging of the axilla. In addition, a separate
analysis evaluated the long-term outcomes of intraoperative testing options in terms of QALYs and costs.
The long-term analysis is intended as an illustration of the relative size of the benefits of intraoperative
diagnosis and the effect of uncertainty on its expected lasting impact.
Description of the model
The model is split into two separate sections (diagnostic and management) to encompass both immediate
and long-term outcomes. As the technology is expected to have a larger impact on the short-term
outcomes, it is this section that we particularly focus on.
Diagnostic pathway
This section of the model is used to both inform the rest of the model and provide the intermediate
outcomes described in the definition of the decision problem (see Chapter 2, Decision question).
The Evidence Review Group diagnostic pathway
Patients enter the model having had a SLNB performed during their initial tumour removal. The model
then splits into three different strategies to encompass each of the possible combinations of diagnostic
tests: intraoperative only (OSNA or Metasin, not in combination), histopathology only or a combination of
an intraoperative assay and follow-up histopathology. These three strategies are shown in Figure 14.
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In the following descriptions, positive test results refer to results that indicate metastases in the SLN.
The three modelled pathways are therefore:
l Current practice. The SLNB is analysed using histopathology of the full node. If positive for metastases a
second surgery is performed in which ALND occurs.
l Add-in strategy. Half of the SLN from the SLNB is analysed during removal of the tumour using one of
the intraoperative tests (OSNA or Metasin). Those with a positive result receive ALND during that
surgery. For those with a negative result, the other half of the SLN is kept to be analysed by
histopathology. Patients whose metastases were not detected at the intraoperative stage but whose
histopathology is positive receive ALND as a second operation.
l Replacement strategy. The full SLN is assessed using the intraoperative test, with no histopathology.
Those with a positive result will receive ALND during their tumour removal.
At this stage we calculate the intermediate costs and patient outcomes. This analysis was developed in
Microsoft Excel 2010 (version 14.0.7128.5000, Microsoft Corporation, Redmond, WA, USA).
Assumptions
In this section of the model the following assumptions are made:
l Compliance to all procedures offered to the patient is 100%. This includes compliance to ALND and
therefore all patients who test positive for SLN metastases receive ALND. This assumption was adopted
on the basis of the opinion elicited from clinical experts advising the ERG on this topic (see Appendix 7
for a list of the clinical experts).
l The failure rate of SLNB, discussed in Chapter 1 (see Accuracy and adverse effects of sentinel lymph
node biopsy), is treated as 0. In reality, SLNB has a failure rate of < 5% (the consensus from clinical
experts advising the ERG on this topic). As this is relatively low and there is no evidence on a difference
in impact when comparing the use of SLNB in intraoperative testing with the use of SLNB in
histopathology, we have to assume that the impact is the same and treat it as 0.
l It is unclear from the clinical effectiveness systematic review what a failed intraoperative test would be,
as it is not something that is discussed in the studies. The number of reports that provide the number of
failed tests is low, which suggests that the failure rates are low; in addition, our experts were not aware of
failure rates, suggesting that the concepts of a failed intraoperative test and the rate of failure are not yet
well established. As the understanding of failure for OSNA is unclear, it is impossible to model successfully
the impact of knowing when a test has failed in the model. Therefore, for the purposes of the model we
assume the known failure rate to be 0. Instances in which the failure status of intraoperative testing is
unknown directly impact on the sensitivity and specificity of the test and therefore can be implicitly
incorporated into the model using sensitivity analysis of the sensitivity and specificity parameter values.
l In the absence of relevant empirical data from studies using full-node analysis, half-node analysis data
are used for all test accuracy data for all pathways. We expect this to underestimate the accuracy of
these tests in a full-node situation and thus serve as a conservative analysis of their benefits.
l Similarly, based on the data, histopathology is assumed to have a sensitivity and specificity of 1 as it is
used as the gold standard in the evaluative studies. This may also slightly underestimate the relative
accuracy of the intraoperative tests, as the accuracy of histopathology will not actually be 1.
Post diagnosis (management pathway)
After the diagnostic pathway our cohort splits into various management subgroups:
l Patients with SLN metastases who test positive for metastases and who receive ALND (in either their first
surgery or as a separate second surgery for ALND) and who also test positive for additional axillary
metastases when the material from their ALND is tested. The proportion of patients assumed to have
additional axillary metastases after a false-positive SLN metastases diagnosis is assumed to be small enough
that it can be modelled as 0%. The proportion of patients assumed to have additional axillary metastases
after a true-positive SLN metastases diagnosis is taken from the Z0011 trial37 and is set to 27.3%.
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l Patients who test positive for metastases and who receive ALND (in either their first surgery or as a
separate second surgery for ALND) but who do not test positive for additional axillary metastases when
the material from their ALND is tested. These patients include those who were correctly identified as
having SLN metastases and those who were incorrectly identified as having SLN metastases.
l Patients without SLN metastases who test negative for metastases and do not receive ALND.
l Patients with SLN metastases who test negative for metastases and do not receive ALND.
A visual representation of these subgroups is provided in Figure 15.
Once these subgroups are established, the model moves into its second section: the management
pathway. This section of the model calculates the long-term outcomes, most notably the costs and QALYs.
We model each of the groups from this point using as a basis the discrete event simulation (DES) model
previously utilised by the School of Health and Related Research Technology Assessment Group
(ScHARR-TAG) team,9,122 with updated parameters.
The School of Health and Related Research model structure
The ScHARR uses a DES model built in Simul8 2009 (Simul8 Corporation, Boston, MA, USA) for its
economic evaluation of diagnostic imaging leading to SLNB or ALND without SLNB (without intraoperative
testing) for the diagnosis of metastasis in early breast cancer. A DES models individual patients with
individual attributes, such as the patient’s diagnostic and disease history. Unlike Markov state transition
models, in which the transition probabilities are evaluated during fixed time intervals, the transit of patients
through states in a DES may occur continuously according to a statistical distribution function. If it is
possible for a patient to make a transition from the current state to multiple states then the model samples
the time to each possible destination and compares them. The destination state with the shortest sampled
time is the one to which the simulated patient moves to.9 DES models are more flexible than Markov
models but, as they are usually more complex, they take longer to build and run and, more importantly,
are more demanding in terms of evidence to populate their parameters.127 As the existing ScHARR model
had already been subject to peer review,122 and because of the high element of uncertainty involved in
extrapolating outcomes beyond the diagnostic phase in this evaluation, the benefits of building a de novo
model did not justify the costs.
A basic layout of the ScHARR model is provided in Figure 16. Once the process of testing for SLN
metastases, surgery for tumour removal and possible ALND has been completed, patients enter a state of
adjuvant therapy. This involves chemotherapy and hormonal therapy (when appropriate) for those
diagnosed with metastases and hormonal therapy alone (when appropriate) in patients diagnosed without
Patients tested for
SLN metastases
SLN metastases 
found, ALND
No SLN
 metastases
found
True-negative
SLN
False-negative
SLN
Mix of false-positive
SLN and some 
true-positive SLN
True-positive
SLN
No further axillary
metastases found
Further axillary
metastases found
FIGURE 15 Post-diagnosis subgroups. This diagram shows the possible pathways of patients immediately post
diagnosis and their true SLN metastases status.
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SLN metastases. After adjuvant therapy patients may move into a disease-free state (post-adjuvant therapy
state) and potentially stay there for the rest of their lifetime. During or after adjuvant therapy, some patients
may have a locoregional relapse (see Glossary). Patients in the post-adjuvant therapy state may experience
locoregional or metastatic relapse. Patients in the locoregional relapse state may go into remission or
advance to metastatic relapse. Patients in remission may remain in that state until death or enter a
metastatic relapse state (for the purposes of the model there cannot be a further locoregional relapse).
The model does not consider metastatic disease curable and therefore patients in this state may move to a
death state only, either from breast cancer or other causes. Patients in all states can die from other causes.
The authors of the ScHARR model claimed that there were problems in deciding whether ALN
metastases identified during follow-up are the result of recurrence or a previous misdiagnosis (a previous
false-negative test). As this problem was beyond the scope of their project, they did not explicitly model it.
In practice, it is difficult to obtain conclusive evidence that a given recurrence results from secondary
metastatic spread (from some subclinical distant site), and recurrence in the axilla would be presumed to
be disease that already existed at presentation but which was not eradicated by standard therapy, that is,
in a LN that was not removed by ALND. The same argument applies to extra-LN recurrences, which
represent cancer cells not removed by surgery or eradicated by systemic therapy. This issue is similarly
beyond the scope of our assessment and therefore we adopt the model’s approach as reasonable for
our purpose.
The following are the ScHARR model assumptions:
l Lymphoedema is the only long-term adverse event considered and is classified as either mild/moderate
or severe, based on the research data available. It affects both costs and quality of life for the rest of
the patient’s life. We also model only lymphoedema as no relevant papers on other long-term adverse
events were found. To incorporate the effect of lymphoedema on patients we populated the respective
parameters using evidence from studies of patient-reported outcomes for lymphoedema.
l Adjuvant therapy occurs for a maximum 5-year period, consistent with the recommended follow-up
period stated in the NICE guidelines for early breast cancer,13 but the model allows for patients to move
to another state before the end of this 5-year period. In this state, patients who test positive for
additional axillary metastases, confirmed on ALND, receive chemotherapy for 6 months followed by
hormonal therapy for 4.5 years. Patients who test negative for SLN metastases or who test positive
for SLN metastases only and not for further axillary metastases on ALND receive hormonal therapy for
5 years.
l After a locoregional relapse further locoregional relapse cannot occur; only metastatic relapse can
occur. This is a simplification of clinical practice but was retained so that the model could be kept
simple and because this was not the main focus of our assessment.
Post-
adjuvant
therapy
Adjuvant
therapy
Locoregional
relapse
Remission
Death by
breast
cancer
Metastatic
relapse
Death by
other
causes
FIGURE 16 The ScHARR model for post diagnosis of axillary metastases.
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l Death rates for non-breast cancer causes are based on UK mortality statistics and are applied across all
health states. These are not adjusted to exclude breast cancer mortality and so they may overestimate
the risk of dying from non-breast cancer causes. In our model we use mortality statistics for England as
this was the population stated in the objective in our protocol. As in the ScHARR model we use the
statistics for women only as a very small proportion of breast cancer cases (< 1%) occur in men.14
Because we relied on the treatment phase of the ScHARR model with limited modifications, we quality
assessed the model and found that it met the standard quality criteria required for health economic
evaluation models.125 The ScHARR model depicts a very similar problem to that analysed in this study, but
does not consider intraoperative testing approaches. Although this is presumably because intraoperative
tests were outside its remit, the authors do not state this. However, this has a limited impact as it affects
only the diagnostic stage of the model, which we do not use. The model does not value productivity
changes, which are beyond our remit too. Overall, the ScHARR model was well reported and transparent
and we therefore felt comfortable adapting it to our purposes. During the course of our review process we
have worked with two of the ScHARR model authors in adapting and updating their model for our
purposes; one (YM) has become a co-author of this report and the support of the other (KC) has
been acknowledged.
Source of the model parameter values
Diagnostic pathway
Test accuracy probabilities
In our analyses histopathology is assumed to be the gold standard and is given an accuracy of 100%
(Table 40), as this generally is how the sensitivities and specificities of the intraoperative tests have been
assessed in the literature (see Chapter 3, Assessment of test accuracy).
Accuracies for Metasin have been provided by authors of unpublished papers40,66 and accuracies for OSNA
were provided by the patient-level results of the clinical systematic review. Sufficient studies on OSNA that
did not adjust for TAB were found to allow us to carry out a meta-analysis for the sensitivity and specificity
of the test. As there were too few studies on OSNA that adjusted for TAB and only two studies on
Metasin, we used the meta-analysed accuracy values for OSNA without adjustment for TAB and the
Sundaresan report40 on Metasin (which did not adjust for TAB) for our base-case analysis and used
the other studies57,58,61 individually in our sensitivity analyses. For neither histopathology nor intraoperative
testing have we accounted for the false-negative rate associated with SLNB. This rate is normally < 10%128
(e.g. Cooper et al.9 model it as 7%) and occurs either as a result of metastases being in a node other than
the SLNB being examined or as a result of the preparation procedure for histopathology. As there are no
data on what proportion of the failure rate would specifically affect histopathology (or intraoperative
TABLE 40 Test accuracy in the base case
Test Sensitivity (%) Specificity (%) Source
Histopathology 100.0 100.0 Assumed (used as the gold standard in studies)
OSNAa 84.5 91.8 Meta-analysis results (see Chapter 3, Assessment of test accuracy)
OSNAb 91.4 93.3 Le Frère-Belda et al.58
100.0 97.2 Khaddage et al.57
89.8 94.5 Snook et al.61
Metasina 92.6 96.3 Sundaresan40
a No adjustment for TAB.
b Adjustment for TAB.
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testing), we have not modelled it. It is therefore important to note that the model may underestimate the
accuracy of the intraoperative tests.
The node-positive prevalence is set at 20% in the base case, which is consistent with the values found in
the systematic review of accuracy studies.
Adverse event probabilities
We found no new relevant studies in the population of interest that served to update the probabilities of
adverse events in the ScHARR model. For the short-term adverse event probabilities we used the original
model’s values.9 We examined the original studies that ScHARR used to populate both long- and
short-term outcomes to verify that the probability values for events in its long-term model applied to our
intermediate outcomes. For lymphoedema we confirmed ScHARR’s values by returning to the same
original sources as ScHARR and similarly splitting patients into those with mild/moderate lymphoedema
and those with severe lymphoedema (Table 41). Patients were divided into these groups either on the
basis of their response30 or on the swelling measurement (> 5 cm was severe in the study by McLaughlin
et al.31). Patients were also split by the treatment to the LNs: either SLNB or ALND. In all of the studies
ALND followed SLNB and therefore the reported probabilities included the risk level of SLNB. The costs,
disutility and probabilities for lymphoedema are incorporated in the treatment phase of the model as it is
an adverse event with long-term implications.
Costs
Costs for tests were taken directly from manufacturer/academic submissions. When only a range of costs
was provided [e.g. the costs for OSNA were given as £300–400 (Nice technical management team
technical analyst, Sarah Byron, 1 July 2012 personal communication)], we took the midpoint of that range
as our base cost (£350 in the case of OSNA). The costs of Metasin provided by the sponsor of the
TABLE 41 Probabilities associated with adverse events
Event Probability Source
Short-term adverse events
Infection
SLNB 0.072 Cooper et al.9
ALND 0.221
Seroma
SLNB 0.020 Cooper et al.9
ALND 0.792
Surgical drain
SLNB 0.021 Cooper et al.9
ALND 0.142
Long-term adverse event: lymphoedema
SLNB 0.068 Crane-Okada et al.30
Mild/moderate lymphoedema 0.045 Adjusted using Mak et al.129
Severe lymphoedema 0.023
ALND 0.214 Crane-Okada et al.,30 McLaughlin et al.,31 Blanchard et al.29
Mild/moderate lymphoedema 0.142 Adjusted using Mak et al.129
Severe lymphoedema 0.072 Adjusted using Mak et al.129
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technology were used. After the analysis had been completed the sponsor provided an indicative update
of the costs (£60–80 for kit reagents, for up to four nodes, and a reagents and consumables cost of £20
per node), which were not used to revise the analysis because of time constraints and because the results
were not likely to be significantly altered. (However, with a private company having taken over the
commercial development of the test, the cost-effectiveness analysis may be updated if and when a
finalised list price for the CE-marked Metasin test is received.) Histopathology costs were based on data
provided by the NHS Technology Adoption Centre, which in turn were based on evidence from a
microcosting study conducted at the Queen Alexandra Hospital123 (reflated to 2010 prices) and reported in
technical detail by researchers at the York Health Economics Consortium (YHEC),124 and include the cost of
confirmation by immunohistochemistry (Table 42).
For surgery costs we relied mainly on NHS reference costs.130 An overall average value for breast surgery
was calculated using costs for lumpectomy and mastectomy [Healthcare Research Group (HRG) codes
JA07D, JA07E, JA07F, JA07G and JA07H for mastectomy and HRG codes JA09E, JA09F, JA09G and
JA09H for lumpectomy, chosen on advice from ScHARR].130 These costs were weighted by two-thirds for
lumpectomy and one-third for mastectomy to represent the split between lumpectomy and mastectomy
cases according to the opinion from our specialist advisors. The cost of a single surgery for ALND used the
reference cost for procedures on the lymphatic system (HRG code WA24Z). There were no reference costs
that included extra costs for SLNB or ALND procedures undertaken during breast surgery. We therefore
used the same procedure as employed by Cooper et al.9 to incorporate these additional costs. Using the
results reported by Pandharipande et al.131 we calculated the ratio between the cost of breast surgery with
SLNB and the cost of breast surgery alone ($7537/$5264) and the ratio between breast surgery with SLNB
and ALNB and breast surgery with SLNB alone ($11,244/$7537). The base cost of breast surgery (£1804.90
from the NHS reference costs130) is then multiplied by these ratios to give the costs for breast surgery with
SLNB and breast surgery with SLNB and ALND.
The costs of short-term adverse events were taken from the same source as the ScHARR model133 as no
other papers were identified. No papers were identified for updating the annual lymphoedema costs and
TABLE 42 Unit costs of diagnostic and primary surgery services
Test or surgery Cost (£) Source
Histopathology 472 Cutress et al.123
OSNA 350 Manufacturer information submitted to NICE
Metasin 74 Manufacturer (Matt Hayday, Head of Corporate Governance,
Princess Alexandra Hospital NHS Trust, Harlow, 19 November 2012,
personal communication)
Breast surgery with SLNB 584 NHS reference costs 2010–2011130 updated using the same method as
ScHARR using the results of Pandharipande et al.131
With intraoperative test 12 Additional time cost calculated: 3 minutes for 54% of patients;67
extra cost124 updated to 2010 costs132
Breast surgery with ALND 3855 Breast surgery cost adjusted using the technique of Cooper et al.9
Secondary operation for ALND 3569 NHS reference costs 2010–2011130
Additional hospital stay for
surgery with ALND
106 Burke and Patton,124 updated to 2010 costs
Additional hospital stay for
second surgery for ALND
512 Burke and Patton,124 updated to 2010 costs
Short-term adverse event 333 Jeruss et al.,133 updated to 2010 prices
Mild lymphoedema 71 Cooper et al.,9 updated to 2010 prices
Moderate/severe lymphoedema 1269 Cooper et al.,9 updated to 2010 prices
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as these were originally provided to ScHARR by the Sheffield Lymphoedema Service we considered this an
appropriate source and updated the costs to 2010.
Most studies report only the time that it takes to run an intraoperative test and not the impact that it has
on the length of surgery. The exception is a recent abstract by Ng et al.,67 which stated that in 54% of
cases breast surgery was complete before the results for OSNA were received. The median time over this
surgery was 3 minutes. Applying this to an entire cohort gives an average waiting time of 1.62 minutes.
To cost this we applied this time delay to costs from the microcosting study from the YHEC,124 which
reports unit costs for various surgical procedures. These costs were updated to 2010 costs using the cost
convertor developed by Shemilt et al.132 Using the costs for a surgeon (£159.74 per hour), theatre staff
(£2.60 per minute) and anaesthetist staff (£124.24 per hour) we calculated that the extra cost of waiting
for intraoperative results was £11.88. We used this value for all intraoperative tests, even though it was
calculated using only OSNA data, as there were no equivalent data for Metasin and none of the reported
Metasin processing times were contrary to any of the assumptions made.
A consequence of an ALND procedure, either in the first breast surgery or in a separate surgery, is extra
days spent in hospital by the patient. The cost of this extended stay was calculated using the results of
the YHEC microcosting study,124 subtracting the length of stay for a standard surgery (2.1 days) from
the length of stay for surgery that includes ALND (2.7 days) and from the combined length of stay for the
first and second surgeries (5 days) for those who have ALND as a separate surgery. These were multiplied
by the updated 2010 ward costs (£176.44 per day124) to give the costs of this extra hospital stay. The cost
of short-term adverse events was adjusted to 2010 prices because, as reported previously, no more recent
reports were found.9,133
In univariate sensitivity analyses, the unit costs of diagnostic testing in primary breast surgery were
varied according to the range of values reported in the literature for its most important cost elements.
The recently published paper by the YHEC provides unit costs and resource use and is widely known.124
We therefore examined costs based on this information. To ensure that it would directly compare with our
approach using NHS reference costs, we examined the length of stay per operation both in our reference
case and using the YHEC data. In our base case the average length of stay for a single breast surgery was
approximately 2 days; this compared with a length of stay in the paper by the YHEC of 2.1 days124
(Table 43). The average length of stay for surgery on the lymphatic system (our ALND-alone procedure)
was approximately 2.65 days, which is not dissimilar from the YHEC average of 2.9 days.124
TABLE 43 Resource use based on YHEC data124
Resource
Surgery with
SLNB
Second
surgery
Surgery with
axillary clearance
Procedure time (minutes) 54 60
Procedure time – biopsy and analysis (minutes) 53
Procedure time – operation (minutes) 40
Anaesthetic preparation/recovery (minutes) 20 20 20
Theatre turnaround time (minutes) 20 20 20
Length of stay (days) 2.1 2.9 2.7
Hospital sterilisation and disinfection unit (trays) 1 1 1
Physiotherapist (minutes) 10 10
MDT appointment (minutes) 10 10
MDT meeting (minutes) 3 3
Source: Burke and Patton.124
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We therefore calculated surgery costs based on the YHEC information, with unit costs updated to 2010
costs (Table 44). As in our base-case analysis we assumed that the ward stay would be the same for all
patients without axillary clearance, regardless of how the SLNB was analysed. The YHEC reported
intraoperative analysis times that were shorter than the surgery times and so no additional time was
factored in in this case. On the advice of our experts, the time taken by the MDT is the same for all
diagnostic testing procedures and therefore the second operation for ALND does not incur an additional
MDT cost as it does in the YHEC report.
Total surgery costs, given in Table 45, are calculated by multiplying the resource use by the relevant
unit cost. For basic surgery this includes the cost of theatre time for each member of the surgical team,
the theatre stock cost, the ward cost for the length of stay and the cost of the MDT meetings.
As additional ward costs for surgery with ALND and ALND alone are already calculated separately as part
of the base-case analysis, these are not included in those particular operation costs. However, these two
surgeries do incur the cost of a physiotherapist, because of the ALND.
As Burke and Patton124 did not present values for the uncertainty around these estimates, in sensitivity
analysis we used a separate report by Burke and Setters134 to obtain alternative values of resource items
that might have the largest effect on the cost difference between diagnostic strategies. The alternative
values that applied were a shortening in the time of surgery with ALND by 10 minutes and changes in the
TABLE 44 Unit costs, updated from 2008 to 2010
Resource Unit cost (£)
Direct costs
Surgeon (per hour) 159.74
Ward costs (per day) 176.44
Indirect costs
Theatre staff (per minute) 2.60
Anaesthetist staff (per hour) 124.24
Theatre stock consumables (by case) 64.73
Anaesthetic administration and junior doctors (by case) 68.91
Hospital sterilisation and disinfection unit (by case) 17.75
Anaesthetic gases (by case) 25.06
Physiotherapist (per hour) 25.06
MDT appointment (per hour) 81.43
MDT meeting (per hour) 644.16
Source: Burke and Patton.124
TABLE 45 Surgery costs
Surgery Cost (£)
Operation with SLNB (with ward costs, MDT meeting) 1282
Operation with SLNB and ALND 1580
ALND only 1284
Source: Burke and Patton.124
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MDT meeting length (range 10–20 minutes). By varying the surgery costs by ±10% we were able to
incorporate the variations that these changes caused.
Utilities
Patients who undergo testing by histopathology have to wait approximately 2 weeks for the results. We
surmised that this would incur some level of disutility to patients because of the associated anxiety of
waiting, and imputed it using the health state valuation equation provided by Dolan.135 Dolan estimated
the health state values of the European Quality of Life-5 Dimensions (EQ-5D) classification system, which
measures health-related quality of life in terms of five dimensions: mobility, self-care, ability to perform
usual activities, pain/discomfort and anxiety/depression. In turn, each of these dimensions is measured on
three levels: no problem, moderate problems and severe problems. The utility weights for these levels were
estimated from responses to relative valuation questions in a survey of the UK general public. For our
purposes, only the utility decrement due to anxiety/depression was relevant and we adopted the
decrement specific to the severe level. The equation for this takes the form:
Y=αþ 2 ADþ A2þ N3 (1)
where α is the constant (0.081) applied to any level of disutility, AD is the constant (0.071) applied to any
level of disutility associated with anxiety or depression, A2 is the constant (0.094) applied to severe levels
of anxiety or depression and N3 is the constant (0.269) applied when any of the five dimensions of the
EQ-5D are recorded as severe. Our patients were assumed to already have a utility of < 1 (meaning that
we did not need to apply the α value) and to be moving from a state of no anxiety/depression to a state of
severe anxiety/depression and it was assumed that this anxiety/depression would be the only dimension
of the EQ-5D that was graded as severe. This gave us a decrement of –0.236 – 0.269= –0.505. Once we
had used the formula to calculate a value for Y, we adjusted it to apply for only 2 weeks. This gave us a
reduction in undiscounted QALYs of 0.019 for the 2 weeks spent waiting for histopathology results.
We also assumed that patients who undergo a second operation would have a disutility. To account for
this we used utilities from the literature.136 None was specific but a value of 0.62 was provided for the
2 months following breast cancer surgery. We subtracted this from the highest utility in the adjuvant
therapy states (0.82) and adjusted for the 2 months to give a disutility of 0.03.
Treatment phase
Health state transition probabilities
No studies were found that allowed us to update all of the health state transition probability values
appropriately and therefore we returned to the papers used by ScHARR and kept all of the parameters
and SEs used in the ScHARR model9 (Table 46). The papers used included previous cost-effectiveness
models131,137,139 and a prospective cohort study.138 The cost-effectiveness models used data from the Early
Breast Cancer Trialists’ Collaborative Group,137,140 Adjuvant! Online18,131 and a retrospective US study.139
When patients enter the model, their maximum life expectancy is set using life tables.141 It is possible for a
patient to die before this time in the model, depending on his or her transitions through the health states.
Each time a patient enters a state, the time to each of the next plausible states is sampled from an
exponential distribution using the annual transition probabilities. The state with the shortest time delay
is the state that the patient then moves to following that delay and the process is then repeated.
This analysis simulates the individual experiences of a cohort of 5000 patients, to calculate patient-level
results (first-order Monte Carlo simulation) and additionally randomly samples from the independent model
parameter distributions (second-order Monte Carlo simulation). There is therefore a probabilistic sensitivity
analysis built into the model.
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Health state costs
Relevant studies and NHS costs were used to calculate the health state costs (Table 47). The cost of
adjuvant therapy was calculated using methods reported elsewhere.9 This assumes that patients with
test-negative SLN status (true or false) and patients who test positive for SLN metastases but who have no
further metastases found on ALND will receive hormonal therapy for 5 years when appropriate. Patients
who were found to have SLN metastases and additional axillary metastases receive chemotherapy for
6 months using regimens commonly used in the UK at corresponding prices.9 They also then receive
hormonal therapy for 4.5 years. To calculate an average cost per patient, assumptions are made about
the hormonal therapy provided. It is assumed that 81% of patients are oestrogen receptor positive
and will therefore respond to hormonal therapy.139 As in the ScHARR model, we assume that, of these,
90% will receive some form of aromatase inhibitor and the other 10% will receive tamoxifen.9 Regardless
of hormonal therapy status, each patient will also have a yearly outpatient follow-up appointment and a
mammogram. The combined average annual cost per patient for hormonal adjuvant therapy and
follow-up is calculated to be £1086.75. The cost of the post-adjuvant therapy state is assumed to be £0
and the costs of locoregional and metastatic relapse and remission and death are taken from the study by
Karnon et al.,143 which was a UK cost–utility analysis that estimated these costs based on a cost study of
199 women in Edinburgh.
All costs are updated to prices for the year 2010 as required and, as we had no data on the uncertainty
around these estimates, values were sampled from a uniform distribution of ±10% around the mean
estimate for sensitivity analysis.
Health state utilities
All health state utilities were derived from the Tengs and Wallace study136 using the same parameters and
SEs as ScHARR (Table 48). The Tengs and Wallace study136 was a comprehensive study and no new data
were available for these particular variables. Each parameter was given a beta distribution.
TABLE 46 Health state transition probabilities
Transition Probability SE Distribution Source
Annual probability of locoregional recurrence: no
SLN metastases/no additional axillary metastases
0.03 0.0017 Beta Cooper et al.,9 Orr et al.137
Annual probability of locoregional recurrence:
SLN metastases and additional axillary metastases
0.09 0.0052 Beta Cooper et al.,9 Orr et al.137
Annual probability of locoregional recurrence:
SLN metastases, tested negative
0.14 0.0082 Beta Cooper et al.,9 Orr et al.137
Annual probability of metastatic recurrence:
true negative, false positive
0.0023 0.00014 Beta Cooper et al.,9
Pandharipande et al.131
Annual probability of metastatic recurrence:
true positive
0.0052 0.00030 Beta Cooper et al.,9
Pandharipande et al.131
Annual probability of metastatic recurrence:
false negative
0.0094 0.00054 Beta Cooper et al.,9
Pandharipande et al.131
Annual probability of metastatic relapse from
locoregional recurrence
0.18 0.010 Beta Cooper et al.,9
Kamby and Sengelov138
Annual probability of death from
locoregional recurrence
0.30 0.017 Beta Cooper et al.,9 Orr et al.137
Annual probability of metastatic relapse
from remission
0.13 0.0075 Beta Cooper et al.,9
Kamby and Sengelov138
Annual probability of death from
metastatic relapse
0.37 0.021 Beta Cooper et al.,9 Ward et al.139
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We also accounted for the general population change in utility that occurs with age, using the same
formula as in the original ScHARR analysis, which adjusted a previously reported formula.145 The utilities for
the health states are adjusted using the following formula at the end of each year in the model:
UGP = 0:9584588− 0:0001728 age− 0:000034 age2 (2)
In our model, the starting age is 56 years, the mode across studies in our systematic review (see Chapter 3,
Population characteristics). Although the formula was not specifically estimated for women, analysis of
Canadian longitudinal population survey data suggests that the evolution of utility with age does not
significantly differ by gender.146
TABLE 47 Health state costs
State Cost (£) Parameter Source
Cost of adjuvant
therapy: TN, FP, FN
1087 Annual cost NHS reference costs 2010–2011130 for outpatient follow-up+NHS
reference costs 2002–2003142 for mammogram, cost updated+
Ward et al.139 cost for hormone therapy, cost updated
Cost of adjuvant
therapy: TP
9447
first year
Cost for
6 months
Cooper et al.,9 cost updated
1087 after
first year
Annual cost after
first 6 months
NHS reference costs 2010–2011130 for outpatient follow-up+
NHS reference costs 2002–2003142 for mammogram, cost
updated+Ward et al.139 cost for hormone therapy, cost updated
Cost post adjuvant
therapy
0 Annual cost Cooper et al.,9 assumption
Cost of
locoregional
recurrence
13,745 Annual cost Karnon et al.;143 2005 prices reflated to 2010 using the Hospital
and Community Health Services Index144
Cost of remission 108 Annual cost Karnon et al.;143 2005 prices reflated to 2010 using the Hospital
and Community Health Services Index144
Cost of metastatic
relapse
10,443 Annual cost Karnon et al.;143 2005 prices reflated to 2010 using the Hospital
and Community Health Services Index144
Cost of death 5713 Cost of event Karnon et al.;143 2005 prices reflated to 2010 using the Hospital
and Community Health Services Index144
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
TABLE 48 Health state utilities
State Utility SE Distribution Source
Adjuvant therapy: TN, FP, FN 0.82 0.18 Beta Tengs and Wallace136 (adjuvant therapy)
Adjuvant therapy: TP 0.74 0.26 Beta Tengs and Wallace136 (chemotherapy)
Post therapy 0.94 0.11 Beta Tengs and Wallace136
Locoregional recurrence 0.70 0.19 Beta Tengs and Wallace136
Remission 0.85 0.19 Beta Tengs and Wallace136 (after first recurrence)
Metastatic relapse 0.40 0.19 Beta Tengs and Wallace136
Death 0.00 By definition
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
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Other utility values, including lifetime utility decrements for lymphoedema into the treatment phase of
9.9% for mild/moderate lymphoedema and 12.3% for severe lymphoedema, were obtained from the
same source129 used in the ScHARR model.9 These were estimated based on quality-of-life data obtained
using the FACT-B+4 questionnaire (Functional Assessment of Cancer Therapy – Breast, adding a four-item
arm subscale) from breast cancer patients who suffer from different degrees of lymphoedema and
therefore they do not necessarily represent the true utility decrements for lymphoedema. However, when
ScHARR performed a sensitivity analysis around these utilities it was found to not significantly affect
the results.9,122
Implementation of sensitivity analyses
In terms of uncertain parameters of the diagnostic phase of the model we focused mainly on the cost
drivers and accuracy as part of sensitivity analyses. We looked at the impact of altering the costs of the
tests and surgeries, particularly the cost of a second surgery, by setting ranges appropriate to the evidence
that we had obtained from the literature. Although there was no additional information on the variation
in costs, we looked at cost ranges of ±10%. As well as looking at the differences in accuracy between
the studies that did not account for TAB and the studies that did, we performed a threshold analysis of
sensitivity in which the specificity is held constant and the sensitivity is increased in steps of 5% from a
minimum of 70% (the lower end of the CI produced in the meta-analysis). This process was repeated for
specificity, holding sensitivity constant. The impact of accuracy and costs was assessed in both the
short-term and long-term results.
For the purposes of assessing the effect of uncertainty in the long-term outcomes on the results, we ran
supplementary univariate sensitivity analysis of the costs of adjuvant therapy, adjusting the mean by ±10%
in two different simulations. Adjuvant therapy is the cost parameter that varies the most in direct relation
to the outcome of the diagnostic tests and therefore is the most likely to impact on the model results.
We also considered the impact of the disutility associated with waiting for histopathology results and a
second operation for ALND. For the disutility associated with anxiety, we examined the scenarios in which
the disutility was 0, in which there was some disutility (0.006, using Dolan’s135 moderate anxiety value
of 0.071, adjusted for 2 weeks) and in which there was extreme disutility (0.023), which used Dolan’s
formula but assumed that there was nothing else wrong with the patient. For the disutility associated with
a second operation, we looked at the scenarios in which the disutility was adjusted by ±20% and in which
the disutility was 0.
For the base-case parameters, a total of 900 simulations were run according to the parameter distributions
(see Tables 46 and 47 and Health state costs) and with other parameters fixed at base-case values and
presented the mean incremental costs and incremental QALYs. One-way and two-way sensitivity analyses
were performed using a total of 500 simulations and, as for the base case, were presented as the mean
incremental cost, mean incremental QALYs and the ratio of these two estimates across model simulations.
Despite the limited evidence on DTA parameters, we also conducted a probabilistic analysis based on
base-case parameter values, accounting for the sampling uncertainty in the sensitivity and specificity of
OSNA from the three study reports that adjusted for TAB (see Table 40), using 900 simulations, assuming
independent variation in diagnostic test and other parameters, but imposing the negative correlation
between OSNA sensitivity and specificity as described by Cooper et al.9 The results are presented as the
probability of OSNA being cost-effective as a function of the cost-effectiveness threshold.
Discount rate
Costs and utilities are discounted at a rate of 3.5% in accordance with NICE guidelines.147
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Measure used to synthesise costs and benefits
Intermediate results
The following measures were used to synthesise costs and health benefits in the diagnostic phase:
l incremental cost per patient
l incremental cost per case correctly diagnosed
l incremental cost per additional positive case detected
l incremental cost per additional negative case detected.
Although we had set out to present, in addition to these measures, estimates of the cost per second
operation avoided, this measure turned out to be of no additional informational value and these results are
therefore not presented.
Long-term analysis
The following measures were used to synthesise costs and health benefits over the lifetime of patients:
l incremental costs
l incremental QALYs
l incremental cost per QALY gained.
Because the status quo, histopathology, was assumed to be the gold standard in the clinical effectiveness
studies, it tended to be the option with the highest benefits (only one study reported evidence that
diagnostic accuracy with OSNA was sufficiently close to that of histopathology to generate more QALYs
with OSNA than with histopathology). To avoid the complication in interpretation that arises with the
incremental cost-effectiveness ratio (ICER) of the new technology, intraoperative testing, which has lower
costs than the status quo, the results are presented for the more relative to the less effective among the
three options, of half-node intraoperative diagnosis, full-node intraoperative diagnosis and histopathology,
according to total QALYs.
Results
Base case
Diagnostic phase
The studies used to inform the economic analyses are presented in Table 40 (see Chapter 3, Assessment of
study quality, for a discussion on the strengths and weakness of the selected studies). For the purpose
of the economic analyses the results are presented by test option and whether estimates of test accuracy
were controlled for TAB.
Ranking the diagnostic strategies by diagnostic accuracy and comparing the incremental costs and yields
between increasingly accurate diagnostic strategies allowed the calculation of incremental costs per
additional patient correctly diagnosed ratios and the identification of dominated options, that is, those that
had higher costs and lower yields than the alternative. Table 49 summarises the cost–accuracy analysis for
accuracy estimates unadjusted for TAB. Under the NHS reference costs130 costing system, half-node OSNA
dominated histopathology for each additional node-positive case detected, but histopathology dominated
half-node OSNA for each additional node-negative case detected and had an incremental cost per
additional negative case detected of £8994 relative to full-node OSNA, which is lower than the
conventional cost-effectiveness threshold. When YHEC cost values124 were used, histopathology dominated
half-node OSNA for all measures of accuracy and consistently had an ICER of < £13,000 compared with
full-node OSNA.
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TABLE 49 Short-term cost–accuracy analysis comparing histopathology with full- and half-node intraoperative
analysis with sensitivity and specificity unadjusted for TAB
Measure
Mean estimates Incremental results
Histopathology
OSNA
Difference half-node
OSNA vs. full-node OSNA
Difference
histopathology vs.
half-node OSNA
Half
node
Full
node
Accuracya 1.0000 0.9344 0.9034 0.0310 0.0656
Sensitivity × prevalenceb 0.2000 0.2000 0.1690 0.0310 0
Specificity × (1 – prevalence)b 0.8000 0.7344 0.7344 0 0.0656
Analysis using NHS reference costs130 for ALND
Cost per patient (£) 3987 3897 3397 500 90
Incremental cost per
additional patient correctly
diagnosed (£)
Half-node OSNA
extendedly dominated
6108c
Incremental cost per
additional node-positive
case detected (£)
16,123 Histopathology
dominated
Incremental cost per
additional node-negative
case detected (£)
Half-node OSNA dominated 8994c
Analysis using costs based on the YHEC model124
Cost per patient (£) 2228 2284 1855 429 –56
Incremental cost per
additional patient correctly
diagnosed (£)
Half-node OSNA
extendedly dominated
3866c
Incremental cost per
additional node-positive
case detected (£)
Half-node OSNA
extendedly dominated
12,046c
Incremental cost per
additional node-negative
case detected (£)
Half-node OSNA dominated 5693c
a Accuracy is defined as the probability of a correct diagnosis.
b Node-positive prevalence fixed at 20%.
c Comparison is histopathology relative to full-node OSNA because of the half-node OSNA option being dominated
(i.e. having higher costs and a lower diagnostic yield than another diagnostic option) or extendedly dominated
(i.e. the incremental cost per additional diagnostic yield is higher than that of another, more accurate option).
In the case of node-negative case detection, half-node OSNA was dominated by full-node OSNA as they had the same
detection rate but full-node OSNA was less expensive. Similarly, for node-positive case detection, histopathology and
half-node OSNA had the same detection rate and so their dominance was dependent purely on which was least expensive.
For NHS reference costs, this was half-node OSNA and so histopathology was dominated; for YHEC costs124 this was
histopathology and so half-node OSNA was dominated. When NHS reference costs130 apply, OSNA half-node is extendedly
dominated, that is, its incremental cost per additional diagnostic yield relative to full-node OSNA is higher than that
of histopathology.
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The discrepancy between the YHEC cost results and the NHS reference cost results occurred for a couple
of reasons. First, YHEC costs for surgery were significantly lower than the NHS reference costs for surgery,
giving greater weight to other costs, such as adverse event costs, but there was also a difference in the
ratios between the different types of surgery (breast surgery with SLNB alone, breast surgery with SLNB
and ALND, breast surgery for ALND alone). In particular, the cost ratio between histopathological and
intraoperative test-positive patients using YHEC costs was significantly lower than that obtained using the
NHS reference costs. This meant that the cost impact of a second surgery for patients diagnosed by
histopathology was greatly reduced and costs such as the additional cost of histopathology in OSNA
test-negative patients and the cost of short-term adverse events in the half-node strategy had a greater
influence. This made the half-node strategy more expensive than histopathology alone. This gave rise to
the seemingly inconsistent results between the NHS reference cost analysis, in which half-node OSNA was
not dominated by histopathology, and the YHEC cost analysis, in which half-node OSNA was dominated
by histopathology.
This analysis was repeated for the three individual OSNA studies that adjusted for TAB and the incremental
results are reported in Table 50. Similar results were found for the studies by Le Frère-Belda et al.58 and
Snook et al.,61 but not for the best-case scenario provided by Khaddage et al.,57 in which sensitivity was
100% and specificity was 97.2%. Here, full-node OSNA had the same accuracy as half-node OSNA and so
histopathology was compared directly with full-node OSNA. Full-node OSNA dominated histopathology for
a node-positive diagnosis and any additional node-negative patients detected by histopathology cost
£27,300 per case identified under the NHS reference costs. This reduced to £17,100 under YHEC costing.
Part of the cost-effectiveness assessment of the short-term outcomes (i.e. of the diagnostic phase)
examined the disutility of second operations and waiting for histopathology results. The diagnostic costs
and utility per patient are reported in Table 51. For strategies that do not involve histopathology, this utility
was 1 as there was neither the need to wait for test results nor a second surgery directly resulting from the
intraoperative test. Using the NHS reference cost scenario, full-node OSNA dominated half-node OSNA
and histopathology as its increased QALY gains, measured until the end of the diagnostic phase, were less
costly. Under the YHEC costing strategy, half-node OSNA provided a small QALY gain over histopathology,
with an ICER of £4832 per QALY gained, but full-node OSNA continued to dominate half-node analysis
and histopathology. It is estimated that 4.1% of the 76.5% of patients who have to wait for confirmatory
postoperative histopathology results under the half-node testing strategy end up with a positive diagnosis
as opposed to the 20% expected positivity rate under the postoperative histopathology-only strategy.
According to these short-term costs and benefits, full-node OSNA is the most cost-effective test for
short-term utility. Using the meta-analysis accuracy values for OSNA (sensitivity 84.5%, specificity 91.8%),
histopathology appears to be cost-effective in terms of short-term accuracy, although this begins to look
questionable when the effect of TAB is accounted for and OSNA has a higher sensitivity and specificity.
In all scenarios OSNA is less costly than histopathology.
Long-term analysis
Thus far, the analysis has considered only the short-term costs and consequences of the different
diagnostic options, effectively assuming that no utility benefits accrue from increased diagnostic accuracy.
In the long-term scenario we examined costs and QALYs, which are presented in Table 52 for the studies
with no adjustment for TAB, and account for all costs and the benefits of accurate diagnosis through
improved patient management net of the disutility of anxiety from waiting for the postoperative diagnosis
and undergoing a second operation. The strategies were then ordered by increasing number of QALYs,
with full-node OSNA having the fewest QALYs (9.222) and histopathology having the most (9.321). As this
demonstrates, the QALY difference was approximately 0.10 (i.e. the equivalent of 5 weeks of life in full
health). This QALY difference occurs as a direct consequence of the accuracy of the tests, as a higher
accuracy leads to a greater number of correct diagnoses. As the purpose of diagnosis is to inform
management strategies, an increase in the number of correct diagnoses leads to an increase in the
correct management of patients and therefore patients gain the most QALYs possible. The QALY gain
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TABLE 52 Long-term outcomes comparing histopathology with intraoperative analysis with no adjustment for TAB
Measure
Mean estimates Incremental results
Histopathology
Half-node
OSNA
Full-node
OSNA
Difference half-node
OSNA vs. full-node
OSNA
Difference histopathology
vs. half-node OSNA
Analysis using NHS reference costs130 for ALND
Cost per patient
(discounted) (£)a
20,530 20,523 20,099 424 7
QALYs
(discounted)a
9.321 9.307 9.222 0.085 0.015
Incremental cost
per QALY
gained (£)a
Half-node OSNA
extendedly dominated
4324b
Analysis using costs based on the YHEC model124
Costs per patient
(discounted) (£)a
18,771 18,910 18,556 353 –139
Incremental cost
per QALY
gained (£)
Half-node OSNA
extendedly dominated
2150b
a Costs and QALYs are discounted at a rate of 3.5%.
b Comparison is histopathology relative to full-node OSNA because of the half-node OSNA option being dominated or
extendedly dominated.
TABLE 51 Short-term costs and disutility (diagnostic phase only)
Measure
Mean estimates Incremental results
Histopathology
OSNA
Difference half-node
OSNA vs. histopathology
Difference full-node
OSNA vs. half-node OSNAHalf node Full node
Analysis using NHS reference costs130 for ALND
Cost per
patient (£)
3987 3897 3397 –90 –500
Utility 0.9739 0.9854 1 0.0115 0.0146
Incremental cost
per QALY
gained
Half-node
OSNA dominated
Histopathology dominateda
Analysis using costs based on the YHEC model124
Cost per
patient (£)
2228 2284 1855 56 –429
Utility 0.9739 0.9854 1 0.0115 0.0146
Incremental cost
per QALY
gained
Half-node OSNA
extendedly dominated
Histopathology dominateda
a Comparison is histopathology relative to full-node OSNA because of the half-node OSNA option being dominated
(i.e. having higher costs and a lower diagnostic yield than another diagnostic option) or extendedly dominated (i.e. the
incremental cost per additional diagnostic yield is higher than that of another, more accurate option).
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from the higher accuracy of histopathology is small, but it may be seen as cost-effective; under the NHS
reference costing and ignoring half-node OSNA, as this is a strategy that is extendedly dominated and
unlikely to continue once OSNA has been validated, histopathology had an ICER of £4324 per QALY
gained compared with full-node OSNA. Under YHEC costing, histopathology dominated half-node OSNA,
that is, OSNA had higher costs and produced fewer QALYs. In this scenario the ICER comparing
histopathology with full-node OSNA was £2150 per QALY gained.
For the TAB-adjusted studies (presented in Table 53), half-node OSNA remained extendedly dominated
using the Le Frère-Belda58 values. In this case, histopathology compared with full-node OSNA had ICERs
of £9493 per QALY gained using NHS reference costs130 and £5215 using YHEC costs.124 Using the
values of Snook et al.,61 half-node OSNA was extendedly dominated using YHEC costs (and histopathology
had an ICER compared with full-node OSNA of < £4850 per QALY gained) but was no longer extendedly
dominated using NHS reference costs, and had an ICER compared with full-node OSNA of £8063 per
QALY gained. Comparing histopathology with half-node OSNA, the ICER was £14,967 per QALY gained.
More importantly, Khaddage et al.57 suggested a much better result for OSNA, with full-node OSNA
dominating half-node OSNA and histopathology (full-node OSNA had a higher QALY gain and lower
costs). This was because of the influence of the short-term disutility for anxiety and a second operation
applied (when applicable) to patients undergoing histopathology testing in the histopathology and OSNA
half-node arms. Without this disutility the results using the Khaddage et al.57 values for sensitivity and
specificity altered slightly so that, although in the long term half-node OSNA was still dominated by
full-node OSNA, this was now because they had the same QALY gain but full-node OSNA was less
expensive. The ICER between histopathology and full-node OSNA was £68,432 per QALY gained using
NHS reference costs and £41,619 per QALY gained using YHEC costs, suggesting that histopathology was
not that cost-effective compared with full-node OSNA.
Sensitivity analysis
For the purposes of sensitivity analysis we chose to report only the findings of the NHS reference
costing strategy.
Accuracy
As the TAB-adjusted results have already indicated, test accuracy has a direct impact on the
cost-effectiveness of the tests. A threshold analysis was therefore conducted to investigate sensitivity and
specificity separately. In the case of threshold analysis for sensitivity, specificity was held constant
and sensitivity was increased in steps of 5% over a range of 70–100%. The opposite was then performed
for specificity. This sensitivity analysis was conducted on the full-node OSNA results, for which the change
in accuracy would be most notable (the overall sensitivity for half-node OSNA was fixed at 100%).
Short-term utility results are not reported as the utility for OSNA was not affected by the accuracy of
the test.
The short-term results of the threshold analysis for sensitivity are presented in Table 54. Table 54
demonstrates that, when specificity is held at 91.8%, the proportion of node-positive cases detected
increased by 1% each time the sensitivity increased by 5%. The short-term costs of OSNA also increased
by approximately £18 for each step increase in sensitivity (therefore decreasing the difference in
costs between OSNA and histopathology) and the combination of both increased the cost–accuracy ICERs
between histopathology and OSNA. The ICER for cost per case correctly identified increased from £5104
per additional case correctly identified by histopathology when OSNA had 70% sensitivity to £8162 per
additional case correctly identified by histopathology when OSNA had 100% sensitivity. The ICERs for cost
per additional node-positive case detected were consistently larger, ranging from £10,685 per additional
node-positive case detected when OSNA had 70% sensitivity to OSNA dominating histopathology when
OSNA had 100% sensitivity. However, in this case, the ICER increased much faster as the sensitivity
of OSNA neared 100%, as Figure 17 shows.
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TABLE 54 Threshold analysis of OSNA sensitivity for results in the diagnostic phase
Measure
Incremental outcomes of histopathology vs. OSNA of varying sensitivitya
Base case:
0.845 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Accuracyb 0.0966 0.1256 0.1156 0.1056 0.0956 0.0856 0.0756 0.0656
Sensitivity × prevalencec 0.031 0.06 0.05 0.04 0.03 0.02 0.01 0
Analysis using NHS reference costs130 for ALND
Cost per patient (£) 590 641 623 606 588 571 553 535
Incremental cost per
additional patient correctly
diagnosed (£)
6108 5104 5394 5737 6153 6666 7315 8162
Incremental cost per
additional node-positive
case detected (£)
19,033 10,685 12,470 15,147 19,609 28,532 55,303 Histopathology
dominated
a With OSNA specificity fixed at 0.918.
b Accuracy is defined as the probability of a correct diagnosis.
c Node-positive prevalence fixed at 20%.
Histopathology was dominated when it had the same diagnostic yield as OSNA but was more expensive.
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FIGURE 17 Comparison of cost–accuracy results for threshold analysis of OSNA sensitivity.
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The long-term results, presented in Table 55, show a similar finding to the accuracy results: as the
sensitivity of OSNA increased, so did the ICER for the cost per QALY gained by histopathology. This ranged
from £2119 per QALY gained when OSNA had a sensitivity 70% to £14,193 per QALY gained when
OSNA had a sensitivity of 95%. At 100% sensitivity OSNA dominated histopathology, having more QALYs
at a lower cost. Unlike the accuracy results, the cost difference between histopathology and OSNA also
increased each time the sensitivity increased. Again, as the sensitivity of OSNA neared 100% the ICER
began to increase much faster, as demonstrated in Figure 18.
The results of the threshold analysis for specificity are presented in Tables 56 and 57. When sensitivity is
held at 84.5%, the proportion of node-negative cases detected by OSNA increases by 4% each time the
specificity is increased by 5% and the cost decreases by approximately £70. As with the threshold analysis
for sensitivity, the accuracy ICERs for histopathology increased with increasing specificity of OSNA. In terms
of the cases correctly identified, the ICERs ranged from £1043 per additional case correctly diagnosed by
histopathology when OSNA had a specificity of 70% to £22,761 per additional case correctly diagnosed
when OSNA had a specificity of 100%. For the node-negative cases, the ICERs ranged from £1178 per
TABLE 55 Long-term results for threshold analysis of OSNA sensitivity
Measure
Incremental outcomes of histopathology vs. OSNA of varying sensitivitya
Base case:
0.845 0.70 0.75 0.80 0.85 0.90 0.95 1.00
QALYs
(discounted)b
0.0997 0.1939 0.1614 0.1289 0.0964 0.0639 0.0314 –0.0011
Analysis using NHS reference costs130 for ALND
Cost per patient
(discounted)b (£)
431 411 418 425 431 438 445 452
Incremental cost
per QALY (£)
4324 2119 2588 3294 4476 6862 14,193 Histopathology
dominated
a With OSNA specificity fixed at 0.918 and node-positive prevalence fixed at 20%.
b Costs and QALYs discounted at a rate of 3.5%.
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FIGURE 18 Comparison of long-term cost-effectiveness for threshold analysis of OSNA sensitivity.
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node-negative case detected when OSNA had a specificity of 70% to OSNA dominating histopathology
when OSNA had a specificity of 100%. This time both cost–accuracy measures had ICERs that increased
more quickly as the specificity of OSNA approached 100%. Figure 19 illustrates this pattern for detecting
node-negative cases. In this figure, the ICER for histopathology increases as the specificity of OSNA
increases. The node-negative cases curve appears truncated because at the maximum specificity (100%)
OSNA dominates histopathology (same diagnostic yield, lower costs), which is not represented on
the graph.
The long-term cost-effectiveness results, presented in Table 57 and Figure 20, show that the long-term
costs of OSNA decreased as the specificity and QALY gain increased. This meant that for the lowest
specificity of 70%, OSNA was dominated by histopathology as it was both more expensive and produced
fewer QALYs. The largest ICER for histopathology, when OSNA had 100% specificity, was £8430 per
QALY gained. As with the previous results, the ICER increase was more pronounced as the cost difference
between histopathology and OSNA increased (i.e. as the specificity of OSNA increased), but this increase
was not as severe as it was for the short-term outcomes in the specificity threshold analysis or for the
long-term cost-effectiveness outcomes in the sensitivity threshold analysis.
TABLE 56 Threshold analysis of OSNA specificity for results in the diagnostic phase
Measure
Incremental outcomes of histopathology vs. OSNA of varying specificitya
Base case:
0.918 0.70 0.75 0.80 0.85 0.90 0.95 1.00
Accuracyb 0.0966 0.2710 0.2310 0.1910 0.1510 0.1110 0.0710 0.0310
Specificity × (1 – prevalence)c 0.0656 0.24 0.20 0.16 0.12 0.08 0.04 0.00
Analysis using NHS reference costs130 for ALND
Cost per patient (£) 590 283 353 424 494 565 635 706
Incremental cost per additional
patient correctly diagnosed (£)
6108 1043 1529 2218 3272 5087 8945 22,761
Incremental cost per additional
node-negative case detected (£)
8994 1178 1766 2648 4118 7058 15,878 Histopathology
dominated
a With OSNA sensitivity fixed at 0.845.
b Accuracy is defined as the probability of a correct diagnosis.
c Node-positive prevalence fixed at 20%.
Here, strategies that are dominated have the same detection rate but are more expensive.
TABLE 57 Long-term results for threshold analysis of OSNA specificity
Measure
Incremental outcomes of histopathology vs. OSNA of varying specificitya
Base case:
0.918 0.70 0.75 0.80 0.85 0.90 0.95 1.00
QALYs (discounted)b 0.0097 0.1660 0.1508 0.1356 0.1203 0.1051 0.0899 0.0747
Analysis using NHS reference costs130 for ALND
Cost per patient (discounted) (£)b 431 –98 24 145 266 387 508 630
Incremental cost per QALY (£) 4324 OSNA
dominated
156 1068 2210 3683 5655 8430
a With OSNA sensitivity fixed at 0.845 and node-positive prevalence fixed at 20%.
b Costs and QALYs discounted at a rate of 3.5%.
OSNA was dominated at a specificity of 0.70 as it had fewer QALYs and higher costs than histopathology.
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These threshold analyses demonstrate no obvious significant differences from the base-case results,
although all ICERs increased as either the sensitivity or the specificity increased. Starting at about 90%, the
increases in sensitivity or specificity resulted in exponential increases in the ICERs. Individually, the findings
from the base case are repeated, with specificity seemingly having a larger impact on the short-term
outcome of cost–accuracy and sensitivity having a larger impact on the long-term cost-effectiveness.
Overall, these threshold analyses suggest that, if the true values of sensitivity and specificity for OSNA lie
within the range of 90–100%, close to the values for the sensitivity and specificity of histopathology,
the cost-effectiveness of OSNA may increase greatly. Furthermore, sensitivity and specificity are not
independent and therefore altering one would alter the other. For simplicity, this analysis does not analyse
the relationship between specificity and sensitivity and therefore it may not adequately represent the
uncertainty in the results. However, as the TAB-adjusted results from Khaddage et al.57 demonstrate, when
both specificity and sensitivity are sufficiently high, OSNA becomes much more cost-effective.
The uncertainty in the results, accounting for the dependency of sampling variation in sensitivity and
specificity, is measured by the probability at which full OSNA is cost-effective relative to postoperative
histopathology. Figure 21 presents this probability as a function of the value of a QALY to NHS
decision-makers. One curve is shown for each of the three studies on the diagnostic performance of OSNA
that adjust for TAB and a fourth curve presents the results corresponding to accuracy values (sensitivity
0.914, specificity 0.968) obtained by combining all data on patients from the three studies, with the
sensitivity and specificity being the weighted averages of the estimates of the individual studies, with the
respective weights given in proportion to the relative sample sizes of the studies. Although adopting the
values reported by Khaddage et al.57 leads to the opposite result to that obtained using sensitivity–specificity
values from the other two studies (i.e. at the £20,000 threshold OSNA has a higher probability of being
cost-effective than histopathology), the study weight in the analysis using combined accuracy data is limited
by its small size relative to the other two studies. On the basis of all available data, at a cost-effectiveness
threshold of £20,000 per QALY, OSNA has a less than one in three chance of being cost-effective.
Prevalence
The prevalence of LN metastases in the population directly affects the accuracy of the tests and their
outcomes. To investigate the effect fully, we considered the effect of prevalence when our base-case value
of 20% was halved to 10% and doubled to 40%.
When prevalence was 10%, histopathology dominated half-node OSNA and had an ICER of < £20,000
per additional case correctly identified compared with full-node OSNA, both overall and when split into
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FIGURE 21 Probability of full-node OSNA being cost-effective by cost-effectiveness threshold.
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node-negative and node-positive patients. Short-term cost–utility results remained the same, with full-node
OSNA dominating the rest. In the long term, histopathology dominated half-node OSNA and the ICER for
histopathology compared with full-node OSNA was £2626 per QALY gained.
When the prevalence was increased to 40%, the accuracy results were similar to those of the base case,
with histopathology being cost-effective for additional cases correctly identified, half-node OSNA
dominating histopathology for detecting additional node-positive patients and full-node OSNA dominating
half-node OSNA for additional node-negative patients detected. The ICER for histopathology compared
with full-node OSNA for detecting node-negatives cases increased to £24,680 per additional case
detected. OSNA once again dominated the short-term utility analyses. In the long term half-node OSNA
dominated histopathology as it now had a slightly higher QALY gain (0.0001). Half-node OSNA had an
ICER of £2208 per QALY gained compared with full-node OSNA.
Short-term costs
In the short term the costs of the tests were altered by ±10%. Altering the cost of histopathology did not
affect the overall outcomes, simply increasing or reducing individual ICERs accordingly. Decreasing the
cost of OSNA to £315 similarly did not greatly affect the results but increasing it to £385 resulted in
histopathology dominating half-node OSNA in the long term, with an ICER of £3972 for histopathology
compared with full-node OSNA.
The cost of separate ALND surgery was altered using values provided in the NHS reference costs.130 A low
second surgery cost (£1608) meant that, in the short term, histopathology dominated half-node OSNA for all
accuracy ICERs and, compared with full-node OSNA, all ICERs were < £7000 per additional case detected.
For short-term utility, full-node OSNA still dominated half-node OSNA and histopathology. In the long term
histopathology dominated half-node OSNA and, compared with full-node OSNA, histopathology had an ICER
of £388 per QALY gained. A high second surgery cost (£4871) had no significant effect on short-term
outcomes. Long-term ICERs increased to £15,384 per QALY gained for histopathology compared with
half-node OSNA and £5469 per QALY gained for half-node OSNA compared with full-node OSNA.
Long-term costs
Adjuvant therapy costs were altered by ±10%. This affected only the long-term results and did not greatly
influence them. A high cost for patients undergoing hormonal adjuvant therapy (£1195) increased the
ICERs slightly, with histopathology having an ICER of £4353 compared with full-node OSNA. A low cost
for patients undergoing chemotherapy (£8502) resulted in the smallest ICERs, reducing the ICER for
histopathology compared with full-node OSNA to £4237 per QALY gained.
The sensitivity analyses performed are presented in Tables 58 and 59. These include sensitivity analyses
performed on the disutility associated with anxiety from waiting for results and a second operation and the
costs of the first breast surgery (with or without ALND). There were no significant differences in the results.
Overall, we found that the most influential parameters were the sensitivity and specificity of OSNA, which
means that it is very important to have good-quality data on these values. Additional two-way sensitivity
analyses (see Appendix 8) showed that, to be cost-effective, full-node OSNA has to have sensitivity and
specificity estimates of ≥ 95%.
Metasin results
As an alternative index test we compared Metasin with histopathology. This was performed as an
illustrative exercise as the accuracy values for Metasin come from a draft paper (Sundaresan40) that had not
yet been peer reviewed at the time of this review. Furthermore, the only cost information for Metasin was
provided by personal correspondence with the Princess Alexandra Hospital on behalf of the author of the
draft paper (Matt Hayday, The Princess Alexandra Hospital NHS Trust, 19 November 2012, personal
communication). This value reflected the cost of the non-CE-marked Metasin test as no list price for the
test is yet available even though Metasin has received a CE mark. The cost-effectiveness analyses may be
updated if and when a finalised list price for the CE-marked Metasin test is received. Updated cost
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estimates were made available after the modelling analyses were completed but as these did not seem
significantly different from those used in the analysis the changes were not implemented.
The cost–accuracy results are reported in Table 60 and show that half-node Metasin is extendedly dominated
by histopathology, which, when compared with full-node OSNA, results in £20,302 per additional case
detected using NHS reference costs130 and £14,990 using YHEC costing.124 As with OSNA, half-node Metasin
dominated histopathology for additional node-positive case detected as it had the same accuracy but was less
expensive than histopathology. Furthermore, full-node Metasin dominated half-node Metasin for detecting
node-negative cases. The ICER for node-negative case detected for histopathology compared with full-node
Metasin was £30,453 using NHS reference costs and £22,484 using YHEC costs. The cost-effectiveness of
histopathology compared with Metasin therefore depends on the costing strategy and threshold used.
TABLE 60 Short-term cost–accuracy analysis comparing histopathology with full-node and half-node intraoperative
Metasin analysis
Measure
Mean estimates Incremental results
Histopathology
Metasin
Difference half-node
Metasin vs.
full-node Metasin
Difference
histopathology
vs. half-node
Metasin
Half
node
Full
node
Accuracya 1.0000 0.9704 0.9556 0.0148 0.0296
Sensitivity × prevalenceb 0.2000 0.2000 0.1852 0.0148 0
Specificity × (1 – prevalence)b 0.8000 0.7704 0.7704 0 0.0296
Analysis using NHS reference costs130 for ALND
Cost per patient (£) 3987 3523 3086 437 465
Incremental cost per additional
patient correctly diagnosed (£)
Half-node Metasin
extendedly dominated
20,302c
Incremental cost per additional
node-positive case detected (£)
29,515 Histopathology
dominated
Incremental cost per additional
node-negative case detected (£)
Half-node Metasin
dominated
30,453c
Analysis using costs based on the YHEC model124
Cost per patient (£) 2228 1966 1562 403 263
Incremental cost per additional
patient correctly diagnosed (£)
Half-node Metasin
extendedly dominated
14,990c
Incremental cost per additional
node-positive case detected (£)
27,230 Histopathology
dominated
Incremental cost per additional
node-negative case detected (£)
Half-node Metasin
dominated
22,484c
a Accuracy is defined as the probability of a correct diagnosis.
b Node-positive prevalence fixed at 20%.
c Comparison is histopathology relative to full-node Metasin because of the half-node Metasin option being dominated
(same diagnostic accuracy as full-node Metasin but more expensive) or extendedly dominated (histopathology had a
smaller ICER compared with full-node Metasin than half-node Metasin did). Here, strategies that are dominated have the
same detection rate but are more expensive.
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Short-term utility results for Metasin are reported in Table 61. Regardless of costing strategy Metasin
dominated histopathology, having a lower cost and producing more QALYs. It is estimated that of the
78.5% of half-node Metasin patients with a negative result, who have to wait for histopathology test
results, 1.9% would go on to have a positive diagnosis, in contrast to the 20% of expected positive
diagnoses with postoperative histopathology. In the long term, histopathology compared with half-node
Metasin had an ICER of > £460,000 per QALY gained using NHS reference costs and an ICER of
> £240,000 per QALY gained using YHEC costs (Table 62). The ICER between half-node and full-node
Metasin remained < £13,000 for both costing strategies.
TABLE 61 Short-term utility for Metasin
Measure
Mean estimates Incremental results
Histopathology
Metasin Difference
half-node Metasin
vs. histopathology
Difference
full-node Metasin vs.
half-node MetasinHalf node Full node
Analysis using NHS reference costs130 for ALND
Cost per patient (£) 3987 3523 3086 –465 –437
Utility 0.9739 0.9849 1 0.0110 0.0151
Incremental cost per
QALY gained (£)
Half-node Metasin
extendedly dominated
Histopathology
dominateda
Analysis using costs based on the YHEC model124
Cost per patient (£) 2228 1966 1562 –263 –403
Incremental cost per
QALY gained (£)
Half-node Metasin
extendedly dominated
Histopathology
dominateda
a Histopathology and half-node Metasin were both dominated by full-node Metasin (and full-node Metasin had a smaller
ICER than half-node Metasin compared with histopathology), which had a higher QALY gain and lower costs.
TABLE 62 Long-term costs and QALYs for Metasin
Measure
Mean estimates Incremental results
Histopathology
Half-node
Metasin
Full-node
Metasin
Difference half-node
Metasin vs. full-node
Metasin
Difference
histopathology vs.
half-node Metasin
Analysis using NHS reference costs130 for ALND
Cost per patient (£) 20,530 20,103 19,702 401 427
QALYs 9.321 9.320 9.288 0.032 0.001
Incremental cost per
QALY gained (£)
12,374 467,113
Analysis using costs based on the YHEC model124
Cost per patient (£) 18,771 18,546 18,179 367 225
Incremental cost per
QALY gained (£)
11,329 246,089
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Chapter 5 Discussion
Statement of principal findings
Clinical effectiveness
Seventeen studies were included that investigated the performance of either OSNA or Metasin for
detecting metastases in the sentinel or axillary LNs of breast cancer patients. Two of the included
studies reported on Metasin; both were unpublished and were reported in draft form. The remaining
15 studies reported on OSNA, with two papers reporting the same study.
The studies were assessed against the Cochrane risk of bias tool148 and the QUADAS-2 tool.43 The majority
of studies were considered to be at low risk of bias, although many were unclear regarding their method of
patient recruitment and lacked detail on patient characteristics. Often, no evidence was given of sample
replicates and reproducibility for molecular analysis. Furthermore, test failures were not reported for most
studies. Reported outcomes were also limited, for example no data were found for clinical outcomes, such
as patient anxiety and number of repeat operations. Only one study56 provided evidence on time in the
operating theatre. A potential conflict of interest also features heavily as one of the two unpublished
Metasin studies was performed at the institution in which the technology was developed and the majority
of the OSNA studies were financially supported by Sysmex.
With regard to test accuracy, there are two main issues. The first is the strong assumption that the
reference standard is the most accurate measure of the target disorder. In this case, the reference standard
(i.e. histopathology), although plausible, has been performed with varying levels of analysis and, as such,
it may not be a true indicator of the target condition. The second concern is TAB, which occurs when
different portions of tissue are allocated to the index and reference tests and cannot then be reused
between them. Studies have dealt with this in a variety of ways, some reanalysing both the histopathology
and the molecular samples, some choosing to reanalyse just one technology and some doing neither. The
majority of studies that have adjusted for TAB have taken a conservative approach by excluding affected
samples, which we consider to be a reasonable practice.
A summary of the results is presented in Table 63. As there were only two studies for Metasin,
a meta-analysis was not performed. The displayed data for this test were taken from draft papers, before
peer review. Therefore, the results, (academic-in-confidence information has been removed), must be used
with caution.
It should be noted that more than one SLN may be removed from a patient, which, as shown in Table 63,
may have implications for sensitivity and specificity data when grouped either by patient or by node.
Adjustment for TAB clearly improves test accuracy, increasing sensitivity of OSNA from 79.9% to 89.0%
and increasing specificity of OSNA from 95.5% to 97.5% at the node level, with similar increases at
patient level.
Studies that analysed ALNs were also included in this review. An increased sensitivity (ALN 95.1% vs. SLN
79.9%) and similar specificity (ALN 94.9% vs. SLN 95.5%) compared with the values found in the analysis
of SLNs were seen before adjustment for TAB. Subsequent TAB adjustment increases the SLN sensitivity
but has little effect on ALN data.
With regard to the time taken to perform the OSNA test, despite the lack of detail in the studies explaining
which aspects of the procedure were monitored, the times reported ranged from < 30 minutes to
39.6 minutes for one node. This increases by approximately 5–10 minutes per additional node analysed.
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Overall, and despite the concerns raised with regard to the reference standard and TAB, we feel that the
studies were well performed and produced consistent results.
Cost-effectiveness
The short-term results, up to the diagnostic phase, suggest that OSNA is less accurate than the reference
standard of histopathology but that it saves costs and results in less quality-of-life losses in patients from
anxiety about a delayed diagnosis and second operation. With regard to Metasin the evidence base is
currently only illustrative and requires validation as it is limited to two unpublished studies and may
therefore be neither of the same quality nor as generalisable as the evidence on OSNA, which has
accumulated over several studies performed in a wider variety of settings. It is possible that there is more
confidence in the accuracy of OSNA and this should be taken into account when assessing the
technologies, as OSNA still has the potential for cost-savings compared with current practice.
Limiting our analysis to the evidence on OSNA compared with histopathology revealed that there may be a
trade-off between histopathology and intraoperative testing but that this depends on the estimates of
costs adopted. Valuing resource use according to the current national reference costs, and judged on the
ability to identify node-positive patients, histopathology was found to be inferior to OSNA. Whether
the higher costs of using OSNA adjunctively are justified by the additional sensitivity of the test strategy,
however, depends on whether decision-makers are prepared to pay £16,000 per additional case detected.
On the other hand, when estimates derived from a microcosting study developed by YHEC in a study
commissioned by the NHS Technology Adoption Centre are used to value resource use, histopathology
may be cost-effective as long as the cost-effectiveness threshold is > £12,000 per node-positive case
detected. In contrast, when the disutility of anxiety and a second operation is taken into account and the
diagnostic options are compared in terms of costs and such disutility, OSNA emerges as the clearly
preferred option with lower costs and less harm (disutility) inflicted on patients.
These results would be sufficient for medical decision-making if one entertained the idea that a more
accurate diagnosis does not have significant health benefits for patients (i.e. QALY gains). Despite the
inherent uncertainty of extrapolating benefits from the diagnostic phase into the remaining lifetime of
patients undergoing SLNB, the present analysis has adapted an existing model of early breast cancer
patient management developed by ScHARR, to gain insight into the potential significance of benefits from
TABLE 63 Summary of the pooled results
Measure Sample type
Adjustment
for TAB No. of studies
Sensitivity
(%) (95% CI)
Specificity
(%) (95% CI)
(Academic-in-
confidence
information has
been removed)
(Academic-in-
confidence
information has
been removed)
(Academic-in-
confidence
information has
been removed)
(Academic-in-
confidence
information has
been removed)
(Academic-in-
confidence
information has
been removed)
(Academic-in-
confidence
information has
been removed)
Pooled OSNA Patient No 5 84.5
(74.7 to 91.0)
91.8
(87.8 to 94.6)
Pooled OSNA Patient Yes 3 91.3
(83.6 to 95.6)
94.2
(91.2 to 96.2)
Pooled OSNA SLN No 4 79.9
(74.2 to 84.6)
95.5
(94.1 to 96.5)
Pooled OSNA SLN Yes 5 89.0
(82.1 to 93.4)
97.5
(96.6 to 98.2)
Pooled OSNA ALN No 6 95.1
(90.0 to 97.6)
94.9
(91.2 to 96.9)
Pooled OSNA ALN Yes 4 96.5
(87.3 to 99.1)
96.2
(93.4 to 97.8)
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diagnostic accuracy gains in this clinical area. After accounting for the disutility of anxiety from waiting for
postoperative diagnostic test results and a second operation, the long-term analysis using the adopted
ScHARR model suggests that histopathology may produce large enough benefits from improved patient
management compared with intraoperative testing approaches to offset its short-term disadvantage
attributable to the costs and disutility associated with a delayed diagnosis and second operation. Indeed,
the results suggest that as long as the NHS is willing to pay > £4000 per QALY gained histopathology
should be retained as the optimal diagnostic approach for metastatic diagnosis in early breast cancer.
The base-case result that histopathology is cost-effective is, however, not robust to adjustment for TAB.
Of the three studies that provided good-quality evidence on sensitivity and specificity, two supported
histopathology as the cost-effective option at the conventional £20,000 per QALY threshold whereas the
third, by Khaddage et al.,57 results in full-node OSNA being unambiguously dominant.
A comment is also warranted regarding the relevant cost-effectiveness threshold for the present analyses.
Typically in cost-effectiveness analyses, the status quo is less effective and less costly than the new
technologies against which it is being compared. In the present case the reverse applies as histopathology,
the current standard, is both more effective (i.e. produces higher QALYs) and more costly than the new
intraoperative approaches. To facilitate interpretation we have presented the results of the three-arm
comparison (intraoperative test with half node vs. intraoperative test with full node vs. histopathology) by
ranking the three options by increasing level of effectiveness and calculating incremental costs, benefits
and ICERs between adjacent options. That way we can retain the standard interpretation of ICERs for
decision-making. However, it is argued by some economists that the threshold for cost-effectiveness
should be higher for new technologies that involve foregoing some benefit in exchange for cost-savings,
as in the case of OSNA or Metasin relative to histopathology in our present analysis. If this is the case then
histopathology may well have an ICER relative to OSNA that is larger than the conventional £20,000 per
QALY threshold and still be considered cost-effective. The problem is that no conventional thresholds for
new technologies with lower costs and lower benefits exist.
Strengths and limitations of the assessment
Clinical effectiveness
The strengths of this systematic review are that it was conducted by an independent research team using
the latest evidence in line with a prespecified protocol. The search strategy did not restrict by study design
and also included forward chasing. The studies were independently screened by two reviewers, with data
extraction and quality appraisal performed by one reviewer and checked by a second. Any disagreements
were resolved by consensus. A large number of abstracts were identified that were not included in the
review as quality appraisal could not be performed. However, a table of results has been compiled in
Appendix 4 for interest.
The assessment of Metasin should be treated with caution. Only two studies were included, both of which
were unpublished and therefore had not been peer reviewed.
For all studies there was a wide variance in the histopathology performed, for example one level, three
level or five level. It is questionable whether the use of one-level histopathology is appropriate as a
reference standard. The methods employed to analyse discordant cases and subsequently adjust for TAB
were not consistent across studies. However, for the majority of studies, a conservative approach of
excluding discordant cases was followed. Studies reported patient-level data, node data, ALN data or SLN
data or a combination of these. Often, for the ALN analysis, the recruited population was relatively small
but a large number of nodes was analysed. On some occasions it was unclear whether fresh or frozen
samples had been used for histopathology.
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Cost-effectiveness
The scope of our analysis was limited by some assumptions adopted to address data limitations. We have
not accounted for the possibility of a second operation because of involved or close margins of the primary
tumour. Indeed, a second operation rate of 9% for OSNA and 39% for histopathology, including 5% and
13%, respectively, for margin insufficiency without ALND resection has been reported.149 No previous
analysis has looked at this complex issue in terms of its costs, let alone its long-term health implications.
Our current analysis does not look at how the cost and health benefit balance of intraoperative testing
relative to histopathology and between intraoperative testing options may be affected by the current
controversy about the effectiveness of ALND, particularly in relation to micrometastatic disease.150 If part of
the claimed advantages of OSNA, the detection of micrometastatic involvement, has no associated survival
benefits, its long-term cost-effectiveness may be overestimated in our present analysis. Undertaking
objective analysis of this issue is complicated, however, as the threshold definitions of micrometastasis for
histopathology and OSNA differ and because of the current uncertainty associated with the emerging
evidence on the benefits of ALND in small tumours found in the SLN.
Another limitation that originated from the lack of evidence to inform our analysis pertained to the
potential loss of valuable information for patient management that full node use by intraoperative testing
incurs relative to histopathology.151 The extent to which this may affect our results is open to highly
speculative judgement.
We have not looked at the cost-effectiveness implications of possible options that have been considered for
increasing the sensitivity of the diagnostic strategies considered here. For example, OSNA reliance on the
CK19 marker for detecting metastasis may lead to the test missing a small proportion of patients with
metastatic breast cancer whose tumours do not express the marker. It has been suggested that preoperative
testing of the primary tumour may identify the subgroup of patients whose tumours do not express CK19
and who require an alternative approach for metastatic diagnosis. The same approach could be adopted for
Metasin, to exclude the possibility that those testing negative may be false-negative cases resulting from the
lack of expression of CK19 and mammaglobin, the markers used by the test to identify positive cases.
Uncertainties
Clinical effectiveness
The primary concern in the studies in which a portion of the node was provided for molecular analysis and
a portion provided for histopathology was TAB. Many studies attempted to address this; however, whether
the discordant results were truly due to TAB or whether a proportion of cases had been missed is unclear.
The histopathology methods were sometimes ambiguously reported and the variety of methods compared
is likely to be reflected in the heterogeneous data.
A significant proportion of the studies was funded by the manufacturers and there may therefore be a
potential conflict of interest.
From the perspective of the patient, the case for intraoperative testing is made in terms of reducing anxiety
about diagnosis and the need for a second operation. Although having a preference for one as opposed to
two operations seems logical a priori, it is by no means obvious that patients will always give more weight
to reduced anxiety from not having a second operation than to the uncertainty of occurrence of ALND
during the first operation. Because there is no available evidence on patient views about this decision,
we adopted the claim at face value in our base-case analysis, but from sensitivity analyses noted that our
conclusion that intraoperative testing is not cost-effective would be strengthened by weakening the effect
on anxiety. Moreover, for patients needing further surgery because of close/involved margins, the benefits
of intraoperative SLNB would be reduced relative to the base case. In contrast to the negative effects of
waiting for the results of SLNB with histopathology, which we accounted for, our modelled analysis could
DISCUSSION
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not account for the benefits in terms of patient management outcomes of additional information
obtainable from postoperative histopathology.
Cost-effectiveness
Throughout our analyses we have assumed that histopathology is the gold standard. There are, however,
indications that histopathologists may miss low-volume metastases.152–154 Because of the low frequency of this
omission relative to the occurrence of TAB, our analysis may have adopted a slightly conservative stance.
Our analysis was based on the estimated rate of axillary node positivity in patients with a positive SLNB
result in a randomised trial (Z0011 study;37 see Chapter 1, Other approaches to treating the spread of
breast cancer tumour cells beyond the sentinel lymph nodes), who were selected from among those with a
better prognosis. Although the positive axillary node rate may therefore be underestimated, the associated
bias in the cost-effectiveness results is attenuated by the fact that the axillary node positivity parameter
affects cost and health outcomes of both intraoperative and histopathology strategies. In any case the bias
makes our results conservative, as it reduces the importance of the sensitivity advantage of postoperative
histopathology relative to OSNA.
The model on which our analysis is based did not account for the adverse effect of ALND in terms of altered
shoulder function.38 This has previously been found to occur post surgery in up to 39% of cases and have
health-related quality of life effects as important as those of lymphoedema,155,156 which were accounted for in
the analysis. We found no studies that evaluated the long-term health-related utility impact of altered shoulder
function in our population. By omitting the impact on shoulder function our analysis is likely to overestimate
the benefits of a correct positive diagnosis and underestimate the benefits of a correct negative test result for
any given diagnostic option. However, this omission, as shown by sensitivity analysis of lymphoedema,
does not matter for our results, depending as they do on differences in costs and benefits between options,
given the small difference in ALND use between the intraoperative and the postoperative diagnostic arms.
The decision model assumed that adjuvant therapy is given for 5 years, as originally specified by SCHARR.9
This may not reflect current practice because, if patients receive hormonal therapy, it is for at least 5 years
after completion of chemotherapy; extended adjuvant letrozole is currently licensed for 5 years after
5 years of tamoxifen, and new evidence suggesting that 10 years of tamoxifen is better than 5 years157
implies that there will be a group of patients who will receive endocrine therapy for 10 years. Although
the treatment course specified in the model may not apply to actual practice, the bias arising would affect
both arms of the analysis and would have a small impact on the difference in costs and benefits and
consequent cost-effectiveness results. Assuming that the extended course of adjuvant therapy is likely to
result in an increase in health benefits by a factor that is higher than the factor for the increase in costs
relative to the ScHARR model’s adjuvant treatment specification, the bias in the treatment pathway would
overestimate the ICER of histopathology relative to OSNA and our results could therefore be seen as
conservative, strengthening the conclusion that OSNA is not cost-effective.
We present our results under two costing approaches, which have been used by other assessment groups
previously. They have significant implications for decision-making because, as discussed in relation to the
short-term comparison between OSNA and histopathology, the two costing approaches have contrasting
results, that is, the status quo, histopathology, is inferior to intraoperative testing in one case and a
cost-effectiveness prospect in the other.
Our probabilistic analysis of uncertainty shows that the results are robust to parameter uncertainty.
However, structural uncertainty may be very important but could not be addressed within the scope of our
review. This means only that our ability to model the patient’s life course is limited, and so we cannot
estimate with precision what the final outcome will be, and suggests that a shorter time frame may be
meaningful for decision-making. In essence, this may be summarised by assuming that differences in
outcomes last only a few years (e.g. 5 years), a period within which patient management and outcomes
may be predicted with precision.
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Chapter 6 Conclusions
Implications for service provision
The OSNA and Metasin tests may provide some advantages over histopathology. They are automated and
standardised, with the capacity to be used intraoperatively. However, information gained by histology, such
as the location of metastatic foci and morphological evaluation, is not provided by these intraoperative tests.
OSNA displays a higher rate of false positives, possibly because of contamination from epithelial cells.
In contrast, false negatives may occur when the breast cancer does not express CK19 protein.
(Academic-in-confidence information has been removed.)
It is not clear that the adoption of OSNA or Metasin will bring significant benefits to patients and
cost-savings to the NHS. There remain important questions regarding whether, ultimately, the reduction in
NHS costs with intraoperative testing is worth the reduction in diagnostic accuracy and potentially inferior
long-term health outcomes for patients. Although the long-term uncertainty of breast cancer patient
management and outcomes may determine long-term patient benefits, thus limiting the effects of the
reduced diagnostic accuracy of the intraoperative tests on survival and quality of life, it is likely that a
decision-maker would err on the side of caution and wait for more evidence before abandoning the
current standard, postoperative histopathology. Some centres may not feel at ease performing ALND
without the information that is currently available at MDT meetings through postoperative histopathology.
Ultimately, in view of the current uncertainty in the evidence base on the benefits of performing ALND and
the impact of this uncertainty on clinicians’ views, there is a possibility that intraoperative testing for SLNs
will not be routine practice in the future.
Suggested research priorities
The uncertainty in decision-making because of a lack of data on, and variation in, available estimates of
diagnostic accuracy and a lack of data on short-term implications of diagnostic approaches and long-term
patient management may be reduced by undertaking further research. Priority should be placed on
documenting the performance of intraoperative tests under different protocols. There is limited
information about the performance of such tests under routine established practice and many of the
existing studies are likely to apply to an early experience with these technologies. Peer-reviewed and
formally published research on Metasin is also essential as the presumed low cost of this test makes it a
potentially attractive option for the NHS.
Greater clarity on the true costs of the alternative tests, and the variation in resource utilisation at the
level of the patient, would help to identify the significance and the distribution of costs and benefits
of intraoperative diagnosis. Observational studies should be conducted to verify and quantify the
hypothesised effects of introducing intraoperative SLNB, namely a reduction in the number of operations
and costs to hospitals and the amelioration of anxiety and its impact on patients’ and their families’ quality
of life by discarding postoperative diagnosis and second operations. Although much uncertainty is likely
to remain over the magnitude of the long-term benefits of increased diagnostic accuracy, a natural
target for great returns on investment in research may be found in documenting what the impact on
patient-reported outcomes is of uncertainty associated with a delayed diagnosis and a second possible
operation. Indeed, we may expect greater prominence of this aspect of the decision-making problem in
populations with a greater prevalence of node-positive SLNs.
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However, improving on the accuracy of estimates for OSNA in particular and overcoming concerns about
TAB and the validity of currently available reference standards may be challenging. A test–treat randomised
trial may be the only way to truly resolve whether the introduction of intraoperative testing in SLNB would
be effective and thus cost-effective. The outcome would need to be the locoregional recurrence rate or
even survival to capture the trade-off between the potential short-term gains associated with a single
operation for achieving ALND and the longer-term disbenefits arising from the occurrence of false-negative
and false-positive cases with intraoperative testing.
Also, a strong assumption in this report is that ALND is the usual best treatment if micro- and
macrometastases, or their equivalents, are identified in a SLNB. Evidence on this is evolving and needs to
be followed closely as it could impact on decision-making around intraoperative testing in SLNB in
the future.
CONCLUSIONS
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Appendix 1 Literature search strategy
The search strategy focuses on the interventions under consideration for this review in the context ofthe specific area in which the tests are applied: the LNs. Also, independently of the interventions, the
search draws in literature on the biological markers CK19 and mammaglobin (in the context of the test
area), which aims to help serve any modelling that may relate to this project. The search was not limited by
language or methodology or to humans exclusively. The search was run from database inception.
Database search results
Table 64 details the databases searched. The Web of Science search included the Conference Proceedings
Citation Index. Records were downloaded and managed in EndNote X5 (Thompson Reuters, Philadelphia,
PA, USA).
TABLE 64 Database search results
Database Results
MEDLINE via Ovid 197
Medline In-Process & Other Non-Indexed Citations via Ovid 15
EMBASE via Ovid 624
Web of Science via ISI 93
Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Cochrane
Methodology Register, Database of Abstracts of Reviews of Effects, Health Technology Assessment Database
and NHS Economic Evaluation Database via The Cochrane Library
18
NHS Economic Evaluation Database (EED) via The Cochrane Library 4
Total 951
EndNote deduplication –286
Unique records to screen 665
For OVID linked sources: http://ovidsp.tx.ovid.com/.
For Web of Science: https://apps.webofknowledge.com/.
For sources accessed through The Cochrane Library: www.thecochranelibrary.com/view/0/AboutTheCochraneLibrary.html.
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Bibliographic search annex
Ovid MEDLINE(R)
Host: Ovid.
Data parameters: 1946 to July week 3 2012.
Date searched: 1 August 2012.
Search strategy: Table 65.
Hits: 197.
TABLE 65 Search strategy for Ovid MEDLINE(R)
# Searches Results
1 Sysmex.mp. 464
2 (RD100i or RD-100i or (RD and 100i) or OSNA or One-step nucleic acid amplification).mp. 23
3 1 or 2 486
4 Metasin.mp. 0
5 “98/79/EC”.tw. 16
6 3 or 4 or 5 502
7 Cytokeratin 19.mp. 1217
8 (CK19 adj5 (gene or lymph)).mp. 42
9 Mammaglobin B/ or Mammaglobin A/ 179
10 mammaglobin.mp. 242
11 7 or 8 or 9 or 10 1441
12 6 or 11 1933
13 Sentinel Lymph Node Biopsy/ 6859
14 exp Lymph Nodes/ 65,568
15 (lymph$ adj3 node$).mp. 169,538
16 13 or 14 or 15 171,356
17 12 and 16 197
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Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
Host: OVID.
Data parameters: from inception to 31 July 2012.
Date searched: 1 August 2012.
Search strategy: Table 66.
Hits: 15.
TABLE 66 Search strategy for Ovid MEDLINE(R) In-Process and Other Non-Indexed Citations
# Searches Results
1 Sysmex.mp. 26
2 (RD100i or RD-100i or (RD adj1 100i) or OSNA or One-step nucleic acid amplification).mp. 5
3 1 or 2 30
4 Metasin.mp. 0
5 “98/79/EC”.tw. 0
6 3 or 4 or 5 30
7 Cytokeratin 19.mp. 61
8 (CK19 adj5 (gene or lymph)).mp. 5
9 Mammaglobin B/ or Mammaglobin A/ 0
10 mammaglobin.mp. 5
11 7 or 8 or 9 or 10 69
12 6 or 11 97
13 Sentinel Lymph Node Biopsy/ 0
14 exp Lymph Nodes/ 0
15 (lymph$ adj3 node$).mp. 4941
16 13 or 14 or 15 4941
17 12 and 16 15
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EMBASE
Host: Ovid.
Data parameters: 1974 to 2012 week 30.
Date searched: 1 August 2012.
Search strategy: Table 67.
Hits: 624.
TABLE 67 Search strategy for EMBASE
# Searches Results
1 Sysmex.mp. 1135
2 (RD100i or RD-100i or (RD and 100i) or OSNA or “One-step nucleic acid amplification”).mp. 98
3 1 or 2 1225
4 Metasin.mp. 11
5 “98/79/EC”.tw. 32
6 3 or 4 or 5 1268
7 Cytokeratin 19.mp. 3691
8 (CK19 adj5 (gene or lymph)).mp. 79
9 Mammaglobin B/ or Mammaglobin A/ 44
10 mammaglobin.mp. 425
11 7 or 8 or 9 or 10 4053
12 6 or 11 5266
13 Sentinel Lymph Node Biopsy/ 7986
14 exp lymph node/ 96,163
15 (lymph$ adj3 node$).mp. 239,855
16 13 or 14 or 15 241,216
17 12 and 16 624
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Web of Science (Science Citation Index Expanded, Social Sciences Citation
Index, Arts and Humanities Citation Index, Conference Proceedings Citation
Index – Science, Conference Proceedings Citation Index – Social Science &
Humanities, Book Citation Index – Science, Book Citation Index –
Social Science and Humanities)
Host: ISI.
Data parameters: 1899–2012.
Date searched: 1 August 2012.
Search strategy: Table 68.
Hits: 93.
TABLE 68 Search strategy for Web of Science
# Searches Results
1 Topic=((“RD100i” or “RD-100i” or (RD NEAR/1 100i) or “OSNA” or “One-step nucleic acid amplification”)) –
2 Topic=(“Metasin”) –
3 1 or 2 93
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The Cochrane Library
Host: www.thecochranelibrary.com/view/0/index.html
Data parameters: Issue 7 of 12, July 2012.
Date searched: 1 August 2012.
Search strategy: Table 69.
Hits: Cochrane Database of Systematic Reviews= 4; Cochrane Central Register of Controlled Trials= 13
and NHS Economic Evaluation Database= 1 (total= 18).
TABLE 69 Search strategy for The Cochrane Library
# Searches Results
1 (Sysmex):ti,ab,kw 10
2 (RD100i or RD-100i or (RD and 100i) or OSNA or (One-step nucleic acid amplification)) 8
3 Metasin 0
4 (#1 OR #2 OR #3) 18
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NHS Economic Evaluations Database (EED)
Host: via The Cochrane Collaboration.
Data parameters: Issue 7 of 12, July 2012.
Date searched: 1 August 2012.
Search strategy: Table 70.
TABLE 70 Search strategy for NHS EED
# Searches Results
1 All Data: Sysmex –
2 All Data: (RD100i or RD-100i or (RD and 100i) or OSNA or (One-step nucleic acid amplification)) –
3 All Data: Metasin 4
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Trial registries
Table 71 shows the trial registries that were searched.
ClinicalTrials.gov
URL: www.clinicaltrials.gov/
Searched: 1 August 2012.
Results: 3 (Table 72).
1. Clinical evaluation of OSNA breast cancer system to extensive frozen section histopathology
(www.clinicaltrials.gov/ct2/show/NCT01368744?term=OSNA&rank=1).
2. Clinical evaluation of OSNA breast cancer system in breast cancer patients receiving neoadjuvant
therapy (www.clinicaltrials.gov/ct2/show/NCT01140776?term=OSNA&rank=2).
3. Clinical evaluation of OSNA breast cancer system to test sentinel lymph nodes from patients with breast
cancer (www.clinicaltrials.gov/ct2/show/NCT01136369?term=OSNA&rank=3).
TABLE 71 Trial registries searched
Registry Results
ClinicalTrials.gov 3
Current Controlled Trials 0
WHO ICTRP 4
EU Clinical Trials Register 0
Total 7
TABLE 72 ClinicalTrials.gov searches
Search Results
OSNA 3
One-step nucleic acid amplification 0
Metasin 0
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Current Controlled Trials
URL: www.controlled-trials.com/
Searched: 1 August 2012.
Results: 0 (Table 73).
World Health Organization International Clinical Trials Registry Platform
URL: www.who.int/ictrp/en/
Searched: 1 August 2012.
Results: 5 (Table 74).
1. Clinical evaluation of OSNA breast cancer system to extensive frozen section histopathology
(http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT01368744).
2. Clinical evaluation of molecular detection for sentinel lymph node examination in breast cancer patients
(http://apps.who.int/trialsearch/Trial.aspx?TrialID=JPRN-UMIN000005321).
3. Clinical evaluation of OSNA breast cancer system in breast cancer patients receiving neoadjuvant
therapy (http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT01140776).
4. Clinical evaluation of OSNA breast cancer system to test sentinel lymph nodes from patients with breast
cancer (http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT01136369).
5. A clinical study of intraoperative diagnosis of sentinel lymph node metastasis in head and neck cancer
patients using bimolecular methods (http://apps.who.int/trialsearch/Trial.aspx?
TrialID=JPRN-UMIN000006508).
TABLE 73 Current Controlled Trials searches
Search Results
OSNA 0
One-step nucleic acid amplification 0
Metasin 0
TABLE 74 World Health Organization (WHO) ICTRP searches
Search Results
OSNA 4
One-step nucleic acid amplification 1
Metasin 0
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EU Clinical Trials Register
URL: www.clinicaltrialsregister.eu/
Searched: 1 August 2012.
Results: 0 (Table 75).
Google searches
Searched: 1 August 2012.
Search term: OSNA
l All of the searches below were conducted using the advanced search function to restrict identified
reports to those in PDF format.
www.sysmex-lifescience.com/files/lifescience_patients_en.pdf
www.sysmex-lifescience.com/files/lifescience_en.pdf
www.sysmex-lifescience.com/files/OSNA%20Produktflyer_EN_150.pdf
www.sysmex-lifescience.com/files/English%20OSNA%20study%20-%20poster%20-%20Pathological%
20society%20London_08-01-2009%20-%20English.pdf
www.sysmex-lifescience.com/files/poster_san_antonio_breast_cancer_meeting_2007_german_
osna_study.pdf
www.osnaelectronics.net/safety_light/interfaces-process-automation.pdf
www.translational-medicine.com/content/pdf/1479-5876-8-83.pdf
www.sysmex-lifescience.com/files/sysmex_OSNA_breastcancer_en.pdf
http://pannonia-pathology.com/sites/default/files/presentations/anna_sapino.pdf
l All of the searches below were conducted using the advanced search function without limit or filter.
www.translational-medicine.com/content/8/1/83
www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=58&abstractID=40334
TABLE 75 EU Clinical Trials Register searches
Search Results
OSNA 0
One-step nucleic acid amplification 0
Metasin 0
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Search term: Metasin
l All of the searches below were conducted using the advanced search function to restrict identified
reports to those in PDF format.
https://docs.google.com/viewer?a=v&q=cache:InSL07ar5KgJ:web.me.com/pathologist/SENTINELNODEPCR/
Update_of_Metasin_files/metasin%2520for%2520aprton.pdf+metasin+filetype:pdf&hl=en&gl=ca&pid=bl&
srcid=ADGEESgSmQ9pWNx71jXzkiy3h8cx63faCeVSXSUFHb–5TwWuD998C-O5NnjXn3B-Hach6ViPCIcLcH
Jlxqeh_-wwmh5jVkCCiFX7GMUEnxr1fwA7doRdlVO9nthcRyDhpF7hWfn4Q3i&sig=AHIEtbR54NhNqzX3z
8M70BiSxseJskXr9A
www.pathsoc.org/files/meetings/winter2010/05.01.106552ProgMAINv10(web).pdf
l All of the searches below were conducted using the advanced search function, without limit or filter.
No hits.
Forward citation chasing
Review of clinical effectiveness
Database: Web of Science.
Host: Thomson Reuters.
Date searched: 15 October 2012.
Search by: Jenny Lowe.
Results: Table 76.
TABLE 76 Forward citation chasing for the clinical effectiveness review
Study Article title Results
Bernet Vegue 201251 Comparison of molecular analysis and histopathology for axillary lymph node staging
in primary breast cancer: results of the B-CLOSER-I study
0
Castellano 201252 Reliability of whole sentinel lymph node analysis by one-step nucleic acid amplification
for intraoperative diagnosis of breast cancer metastases
2
Choi 201053 One-step nucleic acid amplification (OSNA): intraoperative rapid molecular diagnostic
method for the detection of sentinel lymph node metastases in breast cancer patients
in Korean cohort
0
Feldman 201154 A novel automated assay for the rapid identification of metastatic breast carcinoma in
sentinel lymph nodes
9
Godey 201255 Sentinel lymph node analysis in breast cancer: contribution of one-step nucleic acid
amplification (OSNA)
0
Guillen-Paredes 201156 One-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases
as an alternative to conventional postoperative histology in breast cancer: a
cost–benefit analysis
2
Khaddage 201157 Implementation of molecular intra-operative assessment of sentinel lymph node in
breast cancer
4
continued
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Review of cost-effectiveness
Database: Web of Science.
Host: Thomson Reuters.
Date searched: 9 October 2012.
Search by: Chris Cooper.
Results: Table 77.
TABLE 76 Forward citation chasing for the clinical effectiveness review (continued )
Study Article title Results
Le Frére-Belda 2008157 Intra-operative sentinel lymph node metastasis detection in breast cancer by ‘one-step
nucleic acid amplification (OSNA)’ – results of the French multicentre prospective study
0
Osako 201159 Accurate staging of axillary lymph nodes from breast cancer patients using a novel
molecular method
1
Schem 200960 One-step nucleic acid amplification – a molecular method for the detection of lymph
node metastases in breast cancer patients; results of the German study group
25
Snook 201161 Multicentre evaluation of intraoperative molecular analysis of sentinel lymph nodes in
breast carcinoma
11
Tamaki 200962 Molecular detection of lymph node metastases in breast cancer patients: results of a
multicenter trial using the one-step nucleic acid amplification assay
44
Tamaki 201263 Routine clinical use of the one-step nucleic acid amplification assay for detection of
sentinel lymph node metastases in breast cancer patients. Results of a multicenter
study in Japan
0
Tusjimoto 200764 One-step nucleic acid amplification for intraoperative detection of lymph node
metastasis in breast cancer patients
71
Total 169
Deleting duplicate records –76
Unique items to screen 93
Deleting duplicate records
against the master search
–35
Unique items to screen 58
TABLE 77 Forward citation chasing for the cost-effectiveness review
Study Article title Results
Cutress 2010123 Observational and cost analysis of the implementation of breast cancer sentinel node
intraoperative molecular diagnosis
9
Guillen-Paredes
201156
One-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases as an
alternative to conventional postoperative histology in breast cancer: a cost–benefit analysis
2
Iqbal 201287 Implementation of one step nucleic acid amplification (OSNA) for intra-operative assessment
of sentinel lymph nodes in a DGH
0
Total 11
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Appendix 2 Clinical effectiveness: quality
appraisal and data extraction forms
Castellano et al.52
Design Participants Tests Outcomes
Objective: to assess the
reliability of OSNA as a
single test on whole SLNs as
a method of intraoperative
diagnosis and staging of
SLNs in breast cancer
Study design: cohort
Country: Italy
Number of centres: 1
Funding: unknown
Notes: OSNA SLNs were
also analysed using imprint
cytology and the two results
were compared (almost
like a single-gate study
embedded within the
parallel-group study), but
that comparison is not
relevant for this review
Number of participants:
110 OSNA, 169 histology
Number of SLNs or ALNs:
unclear
Recruitment procedure:
unclear
Inclusion criteria: patients
who did not have
suspicious ALNs after
ultrasound or positive
cytological smears. For the
OSNA cohort the primary
tumour had to express
CK19 in > 80% of the
tumour cells
Exclusion criteria: NR
Sample attrition/dropout:
13 patients transferred to
histology because of the
lack of CK19 expression
Index test (technical details): the
minimum weight for one OSNA
reaction was 50mg and the
maximum was 600mg. SLNs were
homogenised using lysis buffer for
90 seconds on ice. CK19 mRNA
was determined on a RD100i
system according to the standard
curve: micrometastases (+) was
defined as 250–5000 CK19 mRNA
copies/µl and macrometastases
(++) was defined as > 5000 CK19
mRNA copies/µl; < 250 CK19
copies/µl indicated a negative result
Reference standard (technical
details): histopathology; four slices
were placed in bioboxes, formalin
fixed and paraffin embedded.
Slices were step sectioned at
100-µm intervals until extinction.
The first two consecutive sections
for each step were used for
haematoxylin–eosin staining and
immunohistochemistry. Metastatic
deposits were measured in two
dimensions and categorised as
follows: pN0(i+), malignant cells
< 0.2mm, single tumour cells or
a cluster of < 200 cells; pN1mi,
micrometastases > 0.2mm and/or
> 200 cells; pN1a, metastases in
one to three ALNs or at least one
metastasis > 2.0mm
Details of SLN detection: SLNs were
identified using a combination of
blue dye and radioactive isotopes.
Blue-stained nodes and nodes
with high radioactive counts were
considered to be SLNs
Extraction and division of SLNs:
SLNs were cleared from fat tissue,
weighed and cut along the short
axis. Four slices were step sectioned
at 100-µm intervals until extinction
Discordance analysis: NA
Outcome assessor: NR
Blinding: NA
Accuracy outcomes:
positive and negative
rates
Process outcomes: NR
Clinical outcomes: NR
Other: NR
Unit of analysis:
patient
Discordant case
analysis: NA
Test failures: NR
NA, not applicable; NR, not reported.
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Participant characteristics
Characteristic OSNA Histology
Patients, n 110 169
Age (years), median (range) 66.7 (38–82) 61.2 (23–86)
Tumour size, n (%)
< 10mm 33 (30) 41 (24)
1.1–1.5 cm 19 (17) 45 (27)
> 1.5 cm 58 (53) 83 (49)
Histopathological type, n (%)
Invasive ductal carcinoma 81 (74) 109 (64)
Invasive lobular carcinoma 16 (14) 29 (17)
DCIS
Other 13 (12) 31 (18)
HER2, n (%)
Negative 108 (98) 144 (85)
Positive 2 (2) 25 (15)
HER2, human epidermal growth factor receptor 2.
Resuts
Total cases Negative, n (%) ITCs (%) Micrometastases, n (%) Macrometastases, n (%)
OSNA 110 78 (71) – 20 (18) 12 (11)
Histology 169 112 (66) 11 (7) 13 (8) 33 (20)
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Methodological issues
Recruitment: unclear
Replicates: unclear whether replicate samples were analysed
Outcome assessment: unclear whether the histology was checked by more than one independent pathologist
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) N
Did the study avoid inappropriate exclusions? (Y/N/U) Y
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference
standard? (Y/N/U)
NA
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index
test? (Y/N/U)
NA
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) U
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) N
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) U
Were samples suspected of TAB excluded from the analysis? (Y/N/U) NA
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; NA, not applicable; U, unclear risk of bias; Y, yes.
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Le Frère-Belda et al.58
Design Participants Tests Outcomes
Objective: to assess OSNA
for intraoperative SLN
metastasis detection in
breast cancer patients, using
final histology as the
reference standard
Study design: single gate
Country: France
Number of centres: 8
Funding: laboratory
consumables funded
by Sysmex
Number of participants: 233
Number of SLNs or ALNs:
503 samples from 456 SLNs
Recruitment procedure: NR
Inclusion criteria: all breast
cancer patients scheduled
for surgery with SLN biopsy
were considered for
enrolment
Exclusion criteria: patients
who had other types of
cancer with metastatic
spread, patients given
neoadjuvant therapy or
patients aged < 18 years
Sample attrition/
dropout: NR
Index test (technical details):
the assay was performed in
duplicate on a pure sample
and on a diluted sample
(1/10). Homogenates were
then stored at –80 °C.
Results were automatically
characterised by the CK19
mRNA copy number/µl of the
original tissue homogenate.
A (++) positive result
(CK19 mRNA copy number
> 5000/µl) was associated
with macrometastasis, a (+)
positive result (copy numbers
between 250 and 5000/µl)
was associated with
micrometastasis and a
negative result (copy
numbers no greater than
250/µl) was associated with
either ITCs or no tumour
Reference standard (technical
details): five ribbons were
cut with a 200-µm skip
space. From each ribbon
three sections were prepared,
one for haematoxylin–eosin
staining and two for
immunohistochemistry.
Macrometastasis was defined
as a tumour deposit > 2mm
and micrometastasis as a
tumour deposit > 0.2mm
and ≤ 2mm. Tumour
deposits ≤ 0.2mm were
categorised as ITCs and
recorded as histologically
negative pN0(i+)
Details of SLN detection: NR
Extraction and division of
SLNs: the excised SLNs were
cut into four equal slices.
Two alternate slices were
prepared for OSNA and the
other two slices were fixed in
4% buffered formaldehyde
and embedded in a paraffin
block
Accuracy outcomes:
sensitivity, specificity, PPV,
NPV, positive likelihood
ratio (LR+), negative
likelihood ratio (LR–)
Process outcome: median
time for OSNA testing
Clinical outcomes: NR
Other: NR
Unit of analysis: patient
and node
Discordant case analysis:
yes
Test failures: yes
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Design Participants Tests Outcomes
Discordance analysis: when
OSNA was positive and
histology negative, consecutive
ribbons with a 200-µm
skip space were cut until
depletion of the remaining
paraffin-embedded SLN slices.
The sections were stained with
haematoxylin–eosin and
immunostained with CK19
and AE1/AE3 antibodies
(a mixture of two different
clones of anticytokeratin
monoclonal antibodies AE1
and AE3). In all cases of
discrepancy, the SLN
homogenates were subjected
to further blind molecular
analysis. qRT-PCR was
performed for CK19 and the
breast tissue-specific markers
SPDEF (SAM pointed domain
containing ETS transcription
factor) and FOXA1 (forkhead
box A1). CK19 protein
expression was assessed using
Western blotting analysis.
If OSNA and the intensive
molecular investigation
showed the same results
(both negative or both
positive) this was taken to
indicate TAB, that is, the
presence of tumour deposit in
either of the two slices used
for histology or the two slices
used for OSNA
Outcome assessor: NR
Blinding: yes
NR, not reported.
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Participant characteristics
Characteristic OSNA
Patients, n 233
Age (years), median (range) 58 (30–93)
Clinical stage, n (%)
0 41 (17.7)
I 175 (75.4)
II 13 (5.6)
III 2 (0.9)
IV 1 (0.4)
Nodal status, n (%)
pN0 225 (97.0)
pN1 7 (3.0)
pN2
pN3
Histopathological type, n (%)
Invasive ductal carcinoma 164 (70.4)
Invasive lobular carcinoma 34 (14.6)
DCIS 23 (9.9)
Other 12 (5.2)
HER2, n (%)
Negative
Positive 13 (6.3)
HER2, human epidermal growth factor receptor 2.
Results
After TAB exclusion:
OSNA
Five-level histopathology
Macrometastasis Micrometastasis ITCs Negative
n = 503 SLNs
++ 37 6 0 3
+ 5 3 1 23
– 3 9 27 386
n = 233 patients
++ 22 6 0 3
+ 2 3 3 17
– 2 7 17 151
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Results
Before TAB exclusion per sample:
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
PPV (%)
(95% CI)
NPV (%)
(95% CI) OSNA LR+ OSNA LR–
Discordance
(%)
80.9 (69.0 to 89.8) 93.9 (91.2 to 96.0) 65.4 (53.7 to 75.8) 97.2 (95.1 to 98.6) 13.2 0.20 7.7
Before TAB exclusion per patient:
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
PPV (%)
(95% CI)
NPV (%)
(95% CI) OSNA LR+ OSNA LR–
Discordance
(%)
78.6 (63.1 to 89.1) 88.0 (82.4 to 92.3) 58.9 (44.9 to 71.9) 94.9 (90.5 to 97.7) 6.5 0.20 7.5
Nodes, n Median time to analysis (minutes)
1 33
2 40
3 48
4 54
Test failures – one sample excluded because of a manipulation error
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Methodological issues
Recruitment: unclear whether patients were recruited consecutively or randomly
Analysis: five centres reused frozen section samples, which may impair their integrity for final histology
Outcome assessment: unclear whether histology was assessed by more than one independent pathologist
Conflict of interest: laboratory consumables were purchased by Sysmex
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) Y
Did the study avoid inappropriate exclusions? (Y/N/U) Y
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference
standard? (Y/N/U)
U
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the
index test? (Y/N/U)
Y
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) U
Are there concerns that the target condition as defined by the reference standard does not
match the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) Y
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) L
Were samples suspected of TAB excluded from the analysis? (Y/N/U) Y
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; U, unclear risk of bias; Y, yes.
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Choi et al.53
Design Participants Tests Outcomes
Objective: to assess
the clinical utility and
applicability of the
OSNA assay in breast
cancer treatment in
Korea by comparing it
with histopathological
examination
Study design: single
gate
Country: Republic
of Korea
Number of centres: 1
Funding: Sysmex
Number of participants:
199 (after exclusions –
see below)
Number of SLNs or
ALNs: 284 SLNs
Recruitment procedure:
NR
Inclusion criteria:
Included patients were
suspected as being
negative for LN
metastasis from initial
clinical assessment, and
were scheduled for
SLNB
Exclusion criteria:
patients receiving
neoadjuvant therapy
before undergoing
SLNB and those who
had already undergone
SLNB were excluded
from the study
Sample attrition/
dropout: one patient
was excluded because
she was finally
diagnosed as not
having breast cancer
but large B-cell
lymphoma
Index test (technical details): each LN
was homogenised in glycine buffer.
The solutions (10 times diluted and
100 times diluted solutions) were mixed
with six different CK19 primers, four
deoxynucleoside triphosphates, reverse
transcriptase, DNA synthetase and
magnesium sulphate. The resulting
solution was reacted at a constant
temperature of 65 °C. Complementary
deoxyribonucleic acid (cDNA) was
synthesised from CK19mRNA in the
LN-homogenised solution using reverse
transcriptase. The degree of DNA
amplified product was calculated using
a calibration curve, with standards of
known CK19mRNA concentration.
A negative result occurred when the
CK19 mRNA concentration of both
the 10 times diluted solution and
the 100 times diluted solution was
<250 copies/µl. In a positive (++) result
the CK19 mRNA concentration in the
10 times diluted solution was ≥5000
copies/µl; in a positive (+) result the
CK19 mRNA concentration in the 10
times diluted solution was <5000
and ≥250 copies/µl; and in a
positive (+I, i.e. positive with reaction
inhibited result) the CK19mRNA
concentration in the 10 times diluted
solution was <250 copies/µl and
the CK19 mRNA concentration in
the 100 times diluted solution was
≥250 copies/µl
Reference standard (technical details):
each SLN was cut along its longitudinal
axis into sections of 1.5- to 2.0-mm
thickness. For the postoperative
histopathological examination, three-
level sections were prepared at 200-µm
intervals. Three sections were obtained
at each level for haematoxylin–eosin
staining, anticytokeratin antibody (AE1/
AE3) immunohistochemical staining
and unstaining. The presence/absence
of metastases was determined from
haematoxylin–eosin staining and AE1/
AE3 staining. Based on the TNM
classification of the American Joint
Committee on Cancer (7th edition),
metastatic deposits were recorded as
ITCs if their largest diameter was
<0.2mm, as micrometastases if they
were >0.2mm but ≤2mm and as
macrometastases if they were >2mm.
LN samples were regarded as positive
if at least one micrometastasis or
macrometastasis was found. ITC
results were considered as negative.
Macrometastasis or micrometastasis
was confirmed by both or either of
intraoperative histopathological
Accuracy outcomes:
sensitivity, specificity, PPV,
NPV, concordance rate
Process outcomes: the
rapidity of the OSNA
assay was investigated by
measuring the turnaround
time (i.e. the time between
starting homogenisation and
obtaining the results of
the assay)
Clinical outcomes: NR
Other: none reported
Unit of analysis: patient
Discordant case analysis: yes
Test failures: NR
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Design Participants Tests Outcomes
examination of frozen section
specimens and postoperative
histopathological examination of
permanent tissue specimens
Details of SLN detection: for the
detection of sentinel nodes, both
radioisotope and blue dye were used in
most patients and radioisotope only
was used in some patients. SLNs were
defined as any blue-stained nodes or
any nodes with radioactive counts
of ≥10%
Extraction and division of SLNs:
resected LNs were equally sectioned
into blocks along their long axis at
2-mm intervals. Two alternate blocks
were subjected to the OSNA assay
and the remaining two blocks were
subjected to intraoperative and
postoperative histopathological
examination. If LNs were <4mm in the
short axis they were cut in half. One
half was subjected to the OSNA assay
and the other half to histopathological
examination. Each LN was subjected to
the OSNA assay and histopathological
examination
Outcome assessor: NR
Blinding: unclear
Discordant case analysis: clinical
information, status of non-SLNs and
expression of CK19 protein in LN
metastatic foci were evaluated on a
patient-level basis
NR, not reported.
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Participant characteristics
Characteristic OSNA plus histology
Patients, n 199
Age (years), median (range) 40–49
Clinical stage, n (%)
0 11 (5.5)
I 132 (66.3)
II 54 (27.1)
III 2 (1.0)
IV 11 (5.5)
Clinical tumour classification, n (%)
T0
Tis 8 (4.0)
T1 129 (64.8)
T2 56 (28.1)
T3 2 (1.0)
T4
Tx 4 (2.0)
Nodal status, n (%)
pN0 153 (76.9)
pN1 37 (18.6)
pN2 5 (2.5)
pN3 4 (2.0)
Histopathological type, n (%)
Invasive ductal carcinoma 165 (82.9)
Invasive lobular carcinoma 9 (4.5)
DCIS 9 (4.5)
Other 16 (8.1)
Results
OSNA
Three-level histopathology
Macrometastasis Micrometastasis ITCs Negative
n = 199 patients
++ 19 2 1 1
+ 3 3 0 4
+i 1 0 0 0
– 4 4 3 154
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Results
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI) Discordance (%)
n= 199 patients 77.8 (0.60 to 0.90) 96.3 (0.92 to 0.99) 7
Nodes, n Mean time to analysis (minutes)
1 35.2
2 44.8
3 50.4
4 50.0
Overall, 39.0 minutes
Methodological issues
Recruitment: unclear
Replicates: unclear whether replicate samples were analysed
Outcome assessment: unclear whether the histology was checked by more than one independent pathologist
Conflict of interest: the study was funded by Sysmex
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) Y
Did the study avoid inappropriate exclusions? (Y/N/U) Y
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference
standard? (Y/N/U)
U
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the
review question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the
index test? (Y/N/U)
U
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) U
Are there concerns that the target condition as defined by the reference standard does not
match the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) Y
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) U
Were samples suspected of TAB excluded from the analysis? (Y/N/U) N
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; U, unclear risk of bias; Y, yes.
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
154
Feldman et al.54
Design Participants Tests Outcomes
Objective: to compare
the performance of
the OSNA system with
that of a detailed
histopathological
examination of the
LN and with
immunohistochemistry
for the detection of
metastatic carcinoma
in axillary SLNs in
patients with
early-stage
breast cancer
Study design: single
gate
Country: USA
Number of centres: 11
Funding: Sysmex
Number of participants: 496
Number of SLNs or ALNs:
1044 SLNs
Recruitment procedure: NR
Inclusion criteria: patients
aged > 18 years with a
clinical Tis, T1 or T2
primary breast cancer who
were awaiting lymphatic
mapping and SLN biopsy
were eligible for enrolment
Exclusion criteria: locally
advanced breast cancer
(tumours classified as
T3 or T4), DCIS in patients
who were undergoing
breast-conserving surgery,
clinically palpable suspicious
ALNs, previous diagnosis of
another type of carcinoma,
previous breast or axillary
surgery and preoperative
neoadjuvant therapy
Sample attrition/
dropout: NR
Index test (technical details): the SLN
slices were homogenised in 4ml of
OSNA lysis buffer and centrifuged
according to the manufacturer’s
instructions. The device was calibrated
to designate samples that contained
≥ 250 copies/µl of CK19 mRNA
as positive for metastatic tumour.
Cut-off values, system calibration and
calculation of the CK19 mRNA level of
the sample from the calibration curve
followed those of Tsujimoto et al.64
Reference standard (technical details):
the SLNs allocated to histopathology
were fixed in formalin and embedded
in paraffin. Pathologists at the
individual clinical sites evaluated the
SLNs according to their local standard
protocols for clinical management.
Paraffin blocks of the SLNs were cut at
200-µm intervals (levels) until all tissue
was depleted. At each level, three 5-µm
sections were cut; the first section
for each level was stained with
haematoxylin–eosin and the third
section from the third level was stained
immunohistochemically using pan-CK
antibodies. The remaining sections
were used for additional staining, as
required. All slides were sent to a
central reference pathology laboratory
for independent, blinded pathologist
evaluation. Tumour deposits in the SLNs
were classified according to American
Joint Committee on Cancer guidelines
Details of SLN detection: blue dye used
in 34 patients (6.9%), technetium-99m
sulphur colloid (radiocolloid) used in
107 patients (21.6%) and both used in
355 patients (71.6%)
Extraction and division of SLNs: SLNs
were included only if they were
4–20mm in size along the long axis
with a thickness ranging from 4mm to
10mm. SLNs were sectioned into an
average of six pieces along the long
axis into 1-mm slices. Alternate slices of
the LN were subjected either to analysis
with the OSNA system or to detailed
histopathological examination
Outcome assessor: two independent
pathologists
Blinding: yes
Discordant case analysis: performed by
Western blotting and qRT-PCR
Accuracy outcomes:
sensitivity and
specificity, agreement,
NPV and PPV
Process outcome: time
to analysis
Clinical outcomes: NR
Other: none
Unit of analysis: SLN
Discordant case
analysis: yes
Test failures: NR
NR, not reported.
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Participant characteristics
Characteristic OSNA plus histology
Patients, n 496
Age (years), median (range) 58.8 (28–88)
Clinical tumour classification, n (%)
T0
Tis 21 (4.2)
T1 327 (65.9)
T2 124 (25)
T3 5 (1)
T4
Tx 19 (3.8)
Nodal status, n (%)
pN0 387 (78)
pN1 84 (16.9)
pN2 14 (2.8)
pN3 4 (0.8)
pNx 7 (1.4)
Histopathological type, n (%)
Invasive ductal carcinoma 348 (70.2)
Invasive lobular carcinoma 40 (8.1)
DCIS
Other 109 (21.7)
HER2, n (%)
Negative
Positive
HER2, human epidermal growth factor receptor 2.
Results
OSNA
Three-level histopathology
Macrometastasis Micrometastasis ITCs Negative
n = 1044 SLNs
++ 77 9 1 8
+ 9 12 0 29
– 9 22 14 854
Sensitivity (%) (95% CI) Specificity (%) (95% CI) Discordance (%)
n= 1044 SLNs 77.5 (69.7 to 84.2) 95.8 (94.3 to 97.0) 6.8
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Results
Nodes, n Interquartile mean time to analysis (minutes)
1 33.0
2 39.6
3 45.2
Methodological issues
Recruitment: unclear whether recruitment was consecutive or randomised
Patient flow: the number of SLNs after discordance (1018) does not comply with the numbers before discordance (1044)
minus the resolved cases (28)
Replicates: unclear whether replicate samples were analysed
Conflict of interest: the study was funded by Sysmex
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) Y
Did the study avoid inappropriate exclusions? (Y/N/U) Y
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference
standard? (Y/N/U)
Y
If a threshold was used, was it prespecified? (Y/N/U) N
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index
test? (Y/N/U)
Y
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) L
Are there concerns that the target condition as defined by the reference standard does not
match the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) Y
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) U
Were samples suspected of TAB excluded from the analysis? (Y/N/U) Y
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; U, unclear risk of bias; Y, yes.
DOI: 10.3310/hta19020 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 2
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Huxley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
157
Bernet Vegue et al.51
Design Participants Tests Outcomes
Objective: description
of the results of the
B-CLOSER-I study with
regard to staging
Study design: single
gate
Country: Spain
Number of centres: 8
Funding: Sysmex
Number of participants: 55 after
exclusions
Number of SLNs or ALNs: 567
ALNs
Recruitment procedure: consecutive
Inclusion criteria: in all cases,
tumours were confirmed as CK19
positive by immunohistochemistry
before SLNB. All patients had
undergone ALND after positive
SLNB diagnosed by OSNA
Exclusion criteria: patients were
excluded if they had metastatic
disease, had received neoadjuvant
therapy or were judged unsuitable
because of concomitant disease,
and if < 10 ALNs were obtained by
ALND
Sample attrition/dropout: two
patients with < 10 ALNs excluded
Index test (technical details): the LN
tissue was homogenised. CK19
mRNA was then amplified by
RT-LAMP (reverse transcription
loop-mediated isothermal
amplification). Results were
classified according to the following
cut-off values for CK19 mRNA
copy number: < 100 copies/µl,
negative; 100–250 copies/ml,
negative (low expression); 250 to
5000 copies/µl, micrometastasis;
and > 5000 copies/µl,
macrometastasis
Reference standard (technical
details): the central tissue slice was
fixed and embedded in paraffin for
histopathological analysis and the
remaining tissue was stored at
–80 °C before analysis by OSNA
assay. A 5-mm paraffin section was
obtained from each central slice and
stained with haematoxylin–eosin.
Macrometastases, micrometastases
and ITCs were defined by American
Joint Committee on Cancer TNM
criteria. When ITCs were identified by
histopathology, serial sections of the
remainder of the block were
analysed for the presence of
micrometastases or macrometastases
Details of SLN detection: NR
Extraction and division of SLNs: in
LNs obtained by ALND weighing
(without surrounding fat) >50mg
(the cut-off for validity using
the OSNA method), a central
longitudinal 1-mm slice was taken
from each node and allocated to
histology, with the rest of the node
assigned to OSNA
Outcome assessor: NR
Blinding: NR
Discordant case analysis: no
further analysis
Accuracy outcome:
concordance
Process outcomes:
NR
Clinical outcomes:
NR
Other: NR
Unit of analysis:
patient and ALN
Discordant case
analysis: cases
reported but no
further analysis
Test failures: NR
NR, not reported.
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Participant characteristics
Characteristic OSNA plus histology
Patients, n 55
Age (years), median (range) 59 (23–87)
Clinical stage, n (%)
0
I 21 (38.2)
II 22 (40)
III 12 (21.8)
IV
Unknown
Histopathological type, n (%)
Invasive ductal carcinoma 44 (80.0)
Invasive lobular carcinoma 7 (12.7)
DCIS 1 (1.8)
Other 3 (5.5)
HER2, n (%)
Negative 49 (89.1)
Positive 6 (10.9)
HER2, human epidermal growth factor receptor 2.
Results
OSNA
One-level histopathology
Macrometastasis Micrometastasis Negative
n = 567 non-SLNs
++ 1 4 14
+ 0 1 25
+i (low expression) 0 0 8
– 0 0 514
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Methodological issues
Recruitment: small sample size with relatively large number of ALNs
Replicates: unclear whether replicate samples were analysed
Outcome assessment: unclear whether the histology was checked by more than one independent pathologist
Conflict of interest: the study was funded by Sysmex
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) Y
Was a cohort study design avoided? (Y/N/U) Y
Did the study avoid inappropriate exclusions? (Y/N/U) Y
Could the selection of patients have introduced bias? (H/L/U) L
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference standard?
(Y/N/U)
U
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) U
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index test?
(Y/N/U)
U
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) U
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) Y
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) L
Were samples suspected of TAB excluded from the analysis? (Y/N/U) L
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; U, unclear risk of bias; Y, yes.
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Godey et al.55
Design Participants Tests Outcomes
Objective: to present
OSNA results in a
routine clinical setting
compared with
histology
Study design: single
gate embedded in
cohort
Country: France
Number of centres:
unclear
Funding: NR
Number of participants: 722
Number of SLNs or ALNs:
810 SLNs
Recruitment procedure: NR
Inclusion criteria: clinically
node-negative early-stage
breast cancer undergoing
axillary SLN procedure
Exclusion criteria: NR
Sample attrition/dropout:
108 patients with in situ
carcinoma, tumour size
> T1c or invasive carcinoma
other than ductal or lobular
forms were excluded from
the OSNA cohort group
in the analysis to avoid
bias, because these
categories of patients
were not represented in
the (historical) histology
cohort group
Index test (technical details): SLNs cleared
from fat and extranodal tissue were
homogenised. SLNs weighing > 600mg
were cut and analysed separately with two
or more molecular analyses. OSNA analysis
was carried out in duplicate with a pure
and a diluted sample (1/10) of SLN lysates.
The CK19 mRNA copy number/µl of lysate
was classified as follows: < 250/µl, no
metastasis; 250–5000/µl, micrometastasis;
> 5000/µl, macrometastasis. The OSNA
assay was not calibrated to detect ITCs.
If the copy number was > 250/µl in the
diluted preparation only, the OSNA result
was classified as positive with inhibition
of the amplification reaction; Patients with
at least one SLN macrometastasis were
classified as macrometastatic, those with at
least one SLN micrometastasis were classed
as micrometastatic and those with at least
one metastasis with inhibition were classed
as metastatic
Reference standard (technical details):
histological analysis was performed on
SLN tissue sections embedded in paraffin
blocks and sectioned every 250 µm until
the block was completely cut. Each level
was initially stained with standard
haematoxylin–eosin. If no metastases were
revealed by conventional staining, then
immunohistochemical labelling of all levels
was carried out. Final examination of
axillary non-SLNs was investigated by
permanent histology (each 2-mm
section of the LN was analysed with
haematoxylin–eosin staining) in both the
OSNA and the historical cohort
Details of SLN detection: localisation of
the sentinel node was identified with
technetium-99m-labelled colloid injected
the day before surgery and 3 hours after
axillary lymphoscintigraphy, followed by
subcutaneous injection of 2ml of patent
blue dye on the day of the procedure. SLNs
were cut by the pathologist and touch
imprints were performed intraoperatively
Extraction and division of SLNs: a 1-mm
thick central slice was stained for
postoperative histology. The remaining
portion of the node was used for OSNA
analysis intraoperatively
Outcome assessor: NR
Blinding: NR
Discordant case analysis: NR
Accuracy outcome:
positivity rate
Process outcome:
time for analysis
Clinical outcomes: NR
Other: NR
Unit of analysis:
patient
Discordant case
analysis: NA
Test failures: issues
with three samples for
OSNA; no further
details
NR, not reported.
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Participant characteristics
Characteristic OSNA Histology
Patients, n 258 355
Age (years), median 56.8 56.9
Clinical tumour classification, n
T0
Tis
T1a, b or c 19, 93, 146 16, 125, 214
T2
T3
T4
Tx
Histopathological type, n
Invasive ductal carcinoma 212 313
Invasive lobular carcinoma 46 42
DCIS
Other
Results
OSNA-positive rate 24.4%, histology-positive rate 24.8%
Technical problems with OSNA for three patients; no further details
Nodes, n Mean (SD) time to analysis (minutes)
1 32.9 (4.9)
2 36.4 (4.5)
3 41.6 (5.2)
4 48.5 (8.7)
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Methodological issues
Replicates: unclear whether replicate samples were analysed
Outcome assessment: unclear whether the histology was checked by more than one independent pathologist
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) N
Did the study avoid inappropriate exclusions? (Y/N/U) N
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference
standard? (Y/N/U)
NA
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) U
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
U
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index
test? (Y/N/U)
U
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) U
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
U
Did all patients receive a reference standard? (Y/N/U) N
Did all patients receive the same reference standard? (Y/N/U) N
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) U
Were samples suspected of TAB excluded from the analysis? (Y/N/U) NA
Are there concerns about selective reporting of outcomes? (H/L/U)a H
H, high risk of bias; L, low risk of bias; N, no; NA, not applicable; U, unclear risk of bias; Y, yes.
a Single-gate results not reported.
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Bernet et al.50
Design Participants Tests Outcomes
Objective: to compare OSNA
with conventional histology
and evaluate the feasibility of
OSNA for intraoperative
evaluation of SLNs in breast
cancer surgery
Study design: observation
Country: Spain
Number of centres: 1
(for trial 2)
Funding: NR
Notes: trial 1 was not
included in this review
because the comparator was
excluded. Trial 2 was included
for process outcomes
Number of
participants: 55
Number of SLNs
or ALNs: unclear
Recruitment
procedure: NR
Inclusion
criteria: NR
Exclusion
criteria: NR
Sample attrition/
dropout: NR
Index test (technical details): the OSNA
protocol consisted of homogenisation of
tissue and subsequent isothermal (65 °C)
amplification of CK19. Tissue
homogenates from each LN were kept
frozen at –80 °C as a backup for possible
future studies
Reference standard (technical details): NA
Details of SLN detection: NR
Extraction and division of SLNs: the entire
node was submitted to the OSNA assay in
all cases, except in nine cases in which
alternate slices were studied by both
methods
Outcome assessor: NA
Blinding: NA
Discordant case analysis: NA
Accuracy outcomes: NA
Process outcome: time
from receipt of node to
analytical report
Unit of analysis: node
Discordant case
analysis: NA
Test failures: NR
NA, not applicable; NR, not reported.
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Participant characteristics
NR
Results
Nodes, n Mean (range) time to analysis (minutes)
1 39.6 (26–70)
Methodological issues
Replicates: unclear whether replicate samples were analysed
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) N
Was a cohort study design avoided? (Y/N/U) NA
Did the study avoid inappropriate exclusions? (Y/N/U) U
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference
standard? (Y/N/U)
U
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index
test? (Y/N/U)
U
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) L
Are there concerns that the target condition as defined by the reference standard does not
match the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) N
Did all patients receive the same reference standard? (Y/N/U) NA
Were all samples (that should have been) included in the analysis? (Y/N/U) U
Could the patient flow have introduced bias? (H/L/U) U
Were samples suspected of TAB excluded from the analysis? (Y/N/U) NA
Are there concerns about selective reporting of outcomes? (H/L/U) U
H, high risk of bias; L, low risk of bias; N, no; NA, not applicable; NR, not reported; U, unclear risk of bias; Y, yes.
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Guillen-Paredes et al.56
Design Participants Tests Outcomes
Objective: to analyse the
economic costs of
intraoperative OSNA
compared with those of
conventional deferred
histological and
immumohistochemical
assay carried out in
hospital
Study design: cohort
Country: Spain
Number of centres: 1
Funding: Foundation for
Healthcare Research and
Training of the Murcia
Region (FFIS)
Number of participants:
Histology 45; OSNA 35
Number of SLNs or ALNs:
114 SLNs
Recruitment procedure: patients
were recruited from an
administrative database that
recorded all SLNBs reported by
the pathology department since
the implementation of this
technique in hospital in 2002 for
the study of SLNs in breast
cancer patients
Inclusion criteria: patients with
breast cancer stages pT1/2 N0
M05 with clinically negative and
ultrasound-negative ALNs who
underwent SNLB along with
appropriate breast cancer
surgery in the same intervention
at the breast unit of the hospital
between 15 October 2008 and
15 December 2009
Exclusion criteria: patients who
had received neoadjuvant
treatment, those who refused
to sign the informed consent,
those who could not undergo
the planned surgery because of
a high anaesthetic risk, those
who had undergone previous
extensive breast surgery, those
who had undergone a SLNB
with local anaesthesia before the
definitive breast surgery (as they
were candidates for immediate
reconstruction or for receiving
neoadjuvant chemotherapy with
clinical N0 to reduce tumour
size), pregnant women and men
Sample attrition/dropout: NR
Index test (technical details):
the SLN was sent fresh to the
pathology department (if more
than one LN was available all
were sent at the same time).
The fat was separated from the
LN and the LN was sectioned if it
weighed > 600mg. The samples
were then lysed and centrifuged.
Results were classified according
to the number of CK19 mRNA
copies per tumour cell: no
metastasis, < 250 copies/µl;
micrometastasis, from 250 to
5000 copies/µl; macrometastasis,
> 5000 copies/µl
Reference standard (technical
details): after initial preparation
of the LN using 4-mm sections
fixed in formalin and embedded
in paraffin, 15 × 4 µm-thick serial
sections were cut and stained
with haematoxylin–eosin and
immunohistochemically for
cytokeratins. A pathologist
examined the samples by
microscope and classified them
as negative (no metastatic cells),
ITCs (focus of malignant cells
< 0.2mm), micrometastasis
(> 0.2mm and ≤ 2mm) and
macrometastasis (> 2mm)
Details of SLN detection: the SLN
was defined as that which had
an activity > 10% of the
maximum activity detected
Extraction and division of SLNs:
details as above
Outcome assessor: pathologist
using a conventional optical
microscope
Blinding: NA
Discordant case analysis: NA
Accuracy outcomes:
NR
Process outcomes:
operative time, days
in hospital, hospital
costs
Clinical outcomes:
complications,
lymphadenectomy
Unit of analysis:
patient
Discordant case
analysis: NA
Test failures: NR
NA, not applicable; NR, not reported.
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Participant characteristics
Classification OSNA Histology
Patients, n 35 45
Age (years), median 55.54 61.89
Clinical tumour classification, n
T0
Tis 2 3
T1 16 13
T2 17 29
T3
T4
Tx
Histopathological type, n
Invasive ductal carcinoma 31 37
Invasive lobular carcinoma 2 5
DCIS 1 2
Other 1 1
Results
Analysis
Mean (SD) intervention time (minutes) Mean (SD) days in hospital
First operation Second operation Total First admission Second admission Total
Histology 57.11 (23.93) 78.33 (NR) 78 (48.02) 1.8 (2.04) 2.41 (1.09) 2.44 (0.78)
OSNA 62.14 (48.02) NA 62.14 (21.93) 1.54 (0.78) NA 1.54 (0.78)
NA, not applicable; NR, not reported.
Test
Complications in first intervention Complications in second intervention
None Minor Major None Minor Major
Histology 28 17 0 4 8 0
OSNA 24 10 1 NA NA NA
NA, not applicable.
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Methodological issues
Replicates: unclear whether replicate samples were analysed
Recruitment: patients do not appear to have been recruited consecutively or randomly
Analysis: unclear whether histopathology results were checked by an independent pathologist
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) N
Did the study avoid inappropriate exclusions? (Y/N/U) Y
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference standard?
(Y/N/U)
NA
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index test?
(Y/N/U)
NA
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) U
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) NA
Did all patients receive the same reference standard? (Y/N/U) NA
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) U
Were samples suspected of TAB excluded from the analysis? (Y/N/U) NA
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; NA, not applicable; U, unclear risk of bias; Y, yes.
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Khaddage et al.57
Design Participants Tests Outcomes
Objective: to evaluate the
intraoperative performance
of OSNA in comparison to
postoperative histology and
then to introduce the
technique into routine
practice
Study design: single gate
Country: France
Number of centres:
multicentre; number NR
Funding: Sysmex
Number of participants:
validation study 46;
routine study 197
Number of SLNs or
ALNs: validation study
80 SLNs; routine study
unclear
Recruitment procedure:
NR
Inclusion criteria: for
both patient cohorts
inclusion criteria were
a minimum age of
18 years and
assignment for SLNB
Exclusion criteria:
neoadjuvant treatment
and the presence of
metastatic disease
other than breast
carcinoma
Sample attrition/
dropout: NR
Index test (technical details): the SLN slices
were homogenised. The results were
presented on the RD-100i in qualitative
categories (++, +, –) and further specified
by CK19 mRNA copy number/µl: 0–249
copies/µl (–), 250–5000 copies/µl (+), and
> 5000 copies/µl (++). A result indicating a
(+) was comparable to the presence of a
micrometastasis and a result indicating a
(++) was comparable to a macrometastasis
Reference standard (technical details):
two alternate slices were embedded in
paraffin and postoperatively cut at
200-µm intervals (five levels). Each level
was subjected to haematoxylin–eosin and
immunohistochemical staining for CK19
protein as well as immunohistochemistry
with AE1/AE3 as a pan-CK marker. For
routine use, a central slide of 1mm from
each SLN was analysed by one level of
haematoxylin–eosin staining and one level
of immunohistochemistry (AE1/AE3).
Non-SLNs were cut into 2-mm slices and
one level of haematoxylin–eosin staining
was performed for each slice. Tumour
deposits were classified according to
the TNM classification of the Union
for International Cancer Control
(sixth edition) and the American Joint
Committee on Cancer (sixth edition).
ITCs or a tumour-free SLN were defined
as a negative histological result
Details of SLN detection: NR
Extraction and division of SLNs: during the
clinical study, nodes were cleared from fat
after SLNB and intraoperatively cut into
four equal slices of 1–2mm thickness. Two
alternate slices were analysed by OSNA
and the remaining two slices were
subjected to histology
Outcome assessor: NR
Blinding: the results of OSNA were not
known to the investigator of histology and
vice versa
Discordant case analysis: consisted of
qRT-PCR for CK19 mRNA and two breast
cancer-specific markers [SAM pointed
domain containing ETS transcription factor,
(SPDEF) and forkhead box A1 (FOXA1)] as
well as beta-actin for RNA control. RNA was
extracted from 200µl of the homogenate.
The cut-off levels for each marker were
determined according to the qRT-PCR results
of a series of histologically positive and
negative LNs from breast cancer patients
Accuracy outcomes:
Concordance,
sensitivity, specificity
Process outcome:
time to analysis
Unit of analysis: node
and patient
Discordant case
analysis: yes
Test failures: NR
NR, not reported.
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Participant characteristics
Characteristic OSNA plus histology validation OSNA plus histology routine
Patients, n 46 197
Age (years), median (range) (≥ 18) (≥ 18)
Clinical tumour classification, n
T0 7 1
Tis 0 21
T1 34 141
T2 2 30
T3 2 1
T4 1 1
Tx
Histopathological type, n
Invasive ductal carcinoma 36 148
Invasive lobular carcinoma 5 16
DCIS 5 21
Other 0 12
Results
Sensitivity (%) Specificity (%) Discordance (%)
Validation study
n= 46 patients before TAB 80.0 97.2 3.7
n= 46 patients after TAB 100 97.2
n= 80 SLNs before TAB 88.2 98.4
n= 80 SLNs after TAB 100 98.4
OSNA
Five-level histopathology – validation study
Macrometastasis Micrometastasis ITCs Negative
n = 80 SLNs
++ 11 2 – 0
+ 2 0 – 1
– 0 0 (2) 2 60 (62)
n = 46 patients
++ 6 2 0 0
+ 0 0 0 1
– 0 0 (2) 2 33 (35)
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Results
OSNA
One-level histopathology – routine use
Macrometastasis Micrometastasis ITCs Negative
n = 197 patients
++ 9 1 – 3
+ 8 7 – 14
– 0 0 – 155
Values in parentheses indicate case numbers before discordant case investigation.
Median time to analysis for two nodes: 37 minutes
Methodological issues
Replicates: unclear whether replicate samples were analysed
Recruitment: unclear whether patients have been recruited consecutively or randomly
Analysis: unclear whether histopathology results were checked by an independent pathologist
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) Y
Did the study avoid inappropriate exclusions? (Y/N/U) Y
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference standard?
(Y/N/U)
Y
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index test?
(Y/N/U)
Y
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) L
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) Y
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) L
Were samples suspected of TAB excluded from the analysis? (Y/N/U) Y
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; U, unclear risk of bias; Y, yes.
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McDowell (unpublished)
Academic-in-confidence
information has
been removed
Academic-in-confidence
information has
been removed
Academic-in-confidence
information has
been removed
Academic-in-confidence
information has
been removed
Academic-in-confidence
information has
been removed
Academic-in-confidence
information has
been removed
Academic-in-confidence
information has
been removed
Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed
Academic-in-confidence information has been removed
Academic-in-confidence information has been removed
Academic-in-confidence information has been removed
Academic-in-confidence information has been removed
Academic-in-confidence information has been removed
Academic-in-confidence information has been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
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Academic-in-confidence
information has
been removed
Academic-in-confidence
information has
been removed
Academic-in-confidence
information has
been removed
Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed Academic-in-confidence
information has
been removed
Academic-in-confidence information has been removed.
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Osako et al.59
Design Participants Tests Outcomes
Objective: to determine
the performance of the
OSNA assay as an
accurate nodal staging
tool compared with
routine histological
examination
Study design: cohort
Country: Japan
Number of centres: 1
Funding: Sysmex
contributed to funding of
laboratory consumables
Number of participants: 183
Number of SLNs or ALNs: NR
Recruitment procedure:
consecutive
Inclusion criteria: patients
with clinically and
ultrasonographically
node-negative pT1–2 breast
cancer who had undergone
ALND after a positive SNLB
with OSNA between April
2009 and September 2010
Exclusion criteria: patients
with three or more positive
SLNs; SLN identification
without using the
radioisotope tracer; previous
excision of primary tumour;
heterochronous ipsilateral
breast cancer recurrence;
neoadjuvant drug therapy
Sample attrition/
dropout: NR
Index test (technical details): after removal
of the extranodal tissue, whole LNs were
homogenised. A standard positive control
containing 5000 copies/µl of CK19 mRNA
and a negative control with no CK19
mRNA were used for quality assurance in
each run. LNs that exceeded the specified
maximum weight of 600mg were cut into
two or more pieces and processed as
separate nodes. The number of CK19
mRNA copies/µl was calculated and
the result assessed in accordance with
the following cut-off classification
levels: ≥5000: positive (++); 250 to
<5000: positive (+); <250 and ≥250 in
diluted (as opposed to measurement)
sample: positive with reaction inhibited
(+i); < 250: negative. All SLNs and a small
number of non-SLNs were assessed
intraoperatively. Almost all non-SLNs in
ALND specimens were assessed
postoperatively after freezing at
–80 °C. The frozen non-SLNs were
assessed in the same manner as fresh
nodes at a later date
Reference standard (technical details):
all non-SLNs were sliced in half along
the long axis after formalin fixation.
One of the cut surfaces was examined
after haematoxylin–eosin staining. Five to
seven nodes were embedded in paraffin
in one cassette. Immunohistochemistry
was not used for evaluation of non-SLNs.
The non-SLN specimens were classified
into three categories according to the
7th American Joint Committee on
Cancer staging manual: positive,
micrometastasis, negative, ITCs
(< 0.2mm) or no tumour cells
Details of SLN detection: the radioisotope
tracer used was 1.5mCi/ml of technetium-
99m phytate. A day before surgery, the
tracer was injected in the area of the
tumour and the retrotumoural space. In
addition, 2–3 ml of vital dye, indigocarmine,
was injected into the peritumoral space or
areola at the time of surgery
Extraction and division of SLNs: all
non-SLNs were sliced in half along the
long axis after formalin fixation.
Discussion refers to three-level histology,
although this is not clear
Outcome assessor: NR
Blinding: NA
Discordant case analysis: NA
Accuracy outcome:
positive rate
Unit of analysis:
patient
Discordant case
analysis: NA
Test failures: NR
NA, not applicable; NR, not reported.
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Participant characteristics
Characteristic OSNA Histology
Patients, n 119 64
Age (years), median (range) 53 (27–86) 56 (39–81)
Nodal status, n (%)
pN0
pN1 115 (96.6) 62 (96.9)
pN2 3 (3.4) 2 (3.1)
pN3
Histopathological type, n (%)
Invasive ductal carcinoma 110 (92.4) 57 (89.1)
Invasive lobular carcinoma 4 (3.4) 2 (3.1)
DCIS
Other/special type 5 (4.2) 5 (7.8)
HER2, n (%)
Negative 106 (89.1) 55 (85.9)
Positive 13 (10.9) 9 (14.1)
HER2, human epidermal growth factor receptor 2.
Results
Test Positive rate for non-SLNs (%) (95% CI)
Histology 20.3 (11.7 to 32.6)
OSNA 55.5 (46.1 to 64.5)
SLN stage
Overall axillary stage for histology
pN1mi pN1a pN2a pN3a
Upstaging rate (%)n n % n % n % n %
pN1mi (sn) 21 19 90.5 1 4.8 1 4.8 0 0 9.5
pN1a (sn) 41 – – 34 82.9 4 9.8 3 7.3 17.1
pN2a (sn) 2 – – – – 2 100 0 0 0
All 64 19 29.7 35 54.7 7 10.9 3 4.7 14.1
mi, micrometastases (> 0.2mm and/or > 200 cells but none > 2.0mm); sn, sentinel node evaluation performed after
treatment.
DOI: 10.3310/hta19020 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 2
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Huxley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
175
Results
SLN stage
Overall axillary stage for OSNA
pN1mi pN1a pN2a pN3a
Upstaging rate (%)n n % n % n % n %
pN1mi (sn) 50 43 86.0 6 12.0 0 0 1 2.0 14.0
pN1a (sn) 65 – – 54 83.1 9 13.8 2 3.1 16.9
pN2a (sn) 4 – – – – 2 50.0 2 50.0 50.0
All 119 43 36.1 60 50.4 11 9.2 5 4.2 16.8
mi, micrometastases (> 0.2mm and/or > 200 cells but none > 2.0mm); sn, sentinel node evaluation performed after
treatment.
Methodological issues
Replicates: unclear whether replicate samples were analysed
Analysis: unclear whether histopathology results were checked by an independent pathologist
Conflict of interest: consumables funded by Sysmex
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) Y
Was a cohort study design avoided? (Y/N/U) N
Did the study avoid inappropriate exclusions? (Y/N/U) Y
Could the selection of patients have introduced bias? (H/L/U) L
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference standard?
(Y/N/U)
U
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index test?
(Y/N/U)
U
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) L
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) N
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) L
Were samples suspected of TAB excluded from the analysis? (Y/N/U) NA
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; NA, not applicable; U, unclear risk of bias; Y, yes.
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Schem et al.60
Design Participants Tests Outcomes
Objective: to evaluate
the performance of
OSNA compared with
that of histology
Study design: single
gate
Country: Germany
Number of centres: 2
Funding: Sysmex
Number of
participants: 93
Number of SLNs or
ALNs: 343 ALNs
Recruitment
procedure: NR
Inclusion criteria: NR
Exclusion criteria: NR
Sample attrition/
dropout: NR
Index test (technical details): two alternate LN slices
out of four were homogenised together. The LN
lysates were stored at −80 °C until further use.
A CK19 mRNA copy number of < 250/µl was
regarded as −; copy numbers between 250 and
5000/µl were regarded as +; and copy numbers
> 5000/µl were regarded as ++
Reference standard (technical details): the two
remaining LN slices were fixed with neutral buffered
formaldehyde and embedded in the same paraffin
block. Each slice was identified by colour coding.
Two initial haematoxylin–eosin sections
(representing frozen sections of the SLN), one initial
level and four additional levels with a 0.1-mm skip
space were cut from the 343 blocks. Each level
consisted of four 4-µm sections: one was used
for haematoxylin–eosin staining, one for
immunohistochemistry with the pan-anti-CK
antibody LU5, one for CK19 immunohistochemistry
and one was a spare section. For the specificity
study, the paraffin blocks of 120 histologically
negative samples, analysed by five-level histology,
were cut into further levels until depletion.
Immunohistochemistry was then performed and
deparaffinised sections were cooked in
tris–ethylenediaminetetraacetic acid–sodium citrate
buffer (pH 7.8) for 4minutes. After blocking,
incubation with the primary antibody was
performed for 40minutes and with the secondary
antibody for 30 minutes. Visualisation was achieved
with diaminobenzidine tetrahydrochloride and
staining employed the LU5 antibody. Metastatic
deposits were recorded, according to the TNM
classification of the Union for International Cancer
Control (sixth edition) and the American Joint
Committee on Cancer (sixth edition), as ITCs if their
largest diameter was < 0.2mm, as micrometastases
if they were > 0.2mm and ≤ 2mm in diameter
and as macrometastases if they were > 2mm
in diameter. LNs with ITCs were considered
as negative
Details of SLN detection: NR
Extraction and division of SLNs: 343 LN samples
were longitudinally cut into four nearly equal slices
with a special cutting tool consisting of three blades
either 1 or 2mm apart. ALNs were categorised
according to their size: ALNs with a minor axis
< 0.4 cm were excluded from the analysis; ALNs
with a minor axis between 0.4 and 0.6 cm (group 1)
were centrally cut into four slices with the 1-mm
cutting tool; ALNs between 0.6 and 1.0 cm (group
2) were centrally cut into four slices with a 2-mm
cutting tool; ALNs with a minor axis > 1.0 cm
(group 3) were either halved or cut into several
pieces, and each piece, depending on its size, was
treated in a similar fashion as described for groups
1 and 2. Alternate slices were allocated to the
OSNA method and to histology at five levels. The
slices used for OSNA were shock frozen in liquid
nitrogen and stored at −80 °C before the analysis
Accuracy outcomes:
concordance,
sensitivity, specificity
Unit of analysis:
node
Discordant case
analysis: yes
Test failures: NR
DOI: 10.3310/hta19020 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 2
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Huxley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
177
Design Participants Tests Outcomes
Outcome assessor: NR
Blinding: Yes
Discordant case analysis: cases with discordant
results between the OSNA assay and five-level
histological examination were subjected to
extended histological work-up that involved slicing
the remaining tissue in the paraffin blocks until
depletion. The homogenates of these discordant
cases were also analysed by Western blotting and
qRT-PCR. When these supplemental analyses gave
the same result as the OSNA assay, the related
samples were excluded from the analysis as TAB
was likely to be the cause of the discrepant results
NR, not reported.
Participant characteristics
Characteristic OSNA plus histology
Patients, n 93
Clinical tumour classification, n
T0
Tis
T1 6
T2 36
T3 4
T4 1
Nodal status, n
pN0 46
pN1 27
pN2 13
pN3 7
Histopathological type, n
Invasive ductal carcinoma 68
Invasive lobular carcinoma 21
DCIS
Other (mixed) 4
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Results
Before TAB exclusion
OSNA
Five-level histopathology
Macrometastasis Micrometastasis ITCs Negative
n = 343 ALNs
++ 90 7 0 9
+ 7 – 1 16
– 0 2 2 209
Sensitivity (%) Specificity (%) Discordance (%)
n= 343 ALNs before exclusion for TAB 98.1 91.7 8.2
n= 330 ALNs after exclusion for TAB 100 95.6 4.5
Methodological issues
Replicates: unclear whether replicate samples were analysed
Analysis: unclear whether histopathology results were checked by an independent pathologist
Conflict of interest: consumables funded by Sysmex
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) Y
Did the study avoid inappropriate exclusions? (Y/N/U) U
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) U
Were the index test results interpreted without knowledge of the results of the reference standard?
(Y/N/U)
Y
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index test?
(Y/N/U)
U
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) U
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) Y
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) U
Were samples suspected of TAB excluded from the analysis? (Y/N/U) Y
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; U, unclear risk of bias; Y, yes.
DOI: 10.3310/hta19020 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 2
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Huxley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
179
Snook et al.61
Design Participants Tests Outcomes
Objective: to evaluate OSNA
as a potential intraoperative
diagnostic tool via a multicentre
prospective study that was
undertaken to reassess the
accuracy of OSNA diagnosis
compared with intensive
histopathological examination
and to investigate the feasibility
of intraoperative use of OSNA
to diagnose LN metastases
Study design: single gate
Country: UK
Number of centres: 4
Funding: The Juniper Trust and
BUFFER (Breast Unit Fund for
Education and Research), both
registered charities, funded the
salary of a clinical research
fellow, who was registered with
the University of Surrey during
the period of her MD research.
There was no financial
contribution from any
commercial organisation
Notes: the study was undertaken
in two phases. The technical
performance phase was
designed to familiarise each site
with the molecular biological
test. The technical performance
and accuracy of the OSNA
method of diagnosing breast
cancer LN metastasis was
compared with histology using
both sentinel and non-sentinel
axillary nodes for analysis. LN
specimens for OSNA analysis
were snap frozen at −80 °C for
analysis at a time suitable for the
laboratory. Each site had to
achieve a concordance of at
least 80% (94% concordance
was achieved across the four
sites following discordant case
analysis) in a minimum of 40 LNs
before starting the second
phase. This next phase, the
clinical equivalence study, was
designed to investigate the
feasibility of the intraoperative
use of OSNA. Only SLNs were
used for this phase. LN
specimens were analysed by
OSNA immediately on arrival at
the histopathology laboratory to
simulate the intraoperative
scenario
Number of participants:
204
Number of SLNs or
ALNs: 393 LNs,
dissected to 417
samples
Recruitment procedure:
NR
Inclusion criteria: SLNs
from patients with a
preoperative diagnosis
of breast carcinoma,
undergoing mastectomy
or breast-conserving
surgery, were identified
and removed surgically
using the standard
technique employed at
each study site
Exclusion criteria:
patients who had
undergone neoadjuvant
chemotherapy and
those with a previous
diagnosis of a potentially
metastatic malignancy
were excluded from the
study
Sample attrition/
dropout: NR
Index test (technical details): lysates
of homogenised LN samples were
prepared manually before
amplification. OSNA provided a
qualitative result (++, + or –) and a
quantitative result (copy number of
CK19 mRNA): (++)/copy number
> 5000/µl (macrometastasis,
> 2mm); (+)/copy number
250–5000/µl (micrometastasis,
> 0.2mm to ≤ 2mm); (−)/copy
number 0–250/µl (negative).
Simultaneous positive and negative
controls were performed with the
specimen analysis to ensure quality
control
Reference standard (technical
details): one initial ribbon and
additional ribbons with a 0.25-mm
skip space were cut from two out of
four alternate slices. From the initial
ribbon and from the subsequent
four ribbons (giving a total of five
levels, equating to 10 levels of
analysis in total as two separate
slices of node were analysed), three
3-µm sections were used for
haematoxylin–eosin staining,
standard immunohistochemistry
with pan-CK clone AE1/AE3 and
CK19 immunohistochemistry. In the
event of discordance, further levels
were taken from the remaining
ribbons, using the same protocol,
until the entire paraffin block had
been examined. Histopathology
slides were examined by
pathologists masked to the results
of OSNA
Details of SLN detection: a
combination of injected
radioisotope, scintigraphy,
hand-held gamma probe and blue
dye injection was used for the
identification of SLNs. SLNs were
identified according to the New
Start criteria (hot, blue, a
combination of both, palpable and
suspicious)
Accuracy outcomes:
concordance,
sensitivity, specificity
Process outcome:
time to test
Unit of analysis:
patient and node
Discordant case
analysis: yes
Test failures: yes
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Design Participants Tests Outcomes
Extraction and division of SLNs:
on arrival in the histopathology
laboratory, each node was
categorised into one of four
groups according to its size
and sliced longitudinally with
a purpose-designed cutting
instrument into four 1- or 2-mm
slices. The total weight of each
node for slicing did not exceed
1.2 g; nodes weighing > 1.2 g were
divided into portions (giving two or
more node samples) before slicing.
Two alternate slices were colour
coded, immediately fixed with
neutral buffered formaldehyde and
processed to paraffin blocks for
histopathological analysis. The
remaining two slices were allocated
to OSNA analysis and snap frozen
at −80°C (technical performance
phase) or analysed immediately for
the clinical equivalence study
Outcome assessor: NR
Blinding: yes
Discordant case analysis: stored
homogenate was analysed further
by qRT–PCR. If the discordant case
investigation supported the OSNA
result, it was concluded that TAB
had occurred and the respective
samples were excluded from the
analysis. Total RNA was extracted
from the homogenates of
discordant samples. qRT-PCR for
breast cancer-specific markers was
then carried out with CK19, SPDEF
(SAM pointed domain containing Ets
transcription factor) and FOXA1
(forkhead box A1). In addition,
Western blot analysis for CK19
using 20 µl of lysate was performed.
At least one marker in addition to
beta-actin had to be positive to
classify a result as truly discordant
NR, not reported.
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Participant characteristics
Characteristic OSNA plus histology
Clinical tumour classification, n
T0
Tis
T1 133
T2 60
T3 5
T4
Histopathological type, n (%)
Invasive ductal carcinoma 160 (78.8)
Invasive lobular carcinoma 22 (10.8)
DCIS
Other 16 (7.9)
Results
After TAB exclusion
OSNA
Five-level histopathology
Macrometastasis Micrometastasis ITC Negative
n = 395 SLNs
++ 48 1 0 0
+ 8 9 0 10
– 4 2 20 293
n = 194 patients
++ 33 1 0 0
+ 5 5 1 7
– 4 1 11 126
Sensitivity (%) Specificity (%) Discordance (%)
n= 417
n= 194 patients after exclusion for TAB 89.8 94.5
n= 395 SLNs after exclusion for TAB 91.7 96.9
Nodes, n Median (range) time to analysis (minutes)
1 32 (22–97)
2 42 (30–73)
3 51 (38–73)
4 62 (46–90)
Test failures: six technical errors reported
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
182
Methodological issues
Replicates: unclear whether replicate samples were analysed
Analysis: unclear whether histopathology results were checked by an independent pathologist
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) Y
Did the study avoid inappropriate exclusions? (Y/N/U) Y
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference standard?
(Y/N/U)
Y
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index test?
(Y/N/U)
Y
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) U
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) Y
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) U
Were samples suspected of TAB excluded from the analysis? (Y/N/U) Y
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; U, unclear risk of bias; Y, yes.
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Sundaresan (unpublished)
Design Participants Tests Outcomes
Objective: NR
Study design: to
describe the validation
of Metasin, a novel real
time PCR assay for the
detection of metastatic
cancer in SLNs from
breast cancer patients
Country: UK
Number of centres: 6
centres
Funding: NR
Number of
participants: 1265
Number of SLNs or
ALNs: 2279 SLNs
Recruitment
procedure: NR
Inclusion criteria: NR
Exclusion criteria: NR
Sample attrition/
dropout: NR
Index (technical details): determination of the
cut-off values was carried out relative to Veridex
data and morphology, for verification of the
thresholds for macrometastasis (> 2mm) and
micrometastasis (< 2mm and > 0.2mm)
categories. The Cp values were determined for
CK19 (Cp values < 25) and mammaglobin
(< 25.9). CK19 thresholds for micrometastasis
(CK19> 25 and < 32) and mammoglobin
(Cp> 25.9 and< 32) were similarly identified. For
RNA extraction and quantification, the research
protocol was adopted from the GeneSearch
assay. Further details have been published since
this review was completed159
Reference standard (technical details): SLNs were
sectioned at three levels/steps of 150 µm. Nodal
micrometastatic (< 2mm and > 0.2mm) and
macrometastatic (> 2mm) disease were
interpreted as positive
Details of SLN detection: SLNs were identified by
a combination of the use of blue dye and
radiation, according to an established
conventional protocol following the New Start
programme
Extraction and division of SLN: six centres
contributed tissue homogenates and RNA from
patients treated for breast cancer. Two centres
provided only frozen RNA. The remaining
institutions contributed lymph node
homogenates stored at –80 °C. LNs were serially
sliced in the longitudinal plane into an even
number of approximately 2-mm slices. Alternate
slices were submitted for conventional
histopathological analysis and for
homogenisation and RNA preparation
Discordance analysis: cases were followed up
by examination of the block by extra levels
and selectively examining with MNF116
immunostaining. Cases in which the molecular
assay was positive but histology was negative
and for which homogenates were available for
analysis were subject to RNA re-extraction and
examination with an independent panel of
markers. Retrospective discordant case analysis
could not be uniformly followed
Outcome assessor: NR
Blinding: NR
Accuracy outcomes:
sensitivity, specificity
and concordance
Clinical outcomes:
NR
Other: NR
Unit of analysis:
patient
Discordant case
analysis: yes
Test failures: 1.2% –
insufficient RNA
NR, not reported.
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Participant characteristics
Not reported
Results
Metasin
Three-level histopathology
Positive Negative
n = 1265 patientsa
Positive 249 36
Negative 20 940
a 20 tests failed for 20 patients and were discarded.
Sensitivity (%) Specificity (%) Discordance (%)
n= 1245 patientsa 92.6 96.3 4.5
a Excludes 20 patients with failed tests.
Nodes (n) Median time to analysis (minutes)
1 36
2 42
3 46
Test failure – 1.2% because of insufficient mRNA in the sample
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Methodological issues
See STARD table (Chapter 3, Results of test accuracy, Table 7)
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) Y
Did the study avoid inappropriate exclusions? (Y/N/U) U
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference standard?
(Y/N/U)
U
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) U
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index test?
(Y/N/U)
U
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) U
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) Y
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) U
Were samples suspected of TAB excluded from the analysis? (H/L/U) N
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; U, unclear risk of bias; Y, yes.
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Tamaki et al.63
Design Participants Tests Outcomes
Objective: to determine
the usefulness of the
OSNA assay for clinical
use in SLNB of breast
cancer
Study design: single
gate
Country: Japan
Number of centres: 11
Funding: Nakatani
Foundation of Electronic
Measuring Technology
Advancement
Number of participants: 439
Number of SLNs or ALNs: 775
Recruitment procedure: NR
Inclusion criteria: patients with
Tis to T2, clinically LN-negative
primary breast cancer who
underwent SLNB between August
2009 and December 2010 at one
of the participating hospitals.
Patients who had a preoperative
diagnosis of DCIS were enrolled
in the study when a surgeon
judged that SLNB was needed.
Patients who underwent SLNB
before receiving preoperative
systemic chemotherapy were also
eligible for the analysis of
sensitivity of the OSNA assay
Exclusion criteria: those who
received chemotherapy or
hormone therapy before SLNB
were excluded from the study.
Men were also excluded
Sample attrition/dropout: 21 of
the originally enrolled patients
were excluded from the analysis
because of significant violations
against the study protocol,
including eight patients who
received preoperative systemic
chemotherapy before SLNB,
10 patients who were not
examined with the OSNA assay,
two patients whose central
sections of the SLN did not
undergo pathological
examination as a permanent
specimen for haematoxylin–eosin
staining and one patient who
was a man. Two patients who
had benign intraductal papilloma
confirmed after surgery, one who
had a clinical T4 tumour and two
who had clinically evident ALN
metastases were also excluded
because they did not meet the
general criteria for SLNB
candidates. Conversely, two
patients who had T3 tumours
that finally were diagnosed as
DCIS and T1 invasive cancer were
included. The final total
enrolment was 413 patients who
had 417 SLNBs eligible
for analysis
Index test (technical details): a SLN
was assessed with the OSNA assay
according to the cut-off levels of
calculated CK19 mRNA copy
number/µl determined by
Tsujimoto et al.64 and the results
were classified as negative
(< 250 copies/µl); (+) positive
(> 250 and < 5000 copies/µl);
(++) positive (5000 copies/µl);
or (+i) positive (inhibited in the
regular sample and > 250 copies/µl
in the diluted sample)
Reference standard (technical
details): a 1-mm slice was cut from
the longitudinal central part of the
SLN, fixed as a permanent section
for staining with H&E and
examined postoperatively by a
pathologist
Details of SLN detection: SLNs were
detected using both radiocolloids
and blue dye, radiocolloids only or
blue dye only
Extraction and division of SLNs:
removed SLNs were assessed
immediately with OSNA. Patients
had ALND recommended
according to OSNA and/or other
clinicopathological factors.
Non-SLNs underwent routine
pathological examination using
H&E staining. Fat tissue
surrounding the SLN was trimmed
off. A 1-mm thick slice was then
cut out from the longitudinal
central part of the SLN, fixed as a
permanent section for staining with
haematoxylin–eosin and examined
postoperatively by a pathologist.
The remaining part of the LN was
immediately examined with the
OSNA assay
Outcome assessor: NR
Blinding: yes
Discordant case analysis: discussed
but not analysed
Accuracy outcomes:
positive rate,
concordance
Unit of analysis:
patient
Discordant case
analysis: discussed but
not analysed
Test failures: unclear –
although 98.3%
examined successfully
with OSNA
NR, not reported.
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Participant characteristics
Characteristic OSNA plus histology
Patients, n 439
Age (years), mean (range) 56.1 (25–90)
Clinical stage, n (%)
0
I 183 (43.9)
II 110 (26.4)
III 70 (16.8)
IV
Unknown 54 (12.9)
Clinical tumour classification, n (%)
T0
Tis 50 (12)
T1 254 (60.9)
T2 111 (26.6)
T3 2 (0.5)
T4
Histopathological type, n (%)
Invasive ductal carcinoma 305 (73.1)
Invasive lobular carcinoma 24 (5.8)
DCIS 53 (12.7)
Other 35 (8.4)
HER2 , n (%)
Positive 51 (12.2)
Negative 334 (87.8)
HER2, human epidermal growth factor receptor 2.
Results
OSNA
One-level histopathology
Positive Negative
n = 417 patients (SLN)
Positive 58 36
Negative 8 315
Discordance (%)
n= 417 patients 5.7
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Methodological issues
Replicates: unclear whether replicate samples were analysed
Analysis: unclear whether histopathology results were checked by an independent pathologist
Recruitment: unclear if recruitment was consecutive or random
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) Y
Did the study avoid inappropriate exclusions? (Y/N/U) Y
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference
standard? (Y/N/U)
U
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) U
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index
test? (Y/N/U)
U
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) U
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) Y
Did all patients receive the same reference standard? (Y/N/U) U
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) L
Were samples suspected of TAB excluded from the analysis? (Y/N/U) N
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; U, unclear risk of bias; Y, yes.
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Tamaki et al.62
Design Participants Tests Outcomes
Objective: to develop a
more efficient method
for intraoperative
detection of LN
metastasis
Study design: single
gate
Country: Japan
Number of centres: 6
Funding: not known –
Sysmex had some
involvement in the
study
Notes: trial 1 – full
histology; trial 2 –
frozen section then
full histology
Number of participants:
two trials: trial 1: n= 36
patients, n= 149 nodes;
trial 2: n= 185 patients,
n= 551 nodes
Recruitment procedure:
unknown
Inclusion criteria: NR
Exclusion criteria: NR
Sample attrition/dropout:
trial 1: five nodes, one
patient withdrew; 19
nodes – lack of lymphatic
tissue; one node –
technical error. Trial 2:
eight nodes, three patients
withdrew; 26 nodes –
six patients had neoadjuvant
chemotherapy; 36 nodes –
lack of lymphatic tissue;
31 nodes did not meet the
study specification
Index test (technical details): pieces
obtained from ALNs were homogenised.
A LN was assessed as negative when
there were < 250 copies/µl of CK19
mRNA and positive when there were
≥ 250 copies/µl
Reference standard (technical details): in
the case of LNs from pN0 patients, two
out of four alternate blocks were further
sliced at 0.2-mm intervals, followed by
examination of each alternate slice
with haematoxylin–eosin and CK19
immunohistochemistry. A total of 144
LNs in which neither micrometastases
nor macrometastases were observed
were used for the study of false-positive
results with OSNA
Details of SLN detection: NR
Extraction and division of SLNs: a fresh
LN with a short axis of 4–12mm was
divided into four blocks at 1- or 2-mm
intervals. Two alternate blocks were
used for OSNA. Two slices were cut from
each of the three cutting surfaces and
used for the permanent three-level
histopathological examination with
haematoxylin–eosin and CK19
immunohistochemistry
Outcome assessor: histology was
checked by independent pathologists
Blinding: NR
Discordant case analysis (trial 2 only):
discordant results between OSNA
and three-level histopathology led to
repeated histopathological analysis of
blocks assigned to histopathology.
All slides were examined and evaluated
by three independent pathologists.
The final analysis of all results of the
histopathological examinations was
performed by a study group comprised
of representatives from the
different facilities
Accuracy outcomes:
concordance,
sensitivity, specificity
Unit of analysis:
node
Discordant case
analysis: yes
Test failures: one
technical error
NR, not reported.
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Participant characteristics
Characteristic
OSNA plus histology
Trial 1 Trial 2
Patients, n 36 185
Age (years), mean 55.9 54.7
Clinical stage, n (%)
0 2 (6) 14 (9)
I 8 (24) 51 (31)
IIA 14 (41) 64 (40)
IIB 3 (9) 28 (17)
III 5 (15) 7 (4)
IV 0 0
Unknown 2 (6) 0
Histopathological type, n (%)
Invasive ductal carcinoma 32 (94) 130 (79)
Invasive lobular carcinoma 1 (3) 7 (4)
DCIS 0 18 (11)
Other 1 (3) 9 (5)
Results
Before TAB exclusions
0.2-mm section histopathology
OSNA Macrometastasis Micrometastasis ITCs Negative
Trial 1: n = 124 ALNs
Positive 16 3 3
Negative 0 1 101
Three-level histopathology
OSNA Macrometastasis Micrometastasis ITCs Negative
Trial 2: n = 450 ALNs
Positive 64 6 22
Negative 4 6 348
Sensitivity (%) (95% CI) Specificity (%) (95% CI) Discordance (%)
Trial 1: n= 124 ALNs 95 (75.1–99.9) 97.1 (91.8–99.4) 3.2
Trial 2: n= 450 ALNs 87.5 (78.2–93.8) 94.1 (91.0–96.3) 7.1
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Methodological issues
Replicates: unclear whether replicate samples were analysed
Analysis: unclear whether histopathology results were checked by an independent pathologist
Recruitment: unclear if recruitment was consecutive or random
Conflict of interest: the study was funded by Sysmex
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) Y
Did the study avoid inappropriate exclusions? (Y/N/U) Y
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference
standard? (Y/N/U)
Y
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index
test? (Y/N/U)
Y
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) L
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) Y
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) L
Were samples suspected of TAB excluded from the analysis? (Y/N/U) Y
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; U, unclear risk of bias; Y, yes.
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Tsujimoto et al.64
Design Participants Tests Outcomes
Objective: to
develop a more
efficient method
for intraoperative
detection of LN
metastasis
Study design:
single gate
Country: Japan
Number of
centres: 6
Funding: NR
Number of participants:
101 patients (81 SLNs
from 49 patients)
Number of SLNs or ALNs:
325 SLNs and ALNs,
81 SLNs
Recruitment procedure: NR
Inclusion criteria: NR
Exclusion criteria: NR
Sample attrition/
dropout: NR
Index test (technical details): a histopathologically
negative LN (≤ 600mg) was homogenised and
centrifuged at 10,000 g for 1 minute at room
temperature. A 20-µl sample of supernatant was
subject to RT-LAMP (reverse transcription
loop-mediated isothermal amplification)
in a gene amplification detector (RD-100i)
Reference standard (technical details): two
slices were cut from each of the three cutting
surfaces and used for permanent three-level
histology with haematoxylin–eosin and CK19
immunohistochemistry. Macrometastasis and
micrometastasis were defined according
to the TNM classification of the Union for
International Cancer Control (sixth edition)
and the American Joint Committee on Cancer
(sixth edition). All samples for histopathology
were examined by independent pathologists
Details of SLN detection: NR
Extraction and division of SLNs: a fresh LN
with a short axis of 4–12mm was divided into
four blocks at 1- or 2-mm intervals. Two out
of four alternate blocks were used for OSNA.
Two slices were cut from each of the three
cutting surfaces and used for the permanent
three-level histopathological examination
with haematoxylin–eosin and CK19
immunohistochemistry
Outcome assessor: three independent pathologists.
Conflicting results were settled consensually
Blinding: unclear, although blinded in paper by
Tamaki et al.,62 which reports on the same trial
Discordant case analysis: in cases with discordant
results between OSNA and three-level histopathology
occurred, a histopathological analysis of the two
blocks assigned to histopathology was repeated.
All slides were examined and evaluated by three
independent pathologists. The final analysis of
all results of the histopathological examinations
was performed by a study group comprised of
representatives from the different facilities. In the
analysis of discordant cases, qRT-PCR and CK19
Western blot analysis of the lysates from discordant
cases were carried out (further details of this
process are provided in the paper). A cut-off
value for CK19 protein expression between
histopathologically positive and negative LNs was
determined by Western blot analysis. The cut-off
value was determined by statistical analysis of
the amount of CK19 measured by Western blot
analysis of 37 histopathologically negative LNs from
16 pN0 patients
Accuracy outcomes:
concordance,
sensitivity, specificity
Process outcome:
time to analysis
Unit of analysis:
node
Discordant case
analysis: yes
Test failures: NR
NR, not reported.
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Participant characteristics
Characteristic OSNA plus histology
Patients, n 101
Age (years), median (range) NR
Clinical stage, n
0 5
I 41
II 49
III 5
IV 1
Nodal status, n
pN0 60
pN1 35
pN2 2
pN3 4
Histopathological type, n
Invasive ductal carcinoma 87
Invasive lobular carcinoma 4
DCIS 5
Others 5
Results
OSNA
Three-level histopathology
Macrometastasis Micrometastasis ITCs Negative
n = 325 SLNs and ALNs
++ 34 0 0 0
+ 6 3 0 4
– 0 2 13 263
n = 81 SLNs
++ 11 0 0 0
+ 1 2 0 1
– 0 2 3 61
0.2-mm interval histopathology
Macrometastasis Micrometastasis ITCs Negative
n = 144 SLNs from pN0 patients
++ 0 0 0 0
+ 0 0 0 0
– 0 0 3 141
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Results
Sensitivity (%) Specificity (%) Discordance (%)
325 nodes (ALNs or SLNs) 91.1 NR 7.4
Time to analysis: < 30 minutes
Methodological issues
Replicates: unclear whether replicate samples were analysed
Analysis: histopathology results were checked by an independent pathologist
Recruitment: unclear if recruitment was consecutive or random
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) Y
Did the study avoid inappropriate exclusions? (Y/N/U) U
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference standard?
(Y/N/U)
Y
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index test?
(Y/N/U)
U
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) L
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) Y
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) U
Were samples suspected of TAB excluded from the analysis? (Y/N/U) N
Are there concerns about selective reporting of outcomes? (H/L/U) U
H, high risk of bias; L, low risk of bias; N, no; U, unclear risk of bias; Y, yes.
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Visser et al.65
Design Participants Tests Outcomes
Objective: to test
the suitability
of OSNA for
intraoperative
SLN analysis
Study design:
single gate
Country:
the Netherlands
Number of
centres: 2
Funding: Sysmex
Number of participants: 32
Number of SLNs or ALNs:
346 ALNs and SLNs
Recruitment procedure: NR
Inclusion criteria: NR
Exclusion criteria: NR
Sample attrition/dropout: NR
Index test (technical details): NR
Reference standard (technical details): LNs
were cut with the blades of the cutting device
1mm apart for LNs with a minor axis of
4–6mm and 2mm apart for LNs with a minor
axis of 6–10mm. LNs with a minor axis
> 10mm were halved and the resulting pieces
were then cut either in 1-mm or the 2-mm
slices depending on the size of the pieces.
From two alternate slices out of four, initially
three 4 µm-thick sections were stained with
haematoxylin–eosin, CAM5.2 (CK8) and an
anti-CK19 antibody respectively. If the initial
sections were tumour positive no further
sections were cut. Otherwise, additional
sections (n= 3) at further levels and at an
interval of 250 µm (usually four) were cut
and analysed. Separate sections containing
non-neoplastic epithelial cells were included in
each staining procedure as a positive control for
both antibodies. The size of a metastasis was
determined by measuring its largest diameter
and the metastasis was categorised as ITCs
(< 0.2mm), micrometastasis (> 0.2mm and
< 2.0mm) or macrometastasis (≥ 2.0mm). LNs
containing ITCs were recorded as LN negative
and designated as N0(i+) according to the
Union for International Cancer Control
(sixth edition) TNM classification
Details of SLN detection: NR
Extraction and division of SLNs: LN samples
were cut in four equal slices. Two of these
slices, alternately chosen, were snap frozen in
liquid nitrogen and stored at –80 °C until OSNA
analysis was performed. The remaining two
slices were fixed in 4% buffered formaldehyde
and embedded in a single paraffin block for
histological examination at five levels
Outcome assessor: microscopic evaluation was
carried out by two pathologists masked to the
results of the OSNA analysis
Blinding: no
Discordant case analysis: the histological
work-up was extended to all levels in the first
120 histologically negative LN samples and
for paraffin blocks of discordant cases. The
homogenised LN lysates of samples with
discordant OSNA vs. histology results were
subjected to qRT-PCR and Western blot
analysis. In case these investigations yielded a
result compatible with a positive OSNA result
these samples were excluded from the final
analysis as they were likely affected by
sampling bias
Accuracy outcomes:
concordance,
sensitivity, specificity
Process outcomes: NR
Clinical outcomes: NR
Unit of analysis: ALN
Discordant case
analysis: yes
Test failures: NR
NR, not reported.
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Participant characteristics
Characteristic OSNA plus histology
Patients, n 32
Age (years), median (range) NR
Clinical stage, n
0 0
I 8
II 15
III 7
IV 2
Unknown
Nodal status, n
pN0 14
pN1 10
pN2 6
pN3 2
Histopathological type, n
Invasive ductal carcinoma 30
Invasive lobular carcinoma 2
DCIS
Other
Results
OSNA
Five-level histopathology
Macrometastasis Micrometastasis ITCs Negative
n = 346 ALNs
++ 50 4 0 2
+ 2 5 0 13
– 1 2 3 264
Sensitivity (%) Specificity (%)
Discordance
(%)
n= 346 ALNs before adjustment for TAB 95.3 94.7 5.2
n= 339 ALNs after adjustment for TAB 95.3 97.1 3.2
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Methodological issues
Replicates: unclear whether replicate samples were analysed
Recruitment: unclear if recruitment was consecutive or random
Conflict of interest: consumables funded by Sysmex
Quality appraisal
Was a consecutive or random sample of patients enrolled? (Y/N/U) U
Was a cohort study design avoided? (Y/N/U) Y
Did the study avoid inappropriate exclusions? (Y/N/U) Y
Could the selection of patients have introduced bias? (H/L/U) U
Concerns that the included patients do not match the review question? (H/L/U) L
Were the index test results interpreted without knowledge of the results of the reference
standard? (Y/N/U)
U
If a threshold was used, was it prespecified? (Y/N/U) Y
Could the conduct or interpretation of the index test have introduced bias? (H/L/U) L
Are there concerns that the index test, its conduct or its interpretation differ from the review
question? (H/L/U)
L
Is the reference standard likely to correctly classify the target condition? (Y/N/U) Y
Were the reference standard results interpreted without knowledge of the results of the index
test? (Y/N/U)
U
Could the reference standard, its conduct or its interpretation have introduced bias? (H/L/U) U
Are there concerns that the target condition as defined by the reference standard does not match
the review question? (H/L/U)
L
Did all patients receive a reference standard? (Y/N/U) Y
Did all patients receive the same reference standard? (Y/N/U) Y
Were all samples (that should have been) included in the analysis? (Y/N/U) Y
Could the patient flow have introduced bias? (H/L/U) U
Were samples suspected of TAB excluded from the analysis? (Y/N/U) Y
Are there concerns about selective reporting of outcomes? (H/L/U) L
H, high risk of bias; L, low risk of bias; N, no; U, unclear risk of bias; Y, yes.
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Appendix 3 Clinical effectiveness review:
excluded studies
Papers excluded
Reason for
exclusion
1. Abdul-Rasool S, Kidson SH, Panieri E, Dent D, Pillay K, Hanekom GS. An evaluation of molecular
markers for improved detection of breast cancer metastases in sentinel nodes. J Clin Pathol
2006;59:289–97
Exclude on
intervention
2. Aihara T, Fujiwara Y, Ooka M, Sakita I, Tamaki Y, Monden M. Mammaglobin B as a novel
marker for detection of breast cancer micrometastases in axillary lymph nodes by reverse
transcription-polymerase chain reaction. Breast Cancer Res Treat 1999;58:137–40
Exclude on
population
3. Allende D, Denninghoff V, Avagnina A, Elsner B. Sentinel lymph nodes study: how to do it right?
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Garcia-Estepa 201068 Systematic review Concordance 91.7–98.2%, sensitivity
87.5%–98.1%, specificity 89–98.5%
Di Filippo 200969 Single gate 247 SLNs Concordance 96.7%, specificity 96.8%,
sensitivity 96.4%
Buglioni 200970 228 SLNs Concordance 96.9%, specificity 97.2%,
sensitivity 96.1%
Buglioni 201071 416 SLNs Concordance 95%, specificity 95%, sensitivity 94%
Kaneko 200772 Single gate 141 ALNs Specificity 96.9% (95% CI 92.3% to 99.3%)
469 ALNs Concordance 93.0% (95% CI 90.3% to 95.1%)
Masuda 200773 178 ALNs Specificity 97.5% (95% CI 93.5% to 99.3%),
positivity rate 17.9%, concordance 94%
(95% CI 91.9% to 95.8%)
Tsuda 200674 144 SLNs Concordance with three-level histology 98%,
specificity 100%
Sato 201175 Single gate 415 patients PPV of OSNA (++) for non-SLN metastases 44.0%,
PPV of OSNA (+) for non-SLN metastases
17.6% (p= 0.01)
417 patients PPV of OSNA (++) for non-SLN metastases 44.0%,
PPV of OSNA (+) for non-SLN metastases
17.6% (p= 0.01)
Takabatake 201176
Peston 200977 Single gate 100 SLNs Concordance 96%, sensitivity 92%, specificity 97%.
OSNA results achieved, on average, within
30 minutes for two nodes
DTA
Snook 200778 45 ALNs Concordance 93.3%, sensitivity 100%,
specificity 91.2%
Snook 200879 Median time for analysis of one SLN 32 minutes
Snook 200780 87 ALNs Concordance 90.8%, sensitivity 90%,
specificity 91%
Kissin 200981 396 SLNs Concordance 96.2%, sensitivity 91.5%, specificity
97.2, PPV 87.7%, NPV 98.1%. Minimum time to
reach a result on a single node was 22 minutes
Nizar 201082 Single gate 31 patients Specificity 82%, sensitivity 50%. OSNA requires
investment of nearly £60,000, with regular servicing
and replenishment of reagents costing nearly
£1500 per month
Chaudhry 201183 Single gate 251 SLNs Sensitivity 93%, specificity 89%, increased to
94% if accounting for TAB
Massey 201184 Cohort Mean time 40.5, 51.8, 54.0 and 61.5 minutes for
one, two, three and four nodes respectively.
Operation time was changed by –48 to +65 minutes
(median +20 minutes)
Beitsch 200785 Single gate 58 SLNs Concordance 94.8%
Tomlins 201186 Single gate 62 SLNs Concordance 95%
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Study Design SLNs Outcomes
Iqbal 201287 Observation 99 SLNs Mean time for SLN analysis 49.7 minutes (range
37–94 minutes). A second operation was avoided
for 33% of all patients studied
Ng 201188 Observation 100 patients Median time for SLNB to be performed 12 minutes
(range 2–57 minutes). Median time for telephone
result 44 minutes (range 28–75 minutes). In 54%
the operation had finished before receiving the
results; median waiting time 3 minutes
Ng 201189 Cohort 200 patients OSNA-positive rate 39%, histology-positive rate 19%
Ng 201190 Observation 100 patients Median time for SLNB to be performed 12 minutes
(range 2–57 minutes). Median time for telephone
result 44 minutes (28–75 minutes). In 54%
the operation had finished before receiving the
results; median waiting time 3 minutes
Ng 201167 Cohort 200 patients OSNA-positive rate 39%, histology-positive rate 19%
Remoundos 201291 Cohort 602 SLNs OSNA-positive rate: macrometastases 19%,
micrometastases 21%; histology-positive rate:
macrometastases 19%, micrometastases 2%
Bilous 201292 Single gate 211 SLNs Specificity 96.3%, sensitivity 95.8%
Godey 201193 Cohort 344 SLNs OSNA-positive rate 21.3%, histology-positive rate
25%, concordance 138/160 patients. Median time
to analysis 35 minutes for two SLNs and ∼5
additional minutes per additional node
Cohort 367 patients OSNA-positive rate 24.32%, histology-positive
rate 24.79%
Peoch 201194 Single gate 197 patients OSNA-positive rate 21.3%. Median time for analysis
for two SLNs 37 minutes
Khaddage 200995 Single gate 80 SLNs Validation study (adjusted for TAB): sensitivity
100%, concordance 97.7%, specificity 97.1%;
routine practice study (unadjusted for TAB):
sensitivity 100%, concordance 94.9%, specificity
92.9%. Median time taken to analyse two SLNs
35–37 minutes
Godey 200996 Single gate 175 SLNs OSNA-positive rate 18%, 7/91 cases discordant.
Median time for analysis for two SLNs 35–37 minutes
Godey 201097 Single gate DTA, time to analysis
Levine 201098 Single gate DTA
US OSNA Breast
Cancer Sentinel Lymph
Node Study
Group 201099
Single gate DTA
Schem 2007100 Single gate 188 LNs DTA
Schem 2010101 Single gate 110 patients Sensitivity 93.3%
Jimbo 2012102 Single gate Concordance 91.5%, sensitivity 90.3%,
specificity 93.3%
Suzuki 2011103 Single gate Concordance 95.1%, specificity 96.9%
Rai 2012104 Observation Average time to result 36 minutes. Of 703 patients,
581 (83%) were OSNA negative, 56 (8.0%) were
OSNA-positive micrometastasis and 66 (9.4%) were
OSNA-positive macrometastasis. PPV OSNA (++)
57.6%, PPV OSNA (+) 17.9%
Wahab 2012105 Single gate 196 SLNs Sensitivity 94%, specificity 96.6%, concordance 96%
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Siso 2012106 Observation 49 patients 53.1% OSNA positivity rate; no comparison with
histopathology; results were contrasted with ALND
Krishmamurthy 2009107 Single gate 279 ALNs Kappa coefficient between histology and OSNA was
0.87 (95% CI 0.72 to 1.00)
Mizoo 2012108 Single gate 36 SLNs Compared with intraoperative frozen section. Mean
time to analysis 38.9 minutes (34.9 minutes for one
node, 46.4 minutes for two nodes, 55 minutes for
three to four nodes)
Al-Ramadhani 2010109 Single gate 122 patients,
275 nodes
Sensitivity and specificity rates of > 95%
Johns 2011110 Single gate 127 patients,
202 SLNs
204/978 cases were histology and Metasin positive
(21%). In total, 21 cases (2.1%) were histology-only
positive and 27 cases (2.7%) were Metasin-only
positive: discordance of 5% of the total
Johns 2011111 Single gate 127 patients,
202 SLNs
The Metasin assay displays the same diagnostic
accuracy as GeneSearch BLN with a considerable
cost reduction
Simoes 2012112 Single gate’ 1167 patients,
2018 SLNs
The false-negative rate (from sampling error) was
0.68% for GeneSearch and 0.92% for Metasin
Sundaresan 2012113 Single gate > 700 cases The Metasin-BLNA assay is cheap (£35) for two
nodes; fast result in < 46 minutes (total assay time
from receipt in laboratory) in > 75% of cases
Sundaresan 2011114 Single gate > 700 cases Discordance < 4% (with histology and GeneSearch)
Holt 2012115 Single gate 485 cases,
493 cases
post-August
2010
Discordance 3.8%against histopathology. After
August 2010, discordance 5%against histopathology
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Appendix 5 Cost-effectiveness: quality appraisal
of studies using the checklist of Drummond
and Jefferson125
Criteria
Cutress
2010123
Guillen-Paredes
201156
Burke
2010124
Cooper 2011,9
Meng 2011122
Classe
2012121
Study design
The research question is stated ✓ ✓ ✓ ✓ ✓
The economic importance of the research
question is stated
✓ ✓ ✓ ✓ ✓
The viewpoint(s) of the analysis are clearly
stated and justified
✓ ✓ ✓ ✓ ✓
The rationale for choosing alternative
programmes or interventions compared
is stated
Partial ✓ ✓ ✗ ✗
The alternatives being compared are
clearly described
✓ ✓ ✓ ✓ ✓
The form of economic evaluation used
is stated
✓ ✓ ✓ ✓ ✓
The choice of form of economic evaluation is
justified in relation to the question addressed
✗ ✗ ✓ ✓ ✗
Data collection
The source(s) of effectiveness estimates used
are stated
✓ ✓ ✓ ✓ ✗
Details of the design and results of the
effectiveness study are given (if based on a
single study)
✓ ✓ ✓ NA ✓
Details of the methods of synthesis or
meta-analysis of estimates are given (if based
on a synthesis of a number of effectiveness
studies)
NA NA NA ✓ NA
The primary outcome measure(s) for the
economic evaluation are clearly stated
Partial ✓ Partial ✓ ✓
Methods to value benefits are stated ✗ ✗ ✗ ✗ ✗
Details of the subjects from whom valuations
were obtained are given
NA NA NA NA NA
Productivity changes (if included) are
reported separately
✗ ✗ ✗ ✗ ✗ Attempted
The relevance of productivity changes to the
study question is discussed
NA NA NA NA NA
Quantities of resource use are reported
separately from their unit costs
✓ ✓ ✓ ✓ ✓
Methods for the estimation of quantities and
unit costs are described
Partial Partial Partial ✓ ✓
Currency and price date are recorded ✓ Partial ✓ ✓ ✓
Details of currency of price adjustments for
inflation or currency conversion are given
✗ ✗ ✗ Partial ✗
DOI: 10.3310/hta19020 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 2
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Huxley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
207
Criteria
Cutress
2010123
Guillen-Paredes
201156
Burke
2010124
Cooper 2011,9
Meng 2011122
Classe
2012121
Details of any model used are given NA NA ✓ ✓ NA
The choice of model used and the key
parameters on which it is based are justified
NA NA ✓ ✓ NA
Analysis and interpretation of results
Time horizon of costs and benefits is stated ✓ ✓ ✓ ✓ ✓
The discount rate(s) is stated NA NA NA ✓ NA
The choice of discount rate(s) is justified NA NA NA ✓ NA
An explanation is given if costs and benefits
are not discounted
NA NA ✓ NA NA
Details of statistical tests and confidence
intervals are given for stochastic data
✗ ✓ ✗ ✓ ✓
The approach to sensitivity analysis is given NA NA ✓ ✓ ✓
The choice of variables for sensitivity analysis
is justified
NA NA ✓ Partial ✗
The ranges over which the variables are
varied are justified
NA NA ✗ ✓ ✗
Relevant alternatives are compared ✓ ✓ ✓ ✓ ✓
Incremental analysis is reported ✗ ✗ ✗ ✓ ✓
Major outcomes are presented in a
disaggregated as well as an aggregated form
✓ ✓ ✗ ✓ ✓
The answer to the study question is given ✓ ✓ Partial ✓ ✓
Conclusions follow from the data reported ✓ ✓ ✓ ✓ ✓
Conclusions are accompanied by the
appropriate caveats
✗ ✗ ✓ ✓ ✗
✓, included; ✗, missing; attempted, missing but attempted; NA, not applicable; partial, partially included.
Only full articles were critically assessed.
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Appendix 6 Cost-effectiveness review:
excluded studies
Papers excluded Reason for exclusion
Cooper 20119 Intervention not intraoperative diagnosis
Meng 2011122 Intervention not intraoperative diagnosis
Classe 2012121 Intervention not relevant to evaluation
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Appendix 7 Expert advisors
Title Name Specialty Affiliation
Mr Simon Pain Consultant Breast and Endocrine Surgeon Norfolk and Norwich University Hospital
Mr Zenon Rayter Consultant Surgeon Bristol Royal Infirmary
Professor Ian Kunkler Consultant and Honorary Professor
in Clinical Oncology
Edinburgh Cancer Centre
Professor Graham Layer Consultant Surgeon and Director
of Professional Standards
Royal Infirmary of Edinburgh
Dr Abeer Shaaban Consultant Pathologist St James’s University Hospital, Leeds
Dr Deirdre Ryan Consultant Pathologist Barts Health NHS Trust, London
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Appendix 8 Two-way threshold analysis of
one-step nucleic acid amplification sensitivity
and specificity
The two-way sensitivity analyses examine the effect of altering both specificity and sensitivity whilefixing other parameters at their base-case values. Here, we present the long-term ICERs comparing
histopathology with full-node OSNA, as this analysis accounts for all costs and benefits of the tests. As a
guide, we chose a cost-effectiveness threshold of £30,000 per QALY gained.
First, we present the results (Table 78) using the range of sensitivity and specificity values that were
used in the one-way threshold analyses (70–100% for both sensitivity and specificity; see Tables 54–57).
This demonstrates that histopathology was cost-effective at a threshold of £30,000 per QALY gained for
most values in the analysis. However, when the specificity was 90% and the sensitivity was 100%, the
ICER increased to > £94,000 per QALY gained. Furthermore, when the sensitivity was 95% and
the specificity was 100%, the ICER increased to > £100,000. When the sensitivity was 100% and the
specificity was ≥ 95%, OSNA dominated histopathology, having lower costs and larger QALY gains.
Table 79 narrows down the range of sensitivity and specificity values at which the ICER crossed the
£30,000 threshold. The increments in specificity are shown in steps of 2%, to keep the table concise.
As the table shows, if the sensitivity of OSNA was 100%, the specificity had to be > 88% for the ICER to
be > £30,000 per QALY gained (at 87% specificity the ICER was £24,928 per QALY gained). When the
specificity was ≥ 92% and the sensitivity was 100%, OSNA dominated histopathology, having higher
QALY gains and lower costs. If the specificity was 100% the sensitivity of OSNA had to be at least 93%
to have an ICER > £30,000 per QALY gained (at 92% sensitivity the ICER was £24,683). In this case the
sensitivity had to reach 96% before OSNA dominated histopathology. As sensitivity and specificity were
decreased below 100%, the ICERs decreased. When we looked at reducing both sensitivity and specificity
but keeping the ICER > £30,000 per QALY gained, the lowest values that they could take were 95% for
specificity and 96% for sensitivity (the ICER was £34,639 per QALY gained compared with histopathology).
Although these results suggest that there are values for sensitivity and specificity at which OSNA may be
considered cost-effective, there is little evidence in the clinical effectiveness review to suggest that these
values are the true sensitivity and specificity of OSNA.
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